Systems and methods for providing treatment management guidance for the diagnosis and management of kidney diseases.
By continuously monitoring blood glucose and 1,5-AG levels, the continuous analyte monitoring system addresses the shortcomings in the accuracy and reliability of existing kidney disease diagnoses, enabling real-time staging and treatment management of kidney diseases and improving the effectiveness of early detection and treatment.
Patent Information
- Application Number
- CN202580028291.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-22
- Filing Date
- 2025-04-22
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies lack accuracy and reliability in diagnosing and staging kidney diseases, and cannot monitor changes in kidney function in real time and continuously. This leads to kidney diseases not being detected in their early stages, which may result in deterioration of the patient's health or even death.
A continuous analyte monitoring system, including a continuous glucose sensor and/or a continuous 1,5-AG sensor, is used to monitor blood glucose and 1,5-dehydroglucosol levels in real time. Combined with sensor electronics modules, real-time analyte data is generated for the staging and treatment management guidance of kidney disease.
It enables real-time staging and treatment management of kidney diseases, provides early warnings and personalized treatment recommendations, prevents kidney function decline and disease progression, and improves the accuracy and timeliness of diagnosis.
Smart Images

Figure CN123125660A_ABST
Abstract
Description
[0001] Cross-references to related applications This application claims priority and interest in U.S. Provisional Application No. 63 / 637,096, filed April 22, 2024, which is hereby assigned to the assignee of this application and is hereby expressly incorporated herein by reference in its entirety, as if fully set forth below and used for all applicable purposes. Background Technology
[0002] The kidneys are responsible for many key functions in the body, including filtering waste and excess fluid (which is excreted in urine) and removing acids produced by the body's cells to maintain a healthy balance of water, salt, and minerals (such as sodium, calcium, phosphorus, and potassium) in the blood. In other words, the kidneys play a major role in homeostasis through renal mechanisms that transport and regulate the secretion, reabsorption, and excretion of water, salt, and minerals.
[0003] Kidney disease is typically classified as acute or chronic based on the duration of the disease and / or whether it is caused by a specific event (e.g., dehydration, medical procedures involving the use of toxic contrast agents or therapeutic agents, or major surgery) or in response to the progression of a long-term disease over time. Chronic kidney disease (CKD) typically progresses in response to a long-term disease (such as hypertension or diabetes) that slowly damages the kidneys and reduces their function over time; or it progresses more rapidly in response to an acute but irreversible kidney injury (e.g., as a result of sepsis or AKI). Symptoms of CKD develop slowly and may not become apparent until little kidney function remains. Acute kidney injury (AKI) occurs as a rapid decline in kidney function. This damage may be reversible within a short period of time, but currently requires monitoring in a hospital. Attached Figure Description
[0004] To gain a more detailed understanding of the features of this disclosure, reference can be made to some aspects illustrated in the accompanying drawings for a more specific description of the aspects briefly summarized above. However, it should be noted that the drawings illustrate only some typical aspects of this disclosure and should therefore not be considered as limiting its scope, as the description may acknowledge other equally valid aspects.
[0005] Figure 1 Examples of a sample treatment management system used in conjunction with embodiments of this disclosure are illustrated.
[0006] Figure 2 The diagram is a conceptual illustration of an example continuous analyte monitoring system according to certain embodiments of the present disclosure, the continuous analyte monitoring system including an example continuous analyte sensor having sensor electronics.
[0007] Figure 3AExample inputs according to certain embodiments of this disclosure are illustrated, as well as calculations based on these inputs for... Figure 1 Example metrics used in the treatment management system.
[0008] Figure 3B This is a flowchart depicting a method for training a machine learning model to predict a patient's kidney disease status and / or kidney health according to certain embodiments of the present disclosure, and for providing recommendations to the patient based on the disease status.
[0009] Figure 4A An example method is described in which an analyte monitoring system configured to at least measure 1,5-anhydroglucosol (1,5-AG) levels is used to provide guidance for the treatment and management of kidney disease, according to certain embodiments of this disclosure.
[0010] Figure 4B This is a flowchart illustrating an example method 401 for providing guidance to a patient in order to calculate the patient's reabsorption threshold according to certain embodiments of the present disclosure.
[0011] Figure 5 Example methods are described according to certain embodiments of this disclosure for using an analyte monitoring system configured to measure at least 1,5-AG to determine a filtration score and provide guidance for the management of kidney disease treatment.
[0012] Figure 6 It describes a configuration for performing certain embodiments according to this disclosure. Figures 4A to 5 A block diagram of the computing device in operation.
[0013] Figures 7A to 7B Exemplary enzyme domain configurations for a continuous multianalyte sensor according to certain embodiments of the present disclosure are depicted.
[0014] Figures 7C to 7D Exemplary enzyme domain configurations for a continuous multianalyte sensor according to certain embodiments of the present disclosure are depicted.
[0015] Figures 8A to 8B An alternative view of an exemplary dual-electrode enzyme domain configuration for a continuous multianalyte sensor according to certain embodiments of this disclosure is depicted.
[0016] Figures 8C to 8D An alternative view of an exemplary dual-electrode enzyme domain configuration for a continuous multianalyte sensor according to certain embodiments of this disclosure is depicted.
[0017] Figure 8E An exemplary dual-electrode configuration for a continuous multianalyte sensor according to certain embodiments of the present disclosure is depicted.
[0018] Figures 9A to 9GA one-sided coplanar analyzer sensor assembly according to certain embodiments of the present disclosure is depicted.
[0019] For ease of understanding, the same reference numerals are used where possible to denote the same elements common to the figures. Elements disclosed in one aspect are intended to be usefully used in other aspects without specific description. Detailed Implementation
[0020] Accurate assessment of renal function is important as a screening tool and for monitoring disease progression and guiding prognosis, at least for kidney disease, and further for comorbidities and / or conditions that place patients at higher risk of developing worsening kidney disease. However, existing techniques for diagnosing and staging kidney disease, including albumin-to-creatinine ratio (ACR) tests, glomerular filtration rate (GFR) tests, GFR measurements via insulin clearance tests, and blood tests for monitoring creatinine levels, face significant challenges in terms of accuracy and reliability. It should be noted that, in this document and for the purposes of this disclosure, kidney disease refers to any loss of kidney function, whether or not that loss of function would be classified as kidney disease according to current scientific standards. Examples of loss of kidney function include chronic kidney failure, known as CKD, or acute kidney failure, known as AKI, the latter typically caused by sudden injury.
[0021] Specifically, these existing technologies are imprecise, inefficient, and lack the sensitivity and specificity necessary to accurately diagnose and stage kidney disease before significant loss of renal function. For example, existing technologies used to diagnose and stage kidney disease are often single-point readings that may be affected by patient activity (such as diet or exercise around or during that time point) or have significant biological delays in reflecting acute events. In other words, there is currently no treatment management system with the technical capability to measure, process, and analyze one or more analytes in real time and continuously, thereby collecting sufficient data over time to allow for the detection of kidney disease and to provide guidance for treatment management. Due to these technical problems and limitations, monitoring the development of kidney disease and / or its progression over time in its early stages is technically impossible, which can prove life-threatening for patients with kidney disease in some cases. Therefore, using existing kidney disease detection technologies, patients are often not diagnosed with kidney disease until they have lost nearly 50% of their renal function, because, as discussed above, currently available technologies and methods only involve using time-point measurements of certain analytes to assess the loss of renal function. Given the time-dependent nature of kidney disease, technological limitations associated with existing diagnostic techniques can lead to worsening symptoms, irreversible decline in overall health, and even death for patients.
[0022] Therefore, certain embodiments of this document provide a technical solution to the aforementioned technical problems by offering a continuous analyte monitoring system (e.g., including at least one of a continuous glucose sensor and / or a continuous 1,5-AG sensor, and at least one sensor electronics module) for staging and / or monitoring kidney disease and providing guidance for treatment management. Measuring analytes (e.g., glucose and 1,5-AG) in a continuous reading manner as proposed herein allows for more accurate monitoring of a patient's renal function over time, monitoring the development of early kidney disease, monitoring the progression of kidney disease over time, and providing real-time guidance for treatment management. This information can also be used to make informed decisions in kidney health assessment, treatment of kidney disease, and / or prevention of kidney disease.
[0023] Some embodiments described herein also provide a treatment management system configured to provide guidance on the treatment management of kidney disease using analyte data generated by the continuous analyte monitoring system described herein. For example, some embodiments provide methods and systems for continuously monitoring analyte data (e.g., at least one of 1,5-AG or glucose levels) and / or non-analyte data to provide guidance on the treatment management of kidney disease, patient-specific feedback (e.g., recommendations on medical interventions, medication (e.g., insulin administration), and / or lifestyle recommendations (e.g., maintaining a specific exercise program, etc.)) thereby preventing functional decline, progression, and / or development of kidney disease.
[0024] For background, 1,5-AG, a pyranose, is a naturally occurring monosaccharide. During periods of hyperglycemia (blood glucose levels above 180 mg / dL), blood concentrations of 1,5-AG decrease and return to normal levels within a relatively short period (e.g., from several days to up to two weeks) in the absence of hyperglycemia. Therefore, 1,5-AG can be measured, and meaningful data and insights can be derived for patients (as described in this article). This can be helpful for patients whose conventional measurements are unreliable (such as those with type 1 or type 2 diabetes) when identifying glycemic variability or a history of hyperglycemia where current blood glucose measurements (such as hemoglobin A1c (HbA1c) and blood glucose) are close to normal. 1,5-AG is ingested from almost all foods during a regular diet and is almost 100% unmetabolized. It is carried in the bloodstream and filtered by the glomeruli, thus entering the kidneys. Once in the kidneys, 1,5-AG is reabsorbed back into the bloodstream through the proximal convoluted tubules of the kidney. A small amount (equal to the intake) of 1,5-AG is released into the urine to maintain a constant level in the blood and tissues.
[0025] Glucose, another pyranose, is a competitive inhibitor of 1,5-AG reabsorption in the kidneys. If blood glucose levels rise above a certain threshold (referred to herein as the “reabsorption threshold”) for any given period of time, the kidneys cannot reabsorb all glucose back into the bloodstream, resulting in increased excretion in the urine (glycosuria). Therefore, blood 1,5-AG levels can respond rapidly to an increase in glucose levels and begin to decrease, continuing to decrease until glucose levels fall below the reabsorption threshold. Once hyperglycemia is corrected, 1,5-AG begins to be reabsorbed from the kidneys back into the bloodstream at a steady rate. If an individual’s glucose levels remain below the reabsorption threshold for a period of time (e.g., from one week to up to four weeks), 1,5-AG can return to its normal levels. Therefore, measuring blood 1,5-AG levels is a test for a recent history of hyperglycemia and can also be used as a sensitive and specific indicator of kidney function, including glomerular filtration efficiency. In some implementations, a patient’s reabsorption threshold is determined, which is the patient’s blood glucose level at which glucose begins to competitively displace the reabsorption of 1,5-AG and at which 1,5-AG levels begin to decrease. The reabsorption threshold is directly related to a patient's renal function and provides further indication of the presence of kidney disease and / or the risk of developing kidney disease, as described below. The reabsorption threshold can be calculated using continuous measurements of glucose levels, or determined using a specific patient's historical glucose levels, or based on values derived from a clinical population.
[0026] As used herein, the term "continuous" analyte monitoring refers to monitoring one or more analytes in a fully continuous, semi-continuous, or periodic manner, resulting in a data stream of analyte values over time. This data stream of analyte values over time is the foundation for deriving meaningful data and insights using the algorithms described herein for staging and monitoring kidney disease and providing guidance for treatment management. In other words, sporadic data points generated by individual point-in-time measurements collected when patients visit their healthcare professionals every few months (e.g., preferably spaced several months apart) cannot form the basis for any meaningful data or insights to be derived. Therefore, without the continuous analyte monitoring system described herein, it would be fundamentally impossible to continuously monitor and stage kidney disease, and to continuously provide guidance for treatment management, as described herein.
[0027] Furthermore, the data stream of analyte values collected over time using the continuous analyte monitoring system proposed herein includes real-time analyte values, which allows for the real-time extraction of meaningful data and insights using the systems and algorithms described herein. The derived real-time data and insights, in turn, allow for real-time staging and monitoring of kidney disease, as well as real-time guidance for treatment management. Real-time analyte values, as defined herein, refer to analyte values that are available and actionable within seconds or minutes after at least one sensor electronics module of the continuous analyte monitoring system performs the following operations: (1) converting a sensor current (i.e., an analog electrical signal) generated by the continuous analyte sensor into a sensor count value; (2) calibrating the count value using the calibration techniques described herein to generate at least glucose and / or 1,5-AG concentration values to account for the sensitivity of the continuous analyte sensor; and (3) transmitting the measured glucose and / or 1,5-AG concentration data (including glucose and / or 1,5-AG concentration values) wirelessly to a display device.
[0028] For example, at least one sensor electronics module can be configured to sample analog electrical signals at a specific sampling period (or rate) (such as every 1 second (1 Hz), 5 seconds, 10 seconds, 30 seconds, 1 minute, 3 minutes, 5 minutes, etc.) and transmit the measured glucose and / or 1,5-AG concentration data to a display device at a specific transmission period (or rate) (which may be the same as (or longer than) the sampling period, such as every 1 minute (0.016 Hz), 5 minutes, 10 minutes, etc.).
[0029] Therefore, the real-time analyte data continuously generated by the continuous analyte monitoring system described herein allows the treatment management system of this paper to monitor and stage kidney disease in real time, and to provide treatment management guidance, which is technically impossible to perform using existing or conventional technologies or systems. Furthermore, due to the real-time nature of this data, it is also impossible for humans to use the algorithms and systems described herein for staging and monitoring kidney disease and providing timely treatment management guidance to continuously process real-time analyte value data streams over time to derive meaningful data and insights. In other words, deriving meaningful data and insights from continuously generated, processed, calibrated, and analyzed real-time data streams using the algorithms and systems described herein is not a task that can be performed mentally. For example, performing real-time and continuous analysis of… Figures 4A to 5 The algorithm described involves using a continuous stream of real-time data generated by a patient continuous analyte monitoring system and / or a significantly large amount of population data (e.g., hundreds or thousands of data points for each of thousands or millions of patients in a patient population), which is not a task that can be accomplished intellectually, especially when it is sometimes done in real time.
[0030] Furthermore, some embodiments of this paper relate to technical solutions to technical problems associated with analyte sensor systems. Specifically, each analyte sensor system manufactured by a sensor manufacturer may behave slightly differently. Therefore, inconsistencies may exist between the sensors and the measurements they produce once in use. Consequently, some embodiments of this paper relate to determining the performance of the analyte sensor system during the manufacturing calibration process (in vitro), which includes quantifying certain sensor operating parameters such as calibration slope (also known as calibration sensitivity), calibration baseline, etc.
[0031] Typically, calibration sensitivity refers to the amount of current generated by the analyte sensor of an analyte sensor system when immersed in a predetermined amount of the analyte to be measured. The current can be expressed in picoamperes (pA) or counts. The amount of analyte measured can be expressed as a concentration level in milligrams per deciliter (mg / dL), and calibration sensitivity can be expressed in pA / (mg / dL) or counts / (mg / dL). The calibration baseline refers to the amount of current generated by the analyte sensor when no analyte is detected, and can also be expressed in pA or counts.
[0032] Calibration sensitivity, calibration baseline, and other information related to the sensitivity profile of the analyte sensor system can be programmed into the sensor electronics module of the analyte sensor system during the manufacturing process, and then used to convert the analyte sensor electrical signal into a measured analyte concentration level. For example, the calibration slope (calibration sensitivity) can be used to predict the initial in vivo sensitivity (M0) and the final in vivo sensitivity (M... f These are programmed into the sensor electronics module and used to convert the analyte sensor electrical signal into a measured analyte concentration level.
[0033] In some implementations, during in vivo use, the sensor electronics module of the analyte sensor system samples the analog electrical signal generated by the analyte sensor to generate an analyte sensor count value, and then, based on the analyte sensor count value, the initial in vivo sensitivity (M0) and the final in vivo sensitivity (M... f This is used to determine the measured analyte concentration level. For example, it can be based on the initial in vivo sensitivity (M0) and the final in vivo sensitivity (M... f The sensitivity function M(t) is used to determine the measured analyte concentration level. The sensitivity function M(t) can be expressed in several different ways, such as in a way that is independent of the elapsed time (t) of in vivo administration. i Simple correction factor, sensitivity and time (t) i The linear relationship between ) and sensitivity and time (t) i The exponential relationship between them, etc. Equation 1 presents the exponential relationship used based on time t. iA technique for determining the measured analyte concentration level (ACL) by using the analyte sensor count (count) at a given location. ACL = count / M(t) i Equation 1 The calibration baseline (baseline) can also be used based on time t. i The analyte sensor count (count) at the analyte location is used to determine the measured analyte concentration level (ACL), and Equation 2 presents a technique: ACL = (count - baseline) / M(t) i Equation 2 Example treatment management system, including example analytical data for determining the presence, progression, or development of kidney disease. Sensors Figure 1 An example treatment management system 100 is illustrated, which uses a continuous analyte monitoring system 104 configured to continuously measure one or more analytes, such as 1,5-AG and glucose levels, to provide kidney disease treatment management guidance to a patient 102 (referred to herein, individually, and collectively, as "patients"). In some embodiments, a patient may be, for example, a patient with kidney disease at different stages, a patient with diabetes (and therefore known to be at risk of developing kidney disease), and / or a healthy patient (e.g., a patient not diagnosed with kidney disease and / or diabetes).
[0034] In some implementations, system 100 includes a continuous analyte monitoring system 104, a display device 107 executing application 106, a treatment management engine 114, a patient database 110, a historical record database 112, a training system 140, and the treatment management engine 114, each of which is described in more detail below.
[0035] As used herein, the term "analyte" is a broad term used in its common sense, including but not limited to substances or chemical components in biological fluids (e.g., blood, interstitial fluid, cerebrospinal fluid, lymph, or urine) or gases (e.g., exhaled breath) that can be analyzed. Analytes can include naturally occurring substances, pharmaceuticals, man-made substances, metabolites, ions, vitamins, minerals, proteins, enzymes, oligonucleotides, and / or reaction products. Analytes used for measurement by the equipment and methods may include, but are not limited to, potassium, glucose, endogenous insulin, prothrombin decarboxylation; acylcarnitine; endogenous insulin; adenine phosphoribosyltransferase; adenosine deaminase; albumin; albumin to creatinine ratio; alpha-fetoprotein; amino acid profile (arginine (Krebs cycle), histidine / uric acid, homocysteine, phenylalanine / tyrosine, tryptophan); androstenedione; antipyrine; arabinitol enantiomers; arginase; benzoyl stigmine (cocaine); biotinylate; biopterin; C-peptide; C-reactive protein; carnitine; muscle. Peptidase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β-hydroxycholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; creatine anhydride; cyclosporine A; cystatin C; d-penicillamine; deethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetyltransferase polymorphism, alcohol dehydrogenase, α1-antitrypsin, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-punjab, hepatitis B virus, HCMV, HIV-1, HTL V-1, MCAD, RNA, PKU, Plasmodium vivax, 21-deoxycortisol); debutylhalopantide; dihydropteridine reductase; diphtheria / tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acid / acylglycine; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free triiodothyronine (FT3); fumarate acetylacetase; galactose / gal-1-phosphate; galactose-1-phosphate uridine diphosphate transferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione Peptide peroxidase; Glycinecholic acid; Glycosylated hemoglobin; Halopanatin; Hemoglobin variants; Hexosamine A; Human erythrocyte carbonic anhydrase I; 17-α-hydroxyprogesterone; Hypoxanthine phosphoribosyltransferase; Immunoreactive trypsin; Lactate; Pyruvate; Lead; Lipoproteins ((a), B / A-1, β); Lysozyme; Mefloquine; Netilmicin; Phenobarbital; Phenytoin; Phytanic acid / norphytanic acid; Progesterone; Prolactin; Prolinease; Purine nucleoside phosphorylase; Proteinuria; Quinine; Reverse triiodothyronine (rT3); Selenium; Serum pancreatic lipase; Sisomicin; Somatostatin C;Specific antibodies that recognize one or more of the following, including: adenovirus, antinuclear antibody, anti-ζ antibody, arbovirus, Orysin virus, dengue virus, Gynecomastia medinae, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia lamblia, Helicobacter pylori, hepatitis B virus, herpesvirus, HIV-1, IgE (atopic), influenza virus, Leishmania donovani, Leptospira, measles / mumps / rubella, Mycobacterium leprae, Mycoplasma pneumoniae, myoglobin, Coccidioidomyces comatus, parainfluenza virus, Plasmodium falciparum, and poliovirus. Ingredients include: Hepatitis virus, Pseudomonas aeruginosa, pre-C3, respiratory syncytial virus, Rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Treponema pallidum, Trypanosoma krusei / Trypanosoma langleyi, vesicular stomatitis virus, Wucet's nematode, yellow fever virus; specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyroid-stimulating hormone (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; leukocytes; and zinc protoporphyrin.
[0036] In some specific implementations, naturally occurring salts, sugars, proteins, fats, vitamins, and hormones (e.g., insulin) in blood or interstitial fluid may also constitute analytes. Analytes can be naturally present in biological fluids, such as metabolites, hormones, antigens, antibodies, etc. Alternatively, analytes can be introduced into the body or are exogenous, such as contrast agents for imaging, radioactive isotopes, chemical reagents, synthetic blood based on fluorocarbons, or drugs or drug compositions, including but not limited to insulin; glucagon, ethanol; cannabis (cannabis, tetrahydrocannabinol, hemp); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorinated hydrocarbons, hydrocarbons); cocaine (cracked cocaine); stimulants (amphetamine, methamphetamine, methylphenidate, Cylert, Preludin, Didrex, PreState, Voranil, Sand). Rex, Plegine; sedatives (barbiturates, methylquinolone, tranquilizers such as diazepam, nitrazepam, metronidazole, tranxene, methylphenidate, tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, piodine, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, percocet, percodan, tussionex, fentanyl, dalofop, analgesic, antidiarrheal); specialty drugs (fentanyl, meperidine, amphetamine, methamphetamine and analogues of phencyclidine, e.g., ecstasy); anabolic steroids; and nicotine. Metabolites of drugs and drug compositions are also envisioned analytes. It can also analyze analytes produced in the body, such as neurochemicals and other chemicals, such as ascorbic acid, uric acid, dopamine, norepinephrine, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT) and 5-hydroxyindoleacetic acid (FHIAA), as well as intermediates in the citric acid cycle.
[0037] Although the analytes that can be measured and analyzed by the apparatus and methods described herein include 1,5-AG and glucose, other analytes listed above may also be considered in some cases.
[0038] In some implementations, the continuous analyte monitoring system 104 is configured to continuously measure one or more analytes and transmit the analyte measurement results to an electronic medical record (EMR) system. Figure 1(Not shown in the image). An EMR system is a software platform that allows for the electronic input, storage, and maintenance of digital health data. EMR systems are typically used in hospitals and / or other nursing facilities to record patients' clinical information over the long term. EMR systems organize and present data in a manner that assists clinicians, such as interpreting health conditions and providing ongoing care, scheduling, billing, and follow-up. Data contained in an EMR system can also be used to create reports for patients for clinical care and / or disease management. In some implementations, the EMR can communicate with a treatment management engine 114 (e.g., via a network) to perform the techniques described herein. Specifically, as described herein, the treatment management engine 114 can acquire patient-associated data, use the acquired data as input to one or more trained models, and output a prediction. In some cases, the EMR can provide data to the treatment management engine 114 as input to one or more models. Additionally, in some cases, the treatment management engine 114 can provide an output prediction to the EMR after making a prediction.
[0039] In some embodiments, the continuous analyte monitoring system 104 is configured to continuously measure one or more analytes and transmit the analyte measurements to a display device 107 for use by application 106. In some embodiments, the continuous analyte monitoring system 104 transmits the analyte measurements to the display device 107 via a wireless connection (e.g., Bluetooth (including Bluetooth Low Energy (BLE)), WiFi, LAN, cellular network, etc.). In some embodiments, the display device 107 is a smartphone. However, in some other embodiments, the display device 107 may alternatively be any other type of computing device, such as a laptop computer, smartwatch, tablet, standalone receiver, or any other computing device capable of executing application 106. In some embodiments, the continuous analyte monitoring system 104 and / or the analyte sensor application 106 transmit the analyte measurements to one or more other individuals interested in the patient's health (e.g., family members or physicians providing real-time treatment and care for the patient). The continuous analyte monitoring system 104... Figure 2 For more detailed description. In some other embodiments, the continuous analyte monitoring system 104 does not transmit analyte measurements to the display device 107, but instead provides the data directly to a third party for diagnostic purposes (e.g., if the patient does not have a display device and / or the display device cannot be paired with the continuous analyte monitoring system).
[0040] Application 106 is a mobile health application configured to receive and analyze analyte measurements from analyte monitoring system 104. Specifically, application 106 stores patient information (including the patient's analyte measurements) in a patient profile 118 associated with the patient for processing and analysis, and for use by treatment management engine 114 to provide treatment management recommendations or guidance to the patient.
[0041] Treatment management engine 114 refers to a set of software instructions having one or more software modules, including a data analysis module (DAM) 116. In some embodiments, treatment management engine 114 executes entirely on one or more computing devices in a private or public cloud. In such embodiments, application 106 communicates with treatment management engine 114 via a network (e.g., the Internet). In some other embodiments, treatment management engine 114 executes partly on one or more local devices (such as display device 107 and / or continuous analyte monitoring system 104) and partly on one or more computing devices in a private or public cloud. In some other embodiments, treatment management engine 114 executes entirely on one or more local devices (such as display device 107 and / or continuous analyte monitoring system 104). As discussed in more detail herein, treatment management engine 114 can provide patients with treatment management recommendations via application 106 for medical interventions, medication, and / or lifestyle changes to improve the patient's kidney disease staging, prevent kidney disease progression, prevent the patient from developing kidney disease, and / or treat kidney disease. The treatment management engine 114 provides treatment management recommendations on medical interventions, medications, and / or lifestyle changes based on information included in the patient profile 118.
[0042] Patient profile 118 may include information about the patient collected from application 106. For example, application 106 provides a set of inputs 130, including analyte measurements received from continuous analyte monitoring system 104, which are stored in patient profile 118. In some embodiments, the inputs 130 provided by application 106 include data other than analyte measurements received from continuous analyte monitoring system 104. For example, application 106 may obtain additional inputs 130 through manual patient input, one or more other non-analyte sensors or devices, non-continuous analyte laboratory test results (e.g., kidney biopsy, liver biopsy, metabolic assays, Fibroscan results, ultrasound imaging, magnetic resonance imaging, electrolyte assays, urine pH testing, etc.), other applications executed on display device 107, etc. Non-analyte sensors and devices include, but are not limited to, insulin pumps, strain sensors, body sound sensors, impedance sensors, electrocardiogram (ECG) sensors, heart rate monitors, blood pressure sensors, respiration sensors, thermometers, sensors or devices provided by display device 107 (e.g., accelerometers, cameras, GPS, heart rate monitors, etc.) or other patient accessories (e.g., smartwatches or fitness trackers), or one or more other sensors or devices that provide relevant information about the patient. The input 130 of the patient profile 118 provided by application 106 is discussed below regarding... Figure 3A To describe in more detail.
[0043] The treatment management engine 114's DAM 116 is configured to process input set 130 to determine one or more metrics 132. Metric 132 (described below regarding...) Figure 3A (Discussed in more detail) In at least some cases, it can broadly indicate a patient's disease status, such as one or more of the patient's general analyte trends, trends associated with the patient's health, etc. In some implementations, indicator 132 can then be used by the treatment management engine 114 as input to provide patients with guidance on the treatment management of their kidney disease. As shown, indicator 132 is also stored in the patient profile 118.
[0044] The patient profile 118 also includes demographic information 120, physiological information 122, disease progression information 124, and / or medication information 126. In some embodiments, this information is provided through patient input, obtained from one or more analyte or non-analyte sensors, or obtained from certain data repositories (e.g., electronic medical records (EMR)). In some embodiments, demographic information 120 includes one or more of the patient's age, race, sex, etc. In some embodiments, physiological information 122 includes one or more of the patient's height, weight, and / or body mass index (BMI). In some embodiments, disease progression information 124 includes information about the patient's illness, such as whether the patient has been previously diagnosed with kidney disease and / or has a history of symptoms of kidney disease, such as diabetes, liver disease, hypertension, etc. In some implementations, information about a patient’s disease may also include the length of time since diagnosis, the level of disease control, adherence to disease management therapy, predicted renal function, other types of diagnoses (e.g., heart disease, hypertension, obesity) or health indicators (e.g., heart rate, exercise, sleep, etc.), and / or similar information.
[0045] In some embodiments, medication information 126 includes information about the amount, frequency, and type of medication taken by the patient. In some embodiments, the amount, frequency, and type of medication taken by the patient are timestamped and correlated with the patient's analyte level, thereby indicating the effect of the amount, frequency, and type of medication on the patient's analyte level.
[0046] In some implementations, medication information includes information about the use of one or more drugs known to damage the kidneys. One or more drugs known to damage the kidneys include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (e.g., Advil, Motrin) and naproxen (e.g., Aleve), vancomycin, iodinated radiocontrast agents (e.g., any contrast dye used in diagnostic tests), angiotensin-converting enzyme (ACE) (e.g., lisinopril, enalapril, and ramipril), aminoglycoside antibiotics (e.g., neomycin, gentamicin, tobramycin, and amikacin), anti-HIV drugs, zoledronic acid (e.g., Zometa, Reclast), phosphonoformic acid, etc.
[0047] In some implementations, medication information includes information about the use of one or more known medications for controlling complications of kidney disease. Known medications for controlling complications of kidney disease include medications for lowering blood pressure and maintaining kidney function (such as ACE inhibitors or angiotensin II receptor blockers), medications for treating anemia (such as erythropoietin supplements), medications for lowering cholesterol levels (such as statins), medications for preventing osteoporosis (such as calcium and vitamin D supplements), phosphate binders, and so on.
[0048] In some implementations, patient profile 118 is dynamic because at least some of the information stored in patient profile 118 is revised over time, and / or new information is added to patient profile 118 by treatment management engine 114 and / or application 106. Therefore, the information in patient profile 118 stored in patient database 110 provides an up-to-date repository of patient-related information.
[0049] In some implementations, patient database 110 refers to a storage server operating in a public or private cloud. Patient database 110 can be implemented as any type of data repository, such as a relational database, a non-relational database, a key-value data repository, a file system including a hierarchical file system, and so on. In some exemplary implementations, patient database 110 is distributed. For example, patient database 110 may include multiple distributed persistent storage devices. Furthermore, patient database 110 can be replicated, allowing the storage devices to be geographically distributed.
[0050] The patient database 110 includes patient profiles 118 associated with multiple patients who interact in a similar manner with an application 106 running on another patient's display device 107. The patient profiles stored in the patient database 110 are accessible not only by the application 106 but also by the treatment management engine 114. The patient profiles in the patient database 110 are accessible by both the application 106 and the treatment management engine 114 via one or more networks (not shown). As described above, the treatment management engine 114, more specifically its DAM 116, can obtain input 130 from the patient database 110 and calculate multiple metrics 132, which can then be stored as application data 128 in the patient profile 118.
[0051] In some implementations, patient profiles 118 stored in patient database 110 are also stored in historical database 112. Patient profiles 118 stored in historical database 112 provide a repository of up-to-date and historical information for each patient in application 106. Therefore, historical database 112 essentially provides all data related to each patient in application 106, where the data is stored according to associated timestamps. The timestamps associated with the information stored in historical database 112 can, for example, identify when the patient-related information was obtained and / or updated.
[0052] Additionally, the historical record database 112 maintains time-series data collected for patients over a specific period, including time-series data collected for patients using the continuous analyte monitoring system 104 and application 106. For example, for a patient who has used the continuous analyte monitoring system 104 and application 106 for up to five years to manage their kidney health, their analyte data includes time-series analyte data associated with that patient maintained during that five-year period.
[0053] Additionally, in some embodiments, the historical data database 112 includes data on one or more patients who are not part of the continuous analyte monitoring system 104 and / or application 106. For example, the historical data database 112 includes information (e.g., patient profiles) related to one or more patients analyzed by, for example, a healthcare professional (or other known methods) and who have not previously been diagnosed with kidney disease, and information (e.g., patient profiles) related to one or more patients analyzed by, for example, a healthcare professional (or other known methods) and who have previously been diagnosed with (different types and stages) kidney disease and / or diabetes or other diagnoses known to increase the risk of kidney disease. The data stored in the historical data database 112 is referred to herein as population data, which may include hundreds or thousands of data points for each of thousands or millions of patients in a patient population. In other words, the data stored in the historical data database 112 and used in some embodiments described herein may include gigabytes, terabytes, petabytes, exabytes, etc.
[0054] The patient-related data stored in the historical database 112 provides time-series data collected throughout the patient's disease lifecycle. For example, this data includes information about the patient prior to diagnosis of kidney disease and / or diabetes, and information associated with the patient during the disease lifecycle, including information related to each stage of progression and / or remission of kidney disease and / or diabetes in the patient, and information related to other diseases such as hyperkalemia, hypokalemia, diabetes, hypertension, hypotension, arrhythmia, heart disease, and similar diseases comorbid with kidney disease. This information can indicate the patient's symptoms, physiological status, analyte levels, the condition of one or more organs, habits (e.g., activity level, food intake, etc.), prescribed medications, etc., throughout the disease lifecycle.
[0055] Although depicted as separate databases for clarity of concept, in some implementations, patient database 110 and historical data database 112 operate as a single database. That is, historical and current data related to patients of the continuous analytical monitoring system 104 and application 106, as well as historical data related to patients who were not previously patients of the continuous analytical monitoring system 104 and application 106, can be stored in a single database. This single database can be a storage server operating in a public or private cloud.
[0056] As previously mentioned, the treatment management system 100 is configured to provide kidney disease treatment management to patients using the continuous analyte monitoring system 104. In some embodiments, the treatment management engine 114 is configured to provide real-time and / or non-real-time kidney disease treatment management guidance to patients and / or other individuals (including, but not limited to, healthcare providers, family members of the patient, caregivers of the patient, researchers, artificial intelligence (AI) engines, and / or other individuals, systems, and / or groups supporting care or learning from data). In some embodiments, the treatment management engine 114 is configured to provide treatment management guidance to patients via display device 107 in the form of alarms, alerts, or notifications. Alarms, alerts, and notifications may be provided in the form of tactile, auditory, or visual notifications, alarms, or alerts. Notifications, alarms, and alerts may be provided to patients on display device 107 while application 106 is running, or as background notifications even when application 106 is running in the background. Alarms, alerts, and notifications inform patients of various treatment management guidance provided by the treatment management engine 114, including guidance on seeking medical interventions for CKD or AKI or adjusting patient medication. For example, the treatment management engine 114 can provide patients with alerts, alarms, and / or notifications to increase or decrease their SGLT2 inhibitor dose.
[0057] For example, the treatment management engine 114 can be used to collect patient-related information from patient profiles 118 stored in the patient database 110, to perform analysis thereon, thereby providing guidance on the treatment management of kidney disease, and in some cases, providing recommendations to the patient based on the treatment management guidance. The treatment management engine 114 is also used to collect patient-related information from patient profiles 118, to perform analysis thereon, to provide guidance on the treatment management of kidney disease, and to provide one or more recommendations regarding medical interventions, medications, and / or lifestyle changes, at least in part, based on the treatment management guidance. Patient profiles 118 can be accessed by the treatment management engine 114 via one or more networks (not shown) to perform this analysis.
[0058] In some implementations, the treatment management engine 114 also collects information from the patient about recent habits to determine the accuracy of kidney disease treatment management guidance. For example, the treatment management engine 114 identifies abnormal patterns in analyte data consistent with a worsening disease state and / or reduced kidney function from the continuous analyte monitoring system 104. During the period of abnormal analyte patterns, the treatment management engine 114 reviews the information collected from the patient to determine whether the abnormal analyte patterns are a result of the disease state or worsening kidney function, or whether the abnormal patterns are a result of, for example, food intake, new medications, or illness or infection.
[0059] Patient profile 118 can be accessed by treatment management engine 114 via one or more networks (not shown) to perform such analysis. In some embodiments, treatment management engine 114 is configured to provide real-time and / or non-real-time treatment management guidance on diabetes to patients and / or other individuals, including but not limited to healthcare providers (HCPs), family members of patients, caregivers of patients, researchers, and / or other individuals, systems, and / or groups supporting care or learning from data.
[0060] In some implementations, the treatment management engine 114 utilizes one or more trained machine learning models capable of providing guidance on kidney disease treatment management based on information collected / received by the treatment management engine 114 from patient profiles 118. Figure 1In an exemplary implementation, the treatment management engine 114 utilizes a trained machine learning model provided by the training system 140. Although depicted as a separate server for clarity, in some implementations, the training system 140 and the treatment management engine 114 operate as a single server or system. That is, the model is trained and used by a single server, or trained and deployed by one or more servers for use on one or more other servers or systems. In some implementations, the model is trained on one or more virtual machines (VMs) running at least partially on one or more physical services in relational and / or non-relational database formats.
[0061] Training system 140 is configured to train a machine learning model using training data, which includes data (e.g., patients or non-patients) associated with one or more patients previously diagnosed with different stages of kidney disease, or with different stages of diabetes at risk of developing kidney disease (e.g., patients or non-patients of continuous analyte monitoring system 104 and / or application 106), and patients not previously diagnosed with kidney disease and / or diabetes (e.g., healthy patients, etc.) (e.g., data from patient profiles). The training data is stored in a historical database 112 and is accessible by training system 140 via one or more networks (not shown) for training the machine learning model.
[0062] Training data refers to a dataset that has already been characterized and labeled. For example, this dataset might include multiple data records, each containing information corresponding to different patient profiles stored in a patient database 110, where each record has been characterized and labeled. In machine learning and pattern recognition, a feature is a single, measurable attribute or characteristic. Typically, features that best characterize patterns in the data are selected to create predictive machine learning models. Data labeling is the process of adding one or more meaningful and informative labels to provide context for the machine learning model to learn from.
[0063] As an illustrative example, each relevant characteristic of a patient (reflected in the corresponding data record) is a feature used to train a machine learning model. Such characteristics include demographic information (e.g., age, sex, ethnicity, etc.), analyte information (e.g., 1,5-AG index, glucose index, etc.), non-analyte sensor information (e.g., strain sensor data, impedance sensor data, body sound sensor data, etc.), medical history and / or disease information (e.g., kidney disease (e.g., CKD, renal failure, acquired cystic kidney disease, kidney stones, polycystic kidney dysplasia, nephrotic syndrome, polycystic kidney disease (PKD)), liver disease (e.g., cirrhosis), diabetes, blood pressure measurements, albumin to creatinine ratio (ACR) test, glomerular filtration rate (GFR) test, blood tests for monitoring potassium levels, historical patient renal metabolic assays, etc.), medication information, and / or any other information relevant to providing a diagnosis and staging prediction of kidney disease or to providing advice to the patient.
[0064] Furthermore, data records are labeled with information corresponding to the model being trained to predict. In one example, if the model is trained to predict whether a patient's kidney disease is worsening, data records in the training dataset are labeled with such a diagnosis. In another example, if the model is trained to output predictions related to kidney function and / or kidney disease development, data records in the training dataset are labeled with one or more such diagnoses. It should be noted that in one example, this model is a multiple-input single-output (MISO) model configured to predict only whether a patient's kidney disease is worsening; in this case, additional MISO models are trained to each predict the patient's kidney health and / or risk of developing kidney disease, including whether the condition is improving or worsening. In another example, this model is a multiple-input multiple-output (MIMO) model configured to predict multiple disease-related predictions (e.g., kidney disease progression, kidney function, kidney disease development, and / or kidney disease risk prediction, etc.).
[0065] The training system 140 then trains the model using the characterized and labeled training data. Specifically, the features of each data record are used as input to the machine learning model, and the generated output is compared with the label associated with the corresponding data record. The model calculates a loss based on the difference between the generated output and the provided label. This loss is then used to modify the model's internal parameters or weights. By iteratively processing each data record corresponding to each historical patient, the model is iteratively refined to generate accurate predictions of kidney disease progression, kidney function, kidney disease development, or recommendations regarding medical interventions, medications, and / or lifestyle changes.
[0066] like Figure 1As illustrated, training system 140 deploys these trained models to treatment management engine 114 for use during runtime. Training system 140 may include one or more computer systems, each including one or more servers or one or more other types of computing devices or systems. For example, treatment management engine 114 obtains patient profiles 118 associated with patients and stored in patient database 110, uses information from patient profiles 118 as input to trained models, and outputs predictions indicative of the patient's kidney disease progression, kidney function, kidney disease development, and / or kidney disease-related feedback (e.g., Figure 1 (Shown as output 144). Output 144, generated by the treatment management engine 114, indicates whether a patient's kidney disease has improved or worsened over time. Output 144 is provided to the patient (e.g., via application 106), the patient's caregiver (e.g., parent, relative, guardian, teacher, physical therapist, fitness instructor, nurse, etc.), the patient's physician or healthcare provider, or any other individual interested in the patient's well-being for the purpose of improving the patient's health, such as individuals who, in some cases, achieve this by implementing recommended treatments and / or seeking medical interventions. Output 144, generated by the treatment management engine 114, is stored in the patient database 110 and is used to train or retrain trained models and / or update rule-based models.
[0067] In some implementations, output 144 generated by the treatment management engine 114 is stored in a patient profile 118. Output 144 may indicate the patient's current or future kidney disease status, kidney function, and recommendations regarding medical interventions, medications, lifestyle changes, etc. Output 144 stored in the patient profile 118 may be continuously updated by the treatment management engine 114. Thus, for example, disease status and recommendations (initially stored as output 144 in the patient profile 118 in the patient database 110, and then passed to the historical database 112) provide an indication of the progression or improvement of the patient's disease status over time, and provide indications of the effectiveness of different medical interventions, medications, and lifestyle changes recommended to the patient to improve their disease status.
[0068] In some implementations, the patient's own historical data is used to train system 140 to train a personalized model for the patient, which provides treatment management guidance and insights regarding the patient's medical history / current disease status, average analyte levels, etc. For example, in some implementations, a model trained on population data is used to provide patients with feedback on disease progression. However, after collecting personalized information associated with the patient (e.g., analyte sensor information, non-analyte sensor information, disease status, etc.), this personalized information is used to further personalize the model. For example, information obtained from the patient over time is used to more accurately determine the development and / or progression of kidney disease, provide personalized recommendations on medical interventions, medications, and / or lifestyle changes, and monitor the decline of the disease status over time.
[0069] Additionally, a patient's historical data can be used to generate a baseline to indicate the progression or regression of the patient's kidney disease, for example, based on the patient's analyte indicators (e.g., baseline, rate of change, lowest and / or highest levels). As an illustrative example, patient data (including multiple analyte measurements) over a two-week period within a previous timeframe (e.g., 1 day, 1 week, 1 month) can be used to generate a baseline that can be compared to the patient's current data to identify whether the patient's kidney disease has improved. In some implementations, the model can also predict or infer a patient's kidney disease and its future improvement / deterioration based on recent data patterns (e.g., analyte data, non-analyte data, eating trends, exercise trends, etc.).
[0070] In some implementations, historical patient population data based on patients with kidney disease and / or diabetes are used to generate a baseline to indicate the progression or regression of the patient's kidney disease. In some other implementations, known clinical evidence and / or data observable through a clinical investigation of procedures can be used to generate a baseline to indicate the progression or regression of the patient's kidney disease.
[0071] In some implementations, AI / ML models are trained to provide recommendations on medical interventions, medications, lifestyle changes, and other types of treatment management to help patients improve their kidney disease status based on their historical data, including how different types of medications, foods, and / or activities have affected their kidney function in the past. In some implementations, AI / ML models are trained to predict the reasons behind certain improvements or deteriorations in a patient's kidney disease status and / or risk of developing kidney disease. For example, application 106 displays a user interface with charts showing the patient's analyte levels using trend lines and, for example, retrospectively indicating how the body's analyte levels affected the patient's kidney disease status at specific points in time.
[0072] In some other implementations, rule-based models are used. For example, rule-based models are used to map patient input, analyte or non-analyte data from one or more continuous analyte sensors 202 and / or non-analyte sensors 206, and / or historical data to certain current or future kidney disease states, the risk of developing kidney disease, recommendations regarding medical interventions, medications, lifestyle changes, etc., using, for example, a rule-based base. In some implementations, rule-based models map certain inputs to kidney disease state predictions, a certain risk of developing kidney disease, and / or recommendations for patients based on patients who have had similar inputs in the past. Some example rules are discussed in this document with respect to methods 400 and 401.
[0073] Figure 2 Figure 200 is a conceptual illustration of an example continuous analyte monitoring system 104, including an example continuous analyte sensor with sensor electronics, according to certain aspects of this disclosure. For example, the continuous analyte monitoring system 104 is configured to continuously monitor one or more analytes in a patient according to certain aspects of this disclosure.
[0074] The continuous analyte monitoring system 104 in the illustrated embodiment includes a sensor electronics module 204 and one or more continuous analyte sensors 202 (referred to herein solely as continuous analyte sensors 202 and collectively as continuous analyte sensors 202) associated with the sensor electronics module 204. The sensor electronics module 204 may wirelessly communicate (e.g., directly or indirectly) with one or more of the display devices 210, 220, 230, and 240. In some embodiments, the sensor electronics module 204 may also wirelessly communicate (e.g., directly or indirectly) with one or more medical devices (such as medical device 208 (referred to herein solely as medical device 208 and collectively as medical device 208)) and / or one or more other non-analyte sensors 206 (referred to herein solely as non-analyte sensors 206 and collectively as non-analyte sensors 206).
[0075] In some embodiments, the continuous analyte sensor 202 may include one or more sensors for detecting and / or measuring an analyte. The continuous analyte sensor 202 may be a multi-analyte sensor configured to continuously measure two or more analytes, or a single-analyte sensor configured to continuously measure a single analyte as a non-invasive device, subcutaneous device, percutaneous device, transdermal device, and / or intravascular device. In some embodiments, the continuous analyte sensor 202 may be configured to continuously measure a patient's analyte levels using one or more techniques, such as enzymatic techniques, chemical techniques, physical techniques, electrochemical techniques, potentiostatic techniques, potentiometric techniques, impedance techniques, spectrophotometric techniques, polarization techniques, calorimetric techniques, iontophoresis techniques, radiation measurement techniques, immunochemical techniques, etc. The term "continuous" as used herein may mean fully continuous, semi-continuous, periodic, etc. In some aspects, the continuous analyte sensor 202 provides a data stream indicating the concentration of one or more analytes in a patient. The data stream may include a raw data signal, which is then converted into a calibrated and / or filtered data stream to provide the patient with an estimated analyte value.
[0076] In some embodiments, the continuous analyte sensor 202 may be a multianalyte sensor configured to continuously measure multiple analytes in a patient. For example, in some embodiments, the continuous multianalyte sensor 202 may be a single sensor configured to measure glucose and / or 1,5-AG in a patient.
[0077] In some embodiments, one or more multianalyte sensors may be used in combination with one or more single analyte sensors. Information from each of the multianalyte sensors and single analyte sensors may be combined to provide treatment management guidance using the methods described herein. In other embodiments, additional non-contact and / or periodic or semi-continuous but time-limited measurements of physiological information may be integrated into the system, such as non-contact heart rate monitoring including information from a scale or a sensor pad beneath the patient while in a chair or bed, detection of the patient's temperature and / or blood flow patterns via an infrared camera, and / or non-contact estimation of height, weight, or other parameters via a vision camera with machine vision.
[0078] In some embodiments, the continuous analyte sensor 202 may include a percutaneous lead having a proximal portion coupled to the sensor electronics module 204 and a distal portion having several electrodes, such as a measuring electrode and a reference electrode. The measuring (or operating) electrode may be coated, covered, treated, embedded, etc., with one or more chemical molecules that react with a specific analyte, and the reference electrode may provide a reference voltage. The measuring electrode may generate an analog electrical signal that is transmitted along a conductor extending from the measuring electrode to the proximal portion of the percutaneous lead coupled to the sensor electronics module 204. After the continuous analyte monitoring system 104 has been applied to the patient's epidermis, the continuous analyte sensor 202 penetrates the epidermis, and the distal portion extends into the dermis and / or subcutaneous tissue beneath the epidermis.
[0079] In some embodiments, the continuous analyte sensor 202 may include a planar substrate having a proximal portion coupled to the sensor electronics module 204 and a distal portion having a plurality of electrodes, such as a measuring electrode and a reference electrode. The measuring (or operating) electrode may be coated, covered, treated, embedded, etc., with one or more chemical molecules that react with a particular analyte, and the reference electrode may provide a reference voltage. The measuring electrode may generate an analog electrical signal that is transmitted along a conductor extending from the measuring electrode to the proximal portion of the continuous analyte sensor 202 coupled to the sensor electronics module 204. After the continuous analyte monitoring system 104 is applied to the host's epidermis, the continuous analyte sensor 202 penetrates the epidermis, and the distal portion extends into the dermis and / or subcutaneous tissue beneath the epidermis.
[0080] In some implementations, in addition to the planar and coaxial sensors described herein, other configurations of the planar and coaxial continuous analyte sensor 202 may be used, such as a multi-analyte sensor comprising multiple measuring electrodes, each measuring electrode generating an analog electrical signal representing the concentration level of a particular analyte.
[0081] Typically, a single analyte sensor generates an analog electrical signal proportional to the concentration level of a specific analyte. Similarly, each multi-analyte sensor generates multiple analog electrical signals, each proportional to the concentration level of a specific analyte. As an illustrative example, a continuous analyte sensor 202 may include a single analyte sensor configured to measure glucose concentration levels, and another single analyte sensor configured to measure a patient's 1,5-AG concentration levels. As another illustrative example, a continuous analyte sensor 202 may include a single analyte sensor configured to measure glucose concentration levels, and one or more multi-analyte sensors configured to measure 1,5-AG concentration levels, potassium concentration levels, lactate concentration levels, creatinine concentration levels, etc. As yet another illustrative example, a continuous analyte sensor 202 may include a multi-analyte sensor configured to measure glucose concentration levels, 1,5-AG concentration levels, potassium concentration levels, lactate concentration levels, creatinine concentration levels, etc. Therefore, the continuous analyte sensor 202 is configured to generate at least one analog electrical signal proportional to the concentration level of a specific analyte, and the sensor electronics module 204 is configured to convert the analog electrical signal into an analyte sensor count value, calibrate the analyte sensor count value based on the sensitivity curve of the continuous analyte sensor 202 to generate a measured analyte concentration level, and transmit the measured analyte concentration level data (including the measured analyte concentration level) to a display device, such as display devices 210, 220, 230, and / or 240, via a wireless connection. For example, the sensor electronics module 204 may be configured to sample the analog electrical signal at a specific sampling period (or rate) (such as every 1 second (1 Hz), 5 seconds, 10 seconds, 30 seconds, 1 minute, 3 minutes, 5 minutes, etc.), and transmit the measured analyte concentration data to the display device at a specific transmission period (or rate) (which may be the same as (or longer than) the sampling period, such as every 1 minute (0.016 Hz), 5 minutes, 10 minutes, 30 minutes, at the end of the wear period, etc.). Depending on the sampling and transmission cycle, the measured analyte concentration data transmitted to the display device includes at least one measured analyte concentration level with an associated time stamp, serial number, etc.
[0082] In some embodiments, the continuous analyte sensor 202 may be coupled to a thermocouple within or alongside a percutaneous lead to provide an analog temperature signal to the sensor electronics module 204, which can be used to correct the analog electrical signal or measured analyte data for temperature. In other embodiments, the thermocouple may be coupled to the sensor electronics module 204 above an adhesive pad, or alternatively, the thermocouple may contact the patient's epidermis through an opening in the adhesive pad.
[0083] In some implementations, the sensor electronics module 204 includes, in particular, a processor 233, a storage element or memory 234, a wireless transmitter / receiver (transceiver) 236, one or more antennas coupled to the wireless transceiver 236, analog electrical signal processing circuitry, analog-to-digital (A / D) signal processing circuitry, digital signal processing circuitry, a power supply (such as a potentiostat) for the continuous analyte sensor 202, etc.
[0084] Processor 233 may be a general-purpose or special-purpose microprocessor, application-specific integrated circuit (ASIC), field-programmable gate array (FPGA), etc., which executes instructions to perform control, calculation, input / output, and other functions of sensor electronics module 204. Processor 233 may include a single integrated circuit (such as a microprocessor device), or multiple integrated circuit devices and / or circuit boards that work together to achieve appropriate functions. In some embodiments, processor 233, memory 234, wireless transceiver 236, A / D signal processing circuitry, and digital signal processing circuitry may be combined into a system-on-a-chip (SoC).
[0085] Generally, processor 233 can be configured to use A / D signal processing circuitry to sample analog electrical signals at regular intervals (such as sampling periods) to generate analyte sensor counts based on the analog electrical signals generated by continuous analyte sensor 202, calibrate the analyte sensor counts based on the sensitivity curve of continuous analyte sensor 202 to generate measured analyte concentration levels, and generate measured analyte data from the measured analyte concentration levels, generating sensor data packets that particularly include the measured analyte concentration level data. Processor 233 can store the measured analyte concentration level data in memory 234 and generate sensor data packets at regular intervals (such as transmission periods) for transmission by wireless transceiver 236 to display devices, such as display devices 210, 220, 230, and / or 240. Processor 233 can also add additional data to the sensor data packets, such as supplementary sensor information including sensor identifiers, sensor status, and temperature corresponding to the measured analyte data. The sensor data packets are then wirelessly transmitted to the display device via a wireless connection. In some embodiments, the wireless connection is Bluetooth or Bluetooth Low Energy (BLE) connection. In such implementations, sensor data packets are transmitted to the display device in the form of Bluetooth or BLE data packets.
[0086] In various implementations, memory 234 may include volatile and non-volatile media. For example, memory 234 may include random access memory (RAM), dynamic RAM (DRAM), static RAM (SRAM), read-only memory (ROM), flash memory, cache memory, and / or any other type of non-transitory computer-readable media. Memory 234 may store one or more analyte sensor system applications, modules, instruction sets, etc., for execution by processor 233, such as instructions for generating measured analyte data from analyte sensor count values.
[0087] The memory 234 may also store certain sensor operating parameters 235, such as calibration slope (or calibration sensitivity), calibration baseline, etc. Specifically, calibration sensitivity, calibration baseline, and other information related to the sensitivity curve of the sensor electronics module 204 can be programmed into the sensor electronics module 204 during the manufacturing process and then used to convert the analyte sensor electrical signal into a measured analyte concentration level. For example, as discussed above, the calibration slope can be used to predict the initial in vivo sensitivity (M0) and the final in vivo sensitivity (M... f This sensitivity is stored in memory 234 and used to convert the analyte sensor electrical signal into a measured analyte concentration level. In some embodiments, the calibration sensitivity (M...) CC 246 and / or calibration baseline 247 can be stored in memory 234.
[0088] In some embodiments, sensor electronics module 204 includes electronic circuitry associated with measuring and processing continuous analyte sensor data, including look-ahead algorithms associated with processing and calibrating the sensor data. Sensor electronics module 204 may be physically connected to continuous analyte sensor 202 and may be integral with (non-releasably attached to) or releasably attached to continuous analyte sensor 202. Sensor electronics module 204 may include hardware, firmware, and / or software enabling the measurement of analyte levels via continuous analyte sensor 202. For example, sensor electronics module 204 may include an electrochemical simulation front end (e.g., a potentiostat, galvanostat, galvanometer, etc.), a power supply for powering the sensor, other components for signal processing and data storage, and a telemetry module for transmitting data from the sensor electronics module to, for example, one or more display devices. The electronics may be mounted to a printed circuit board (PCB) and can take many forms. For example, the electronics may take the form of integrated circuits (ICs), such as application-specific integrated circuits (ASICs), microcontrollers, and / or processors.
[0089] Display devices 210, 220, 230, and / or 240 are configured to display displayable sensor data, including analyte data that can be transmitted by sensor electronics module 204. Each of display devices 210, 220, 230, or 240 may include a display, such as touchscreen displays 212, 222, 232, and / or 242, for displaying sensor data to a patient and / or for receiving input from the patient. For example, a graphical user interface (GUI) may be presented to the patient for such purposes. In some embodiments, the display devices may include other types of user interfaces, such as a voice user interface, instead of or as a supplement to a touchscreen display, for transmitting sensor data to the patient and / or for receiving patient input. Display devices 210, 220, 230, and 240 may be Figure 1 The example of display device 107 shown in the figure is used to... Figure 1 The system displays sensor data to the patient and / or receives input from the patient.
[0090] In some implementations, one, some, or all of the display devices are configured to display the sensor data as is, or otherwise convey (e.g., in language) the sensor data as it is transmitted from the sensor electronics module (e.g., in a custom data packet transmitted to the display device based on corresponding preferences), without any additional look-ahead processing required for the calibration and real-time display of the sensor data.
[0091] Multiple display devices may include custom display devices specifically designed to display certain types of displayable sensor data associated with analyte data received from the sensor electronics module. In some embodiments, multiple display devices may be configured to provide alarms / alarms based on displayable sensor data. Display device 210 is an example of such a custom device. In some embodiments, one of the multiple display devices is a smartphone, such as display device 220, which uses a commercial operating system (OS) to represent the mobile phone and is configured to display a graphical representation of continuous sensor data, including, for example, current and historical data. Other display devices may include other handheld devices, such as display device 230 representing a tablet computer, display device 240 representing a smartwatch or fitness tracker, medical device 208 (e.g., an insulin infusion device or blood glucose meter), and / or a desktop or laptop computer (not shown).
[0092] Because different display devices offer different user interfaces, the content of the data packets (e.g., the amount, format, and / or type of data to be displayed, alarms, etc.) can be customized for each specific display device (e.g., programmed differently by the manufacturer and / or by the end patient). Therefore, in some embodiments, multiple different display devices can directly communicate wirelessly with sensor electronics modules (e.g., on-skin sensor electronics module 204, such as one physically connected to the continuous analyte sensor 202) during a sensor session to enable multiple different types and / or levels of display and / or functionality associated with the displayable sensor data.
[0093] As mentioned, the sensor electronics module 204 can communicate with the medical device 208. In some example embodiments of this disclosure, the medical device 208 can be a passive device. For example, the medical device 208 can be an insulin pump for administering insulin to a patient. For a variety of reasons, such an insulin pump may need to receive and track glucose and / or 1,5-AG values transmitted from the continuous analyte monitoring system 104, wherein the continuous analyte sensor 202 is configured to measure at least glucose and 1,5-AG.
[0094] Additionally, as mentioned, the sensor electronics module 204 can also communicate with other non-analyte sensors 206. Non-analyte sensors 206 may include, but are not limited to, altimeter sensors, accelerometer sensors, GPS sensors, temperature sensors, respiratory rate sensors, strain sensors, impedance sensors, body sound sensors, electrophysiological sensors, photophysiological sensors, etc. Non-analyte sensors 206 may also include monitors such as heart rate monitors, blood pressure monitors, pulse oximeters, calorie intake monitors, indirect calorimetry devices, and drug delivery devices. One or more of these non-analyte sensors 206 can provide data to the treatment management engine 114, which is further described below. In some aspects, patients can manually provide data for... Figure 1 The training system 140 and / or the treatment management engine 114 are processed.
[0095] In some implementations, the nonanalyte sensor 206 may also include sensors for measuring skin temperature, core temperature, perspiration rate, and / or sweat composition.
[0096] In some implementations, the nonanalyte sensor 206 can be combined in any other configuration, such as, for example, with one or more continuous analyte sensors 202. As an illustrative example, the nonanalyte sensor (e.g., a body sound sensor) can be combined with continuous glucose and / or 1,5-AG sensors 202 to form a glucose, 1,5-AG, and body sound sensor for transmitting sensor data to the sensor electronics module 204 using a common communication circuit.
[0097] In some implementations, a wireless access point (WAP) can be used to couple one or more of the continuous analyte monitoring system 104, multiple display devices, medical device 208, and / or non-analyte sensor 206 to each other. For example, the WAP can provide Wi-Fi and / or cellular (e.g., 4G, LTE, 5G, 6G, LTE CAT-M1, NB-IoT, WiMAX, UWB) connectivity between these devices. Near Field Communication (NFC), Thread home automation communication systems, Matter home automation communication systems, and / or Bluetooth can also be used. Figure 2 The devices depicted in schematic diagram 200.
[0098] Figure 3A Example inputs are illustrated according to some of the embodiments disclosed herein, and calculations are performed based on these inputs for... Figure 1 Example metrics used in the treatment management system. Specifically, Figure 3A Provided for Figure 1 More detailed examples of the example inputs and example metrics introduced in the document.
[0099] Figure 3A Example input 130 on the left, application 106 and DAM 116 in the middle, and indicator 132 on the right are illustrated. In some embodiments, each of the indicators 132 may correspond to one or more values, such as discrete numerical values, ranges, or qualitative values (high / medium / low, stable / unstable, etc.). Application 106 obtains input 130 through one or more channels (e.g., manual patient input, sensors, other applications executed on display device 107, EMR system, etc.). As previously mentioned, in some embodiments, input 130 may be processed by DAM 116 to output multiple indicators, such as indicator 132. Input 130 and indicator 132 may be used by training system 140 and treatment management engine 114 to train and deploy one or more machine learning models to provide patients with guidance on the treatment management of kidney disease, as well as other functions described herein.
[0100] In some embodiments, starting from input 130, patient statistics, such as age, sex, height, weight, BMI, body composition (e.g., body fat percentage), build, physique, or other information, may also be provided as input. In some embodiments, patient statistics are provided via a user interface, an interface with an electronic source such as an electronic medical record, and / or from a measuring device. In some embodiments, the measuring device includes one or more of a wireless (e.g., Bluetooth-enabled) scale and / or a camera, which may communicate, for example, with display device 107 to provide patient data.
[0101] In some implementations, treatment / medication information is also provided as input. Medication information may include information about the type, dosage, and / or timing of one or more medications the patient will take. As mentioned herein, medication information may include information about one or more blood glucose control medications (e.g., metformin), glucagon-like peptide-1 receptor agonist (GLP-1) medications, one or more medications known to damage the kidneys, one or more medications known to control complications of kidney disease prescribed to the patient, and / or one or more medications used to treat one or more symptoms of kidney disease, hyperkalemia, hypokalemia, diabetes, and / or other conditions and diseases the patient may have. Input related to medication information may be one or more medication and / or pill trackers to monitor the administration of oral medications. Treatment information may include information about different lifestyle habits, surgical procedures, and / or other non-invasive procedures recommended by the patient's physician. For example, the patient's physician may advise the patient to increase / decrease their glucose intake, exercise for at least thirty minutes daily, and / or increase insulin doses or other medications to maintain and / or improve kidney health, glucose homeostasis, overall health, etc. In some implementations, treatment / medication information may be provided via manual patient input.
[0102] In some embodiments, analyte sensor data may also be provided as input, for example, via the continuous analyte monitoring system 104. In some embodiments, the analyte sensor data may include 1,5-AG and / or glucose levels measured by at least one single analyte sensor (or multiple analyte sensors) in the continuous analyte monitoring system 104.
[0103] In some implementations, it is also possible to obtain data from one or more non-analyte sensors (such as those related to...). Figure 2The described nonanalyte sensor 206 receives input. Input from such a nonanalyte sensor 206 may include information relating to a patient's heart rate, heart rate variability, respiratory rate, respiratory rate variability, oxygen saturation, blood pressure, or body temperature (e.g., for detecting disease, physical activity, etc.). In some embodiments, the electromagnetic sensor may also detect low-power radio frequency (RF) fields emitted from objects or tools that are in contact with or near the object, which can provide information about the patient's activity or location.
[0104] In some implementations, input received from the non-analyte sensor may include input related to the patient's insulin delivery. Specifically, input related to the patient's insulin delivery may be received via a wireless connection on the smart insulin pen, via patient input, and / or from the insulin pump. Insulin delivery information may include one or more of the following: insulin volume, delivery time, etc. Other parameters, such as insulin duration of action, insulin activity rate, or duration of insulin action, may also be received as input.
[0105] In some implementations, input received from non-analyte sensors may include input related to patient medication delivery (e.g., via an injectable drug syringe and / or pump). Exemplary medications may include those that affect metabolic function and / or analyte levels (such as glucose and 1,5-AG). For example, these medications may include GLP-1 drugs, SGLT2 inhibitor drugs, metformin or other hypoglycemic agents, and other similar drugs with similar effects. Specifically, input related to patient medication delivery may be received via a wireless connection on the drug delivery syringe and / or pump and / or via patient input. Medication delivery information may include one or more of the following: GLP-1 dose, delivery time, dosing frequency, delivery method, etc.
[0106] In some implementations, starting from input 130, food intake information may include information about one or more of meals, snacks, and / or beverages, such as portion size, composition (carbohydrates, fats, proteins, etc.), order of intake, and time of intake. In some implementations, food intake information may be provided by the patient through manual input, by providing photos via an application configured to identify food types and quantities, and / or by scanning barcodes or menus. In various examples, meal portions may be manually entered as one or more of calories, quantity (“three cookies”), menu item (“royale with cheese”), and / or food exchange portions (1 serving of fruit, 1 serving of dairy). In some examples, meal information may be received via a user-friendly interface provided by application 106.
[0107] In some implementations, food intake information (type of food (e.g., liquid or solid, snack or meal, etc.) and / or composition of food (e.g., carbohydrates, fats, proteins, etc.)) can be automatically determined based on information provided by one or more sensors. Some example sensors may include body sound sensors (e.g., abdominal sounds can be used to detect meal type, such as liquid / solid food, snack / meal, etc.), radio frequency sensors (e.g., reading relevant nutritional information from an RFID IC embedded in the packaging of food or beverage items), cameras, hyperspectral cameras, and / or analyte (e.g., glucose, creatinine, lactate, etc.) sensors to determine the type and / or composition of food.
[0108] In some implementations, medical history and / or disease diagnoses (e.g., kidney disease, hyperkalemia, hypokalemia, diabetes, hypertension, heart disease, liver disease, blood pressure measurements, albumin-to-creatinine ratio (ACR) test, glomerular filtration rate (GFR) test, blood tests for monitoring potassium or creatinine levels, historical patient renal metabolic assays, etc.) can be provided as input. For example, a patient may already have a diagnosis of kidney disease, and this diagnosis can be provided via manual patient input. In some implementations, disease diagnoses can also be provided via interfacing with electronic sources such as electronic medical records.
[0109] In some implementations, time may also be provided as input, such as the time of day or time from a real-time clock. For example, in some implementations, the input analyte data may be timestamped to indicate the date and time the analyte measurement was performed on the patient.
[0110] Patient inputs from any of the inputs mentioned above 130 can be made via the continuous analyte monitoring system 104, the non-analyte sensor 206, and / or the user interface (such as... Figure 1 The user interface of the display device 107 is provided. As described above, in some embodiments, the DAM 116 determines or calculates patient indicators 132 based on input 130. An example list of indicators 132 is provided in Figure 3A As shown in the image.
[0111] In some implementations, the glucose index can be determined based on sensor data, such as glucose measurements obtained from a continuous glucose sensor in the continuous analyte monitoring system 104. For example, the glucose index refers to timestamped glucose measurements or values that are continuously generated and stored over time. In some examples, the glucose index can also be determined, for example, based on historical data under specific conditions, such as a given combination of food intake, insulin, and / or exercise.
[0112] In some implementations, minimum and maximum glucose levels can be determined based on sensor data. For example, daily minimum and maximum glucose values can be determined for each day within a specified time period (e.g., a week or a month). In some implementations, minimum and maximum glucose levels can be determined based on average minimum and maximum values within a specified time period (e.g., a week or a month). In some implementations, DAM 116 can continuously or periodically calculate the normal glucose range, add a timestamp, and store the corresponding information in the patient's profile 118.
[0113] In other implementations, normal minimum and maximum glucose levels can be determined based on population data (e.g., from data records or patients with a history of kidney disease). In such implementations, each patient may have individualized, customized, acceptable minimum and / or maximum glucose values, which may be determined, for example, based on the time period during which the patient is fasting or eating.
[0114] In some embodiments, a glucose baseline can be determined based on sensor data, such as glucose measurements obtained from a continuous glucose sensor in a continuous analyte monitoring system 104. A glucose baseline represents a patient's normal glucose level over a period of time during which fluctuations in glucose production are generally not expected. A patient's baseline glucose level is generally expected to remain constant over time unless challenged, for example, by behaviors such as eating or exercising. Furthermore, a patient's baseline glucose level can also vary based on the patient's health condition, particularly improvements or declines in liver and / or kidney health. Additionally, each patient may have a different glucose baseline. In some embodiments, a patient's glucose baseline can be determined by calculating the average glucose level over a predetermined period of time during which fluctuations are not expected.
[0115] For example, a patient's baseline glucose level can be determined during a period of time when the patient is sleeping, sitting in a chair, or during other periods when the patient is sedentary and has not consumed foods or medications that would lower or increase glucose levels. In some embodiments, DAM 116 can calculate the glucose baseline continuously, semi-continuously, or periodically, timestamp it, and store the corresponding information in the patient's profile 118. In some embodiments, DAM 116 can use glucose levels measured during a period when the patient is sedentary, has not consumed high-glucose foods, and there are no external conditions that would affect the glucose baseline to calculate the glucose baseline.
[0116] In some other implementations, DAM 116 may use glucose levels measured during a time period in which the patient is exercising and / or ingesting glucose, and / or where external conditions affecting baseline glucose levels are present, at least for a portion of that time period. In such cases, in some examples, DAM 116 may first identify which measured glucose values will be used to calculate the baseline glucose level by recognizing glucose values that may have been affected by external events such as food intake, exercise, medication, or other disturbances that could interfere with the capture of baseline glucose measurements. DAM 116 may then exclude such measurements when calculating the patient's baseline glucose level. In some other examples, DAM 116 may calculate the baseline glucose level by first determining a percentage of the glucose values measured during a specific time period that represent the lowest measured glucose value. DAM 116 may then calculate the average of that percentage to determine the baseline glucose level.
[0117] In some implementations, the glucose rate of change can be determined based on glucose levels (e.g., glucose measurements obtained from a continuous glucose sensor in the continuous analyte monitoring system 104). The glucose rate of change refers to the rate at which one or more timestamped glucose measurements or values change relative to one or more other timestamped glucose measurements or values. The glucose rate of change can be determined over a second or more, a minute or more, an hour or more, a day or more, etc. Furthermore, the glucose rate of change can be positive, negative, or absolute.
[0118] In some implementations, a reabsorption threshold can be determined. The reabsorption threshold refers to the level of glucose at which glucose competitively displaces 1,5-AG absorption, resulting in 1,5-AG being cleared (filtered) rather than reabsorbed into the bloodstream via the kidneys. 1,5-AG is normally reabsorbed in the kidneys, meaning it is taken up from the filtered fluid back into the bloodstream. When glucose competitively displaces 1,5-AG absorption, it means that elevated blood glucose levels exceed the kidneys' ability to reabsorb 1,5-AG, leading to a decrease in serum 1,5-AG levels. Generally, for healthy patients, the clinical reabsorption threshold at which 1,5-AG begins to be cleared rather than reabsorbed is around 180 mg / dL. However, the reabsorption threshold can be patient-specific and varies depending on the patient's glycemic and renal health. Furthermore, the reabsorption threshold may differ between different groups based on age, sex, or specific health conditions.
[0119] Therefore, as described in more detail below, the embodiments of this invention allow for the determination of patient-specific reabsorption thresholds by continuously monitoring glucose and 1,5-AG levels over time and identifying the glucose level at which 1,5-AG levels begin to decline. In some embodiments, the reabsorption threshold may represent a moving average of multiple reabsorption thresholds calculated for the patient over time. For example, a first reabsorption threshold, a second reabsorption threshold, and a third reabsorption threshold may be calculated for the patient over a first time period, and the average of these three reabsorption thresholds may be used as the patient's reabsorption rate to provide a more accurate representation of the patient's typical reabsorption threshold and mitigate the impact of outliers or abnormal readings.
[0120] In some implementations, the 1,5-AG index can be determined based on sensor data (e.g., 1,5-AG measurements obtained from a continuous 1,5-AG sensor in the continuous analyte monitoring system 104). For example, the 1,5-AG index refers to timestamped 1,5-AG measurements or values that are continuously generated and stored over time.
[0121] In some implementations, the minimum and maximum 1,5-AG levels can be determined based on sensor data. For example, the minimum and maximum 1,5-AG values for each day within a specified time period (e.g., one week or one month) can be determined. In some implementations, the minimum and maximum 1,5-AG levels can be determined based on the average minimum and maximum values within a specified time period (e.g., one week or one month). In some implementations, DAM 116 can continuously or periodically calculate the normal 1,5-AG range, add a timestamp, and store the corresponding information in the patient's profile 118.
[0122] In other implementations, normal minimum and maximum 1,5-AG levels can be determined based on population data (e.g., from data records or patients with a history of kidney disease). In such implementations, each patient can have individualized, customized, acceptable minimum and / or maximum 1,5-AG values, which can be determined, for example, based on various time periods during which the patient is fasting or eating.
[0123] In some implementations, the 1,5-AG baseline can be determined based on sensor data, such as 1,5-AG measurements obtained from a continuous 1,5-AG sensor in the continuous analyte monitoring system 104. The 1,5-AG baseline represents a patient's normal 1,5-AG level during a period when fluctuations in 1,5-AG are generally not expected. A patient's baseline 1,5-AG level is generally expected to remain constant over time unless challenged, for example, by behaviors such as ingesting 1,5-AG-rich foods or supplements. Furthermore, the 1,5-AG baseline can be determined during periods when the patient does not experience high glucose levels. High glucose levels may result in a lower 1,5-AG baseline and can therefore be an indicator that 1,5-AG absorption is being competitively squeezed out.
[0124] Furthermore, a patient's baseline 1,5-AG level can vary based on their health condition, such as improvement or decline in kidney health, particularly. Additionally, each patient can have a different 1,5-AG baseline. In some implementations, a patient's 1,5-AG baseline can be determined by calculating the average 1,5-AG level over a predetermined period of time over which fluctuations are not expected.
[0125] For example, a patient's baseline 1,5-AG level can be determined during a period of time when the patient is sleeping, sitting in a chair, or during other periods when the patient is sedentary and has not ingested foods or medications that would decrease or increase 1,5-AG levels. In some embodiments, DAM 116 can calculate the 1,5-AG baseline continuously, semi-continuously, or periodically, timestamp it, and store the corresponding information in the patient's profile 118. In some embodiments, DAM 116 can calculate the 1,5-AG baseline using 1,5-AG levels measured during a period when the patient is sedentary, has not ingested high-1,5-AG foods, and there are no external conditions that would affect the 1,5-AG baseline. In some embodiments, DAM 116 can calculate the 1,5-AG baseline level by first determining the percentage of 1,5-AG values measured during a specific time period that represent the lowest 1,5-AG value measured. DAM 116 can then calculate the average of this percentage to determine the 1,5-AG baseline level.
[0126] In some implementations, the 1,5-AG rate of change can be determined based on the 1,5-AG level (e.g., 1,5-AG measurements obtained from a continuous 1,5-AG sensor in the continuous analyte monitoring system 104). The 1,5-AG rate of change refers to the rate at which one or more timestamped 1,5-AG measurements or values change relative to one or more other timestamped 1,5-AG measurements or values. The 1,5-AG rate of change can be determined over a second or more, a minute or more, an hour or more, a day or more, etc. Furthermore, the 1,5-AG rate of change can be positive, negative, or absolute. It should be noted that the 1,5-AG rate of change can indicate the rate of change in 1,5-AG absorption or the rate of change in 1,5-AG clearance, which are different indicators. For example, if the measured rate of change is positive, it indicates the rate of change in absorption, while a negative rate of change can indicate the rate of change in clearance. Assuming constant 1,5-AG production, the rate of change in 1,5-AG clearance at various glucose levels is directly related to kidney health.
[0127] In some implementations, one or more glucose and / or 1,5-AG indicators can be determined over one or more time periods following the ingestion of foods containing 1,5-AG (e.g., meat, soy, etc.) or 1,5-AG supplements. In such an example, the treatment management engine first determines whether the patient has reached their baseline peak 1,5-AG level. As described, 1,5-AG is a stable analyte whose peak 1,5-AG level occurs over a period of time and can be determined at the peak of the 1,5-AG curve once 1,5-AG stops increasing. This peak value is typically within the normal range of 1,5-AG in the patient's body when the kidneys reabsorb 1,5-AG over a period of time (which usually occurs if glucose levels do not competitively displace 1,5-AG for a sufficient period of time). Once the treatment management engine has determined that the patient is at their baseline (peak) 1,5-AG level, the engine can determine the patient's glucose level and monitor for increases that reach or exceed the patient's absorption threshold. This can be achieved by monitoring when the patient experiences a peak (or a gradual increase) in glucose levels (which can occur in response to food), or by the treatment management engine 114 guiding the patient to ingest glucose during an OGTT. The treatment management engine 114 can then monitor glucose levels when 1,5-AG levels begin to decline to determine the patient's reabsorption threshold.
[0128] In some implementations, health and disease indicators can be determined based on one or more of the following: patient input (e.g., pregnancy information or known disease and / or infection information), information from physiological sensors (e.g., body temperature), activity sensor information, or combinations thereof. In some implementations, based on the values of health and disease indicators, for example, a patient's state can be defined as one or more of the following: healthy, sick, energetic, or exhausted.
[0129] In some implementations, disease staging indicators (such as those for kidney disease) can be based on, for example, Figure 1 The patient inputs or outputs provided by the illustrated treatment management engine 114 are used to determine the stage of kidney disease. In some embodiments, example disease stages may include AKI, stage 1 CKD with normal or high GFR (e.g., GFR > 90 mL / min), stage 2 mild CKD (e.g., GFR = 60 mL / min - 89 mL / min), stage 3A moderate CKD (e.g., GFR = 45 mL / min - 59 mL / min), stage 3B moderate CKD (e.g., GFR = 30 mL / min - 44 mL / min), stage 4 severe CKD (e.g., GFR = 15 mL / min - 29 mL / min), and stage 5 end-stage CKD (e.g., GFR < 15 mL / min). In some embodiments, example disease stages may be represented as GFR values / ranges, severity scores, etc.
[0130] In some implementations, meal status indicators can indicate a patient's state in terms of food intake. For example, meal status can indicate whether the patient is in a fasting state, a pre-meal state, an eating state, a post-meal response state, or a stable state. In some implementations, meal status can also indicate the amount of nutrients in the body, such as ingested meals, snacks, or beverages, and can be determined, for example, based on food intake information, meal timing information, and / or digestion rate information, which can be correlated with food type, quantity, and / or order (e.g., which food / beverage was eaten first).
[0131] In some implementations, the meal habit index is based on the content and timing of the patient's meals. For example, in one example, if the meal habit index is scaled from 0 to 1, the better / healthier the meals a patient consumes, the closer the patient's meal habit index will be to 1. A better / healthier meal can be defined as one that does not cause the patient's analyte (e.g., glucose) levels to exceed the patient's normal range (e.g., 70 mg / dL to 180 mg / dL glucose or the patient's desired range). Additionally, in this example, the more closely the patient's food intake follows a certain schedule, the closer their meal habit index will be to 1. In some implementations, the meal habit index may reflect the content of the patient's meals, where, for example, three numbers may indicate the percentages of carbohydrates, protein, and fat.
[0132] In some implementations, medication habit indicators are based on a patient's prescribed medications and a determination of whether those medications can affect the patient's analyte levels. For example, by analyzing a patient's medication habits, DAM 116 can determine whether a patient's medications can affect the patient's analyte measurements at a specific time. For instance, if a patient is taking an SGLT2 inhibitor, the SGLT2 inhibitor can block the reabsorption of 1,5-AG. In this case, the decrease in the patient's 1,5-AG level is directly related to the amount of 1,5-AG filtered from the patient's kidneys, and therefore directly related to the patient's kidney health.
[0133] Based on a patient's medication habits, DAM 116 can, for example, determine whether a patient's analyte levels are a result of medication use or a consequence of deteriorating renal function. Medication habit indicators can be timestamped, allowing them to be correlated with a patient's analyte levels simultaneously.
[0134] In some implementations, the treatment management engine 114 can determine a patient's 1,5-AG clearance rate based on their medication habits. Specifically, because SGLT2 inhibitors accelerate 1,5-AG filtration by lowering the glucose threshold where 1,5-AG is competitively squeezed out, 1,5-AG must be filtered through the patient's kidneys and excreted in the urine. The presence of radiolabeled 1,5-AG in the patient's urine directly indicates the rate of 1,5-AG clearance through the patient's kidneys. For example, if a patient is taking an SGLT2 inhibitor, the patient can be instructed to ingest a radiolabeled 1,5-AG supplement and then provide a urine sample to monitor the clearance of radiolabeled 1,5-AG through the patient's kidneys. Alternatively, as described below, measurements of 1,5-AG clearance without the use of radiolabeled supplements can also be used to determine the patient's kidney health.
[0135] Alternatively, the treatment management engine 114 can instruct patients not taking SGLT2 inhibitors to ingest a radiolabeled 1,5-AG supplement to determine the 1,5-AG absorption rate and 1,5-AG clearance rate. In this example, the patient is also reabsorbing 1,5-AG; therefore, when monitoring the presence of radiolabeled 1,5-AG in the patient's urine to determine the 1,5-AG clearance rate, the 1,5-AG absorption rate can also be inferred based on the patient's 1,5-AG clearance rate and 1,5-AG levels. The 1,5-AG clearance rate and absorption rate can be further monitored based on the patient's known glucose levels during a specified time period to determine how various glucose levels, as described herein, compete with 1,5-AG for reabsorption.
[0136] In some implementations, medication adherence is measured by one or more indicators that indicate how well a patient follows their medication regimen. In some implementations, medication adherence indicators are calculated based on one or more of the following: the time the patient takes medication (e.g., whether the patient takes medication on time or as scheduled), the type of medication (e.g., whether the patient takes the correct type of medication), and the dosage of medication (e.g., whether the patient takes the correct dosage).
[0137] In some implementations, the body temperature index can be calculated by the DAM 116 based on input 130, more specifically based on non-analyte sensor data from the temperature sensor. In some implementations, the heart rate index can be calculated by the DAM 116 based on input 130, more specifically based on non-analyte sensor data from the heart rate sensor. In some implementations, the respiratory rate index can be calculated by the DAM 116 based on input 130, more specifically based on non-analyte sensor data from the respiratory rate sensor.
[0138] In some implementations, the machine learning model deployed by the treatment management engine 114 includes one or more models trained by the training system 140, such as Figure 1 exemplified. Figure 3A The technology used to train machine learning models deployed by the treatment management engine 114 to predict current or future kidney disease status and / or provide recommendations on medical interventions, medications, and / or lifestyle changes is described in more detail.
[0139] Figure 3B This is a flowchart depicting a method 300 for training a machine learning model to classify patients, predict their current or future kidney disease status, and / or provide recommendations to patients based on their disease status. In some embodiments, method 300 is used to train a model for predicting current or future kidney disease status, such as... Figure 1 exemplified.
[0140] Method 300 begins at box 302 and is performed by a training server system (such as...) Figure 1 The illustrated training system 140) obtains data from historical databases (such as...). Figure 1 Data can be retrieved from the illustrated historical database 112. As mentioned herein, the historical database 112 can be used by patients (such as those in continuous analyte monitoring systems and connected mobile health applications) for continuous analyte monitoring systems. Figure 1 The illustrated continuous analyte monitoring system 104 and application 106 provide a repository for current and historical information on patients, as well as data for one or more patients who are not or were not previously patients of the continuous analyte monitoring system 104 and / or application 106. In some embodiments, the historical record database 112 may include one or more datasets of historical patients who are healthy patients, patients with kidney disease, and / or patients with diabetes.
[0141] Retrieving data from the historical database 112 by the training system 140 at box 302 may include retrieving all information maintained by the historical database 112 or any subset thereof. For example, in the case where the historical database 112 stores information on 100,000 patients (e.g., non-patients as well as patients of the continuous analyte monitoring system 104 and application 106), the data retrieved by the training system 140 to train one or more machine learning models may include information on all 100,000 patients or only a subset of data on those patients, such as data associated only with 50,000 patients or data only from the past ten years.
[0142] As an illustrative example, integration with on-premises or cloud-based medical record databases via the Rapid Healthcare Interoperability Resource (FHIR), web application programming interfaces (APIs), Health Level 7 (HL7), and / or other computer interface languages enables the aggregation of healthcare history for baseline assessment, in addition to aggregating de-identifiable patient data from cloud-based repositories. Similarly, when integrating with a medical record database, integration can be achieved either by directly interfacing with an electronic health record system or through one or more intermediary systems (e.g., interface engines, etc.).
[0143] As an illustrative example, at box 302, training system 140 can retrieve information from a historical database 112 of 100,000 patients with various disease states (e.g., healthy patients, patients with kidney disease, and / or patients with diabetes) to train a model to predict the current or future kidney disease state of patients and provide recommendations to them. Each of these 100,000 patients may have a corresponding data record stored in historical database 112 (e.g., based on its corresponding patient profile). Each patient profile 118 may include information such as information about... Figure 3A The information discussed.
[0144] Then, training system 140 uses the information in each record to train an artificial intelligence or ML model (referred to herein as an "ML model" for simplicity). Examples of the types of information included in a patient profile are provided above. The information in each of these records can be characterized (e.g., manually or by training system 140) to produce features that can be used as input features to train the ML model. For example, patient records may include or be used to generate features related to the patient's demographic information (e.g., patient's age, patient's sex, etc.), analyte information (such as 1,5-AG and glucose indicators), non-analyte information, and / or any other data points in the patient record (e.g., input 130, indicator 132, etc.). The features used to train the machine learning model may differ in different implementations.
[0145] In some implementations, each historical patient record retrieved from the historical records database 112 is further associated with tags indicating the patient's medical diagnosis (e.g., a healthy patient, a patient with kidney disease, and / or a patient with diabetes), current kidney disease status, etc. The tags on the records will depend on what the model is trained to predict.
[0146] At box 304, method 300 continues, with training system 140 training one or more machine learning models based on features and labels associated with historical patient records. In some implementations, the training server trains the model by providing features as input. This model may be a new model initialized with random weights and parameters, or it may be partially or fully pre-trained (e.g., based on previous training epochs). Based on the input features, the model in training generates some output. In some implementations, the output may include current or future kidney disease status, and / or recommendations regarding medical interventions, medications, and / or lifestyle changes to improve the patient's kidney disease status, or similar output. Note that the output may be in the form of categorization, recommendations, and / or other types of output.
[0147] In some implementations, the training system 140 compares the generated output with actual labels associated with corresponding historical patient records to calculate a loss based on the difference between the actual and generated results. This loss is then used to refine one or more internal weights and parameters of the model (e.g., via backpropagation) so that the model learns to predict current or future kidney disease status and / or provide recommendations on treatment, medication, and / or lifestyle changes to more accurately improve a patient's kidney disease status.
[0148] One of several machine learning algorithms can be used to train the model described above. For example, one of the following algorithms can be used: supervised learning algorithm, neural network algorithm, deep neural network algorithm, deep learning algorithm, etc.
[0149] At box 306, training system 140 deploys a trained model to make predictions associated with current or future kidney disease status during runtime. In some implementations, this includes transferring an instruction (e.g., a weight vector) of the trained model that can be used to instantiate the model on another device. For example, training system 140 may transfer the weights of the trained model to treatment management engine 114, which may be executed on display device 107, etc. The model can then be used with application 106 to determine a patient's current or future kidney disease status in real time and / or make other types of recommendations discussed above. In some implementations, training system 140 may continue training the model “online” using input features and labels associated with new patient records.
[0150] in addition, Figure 3A The training method illustrated in the example, which uses historical patient records, can also be used to train models using patient-specific records to create more personalized models that make predictions associated with current or future kidney disease status. For example, a model trained using historical patient records and deployed for a specific patient can be further retrained after deployment. For instance, after a model is deployed for a specific patient, it can be retrained to create a more personalized model for that patient. A more personalized model can more accurately predict a patient's disease status based on the patient's own data (rather than just historical patient record data) (including the patient's own inputs 130 and indicators 132).
[0151] Example Methods for Providing Patients with Guidance on Kidney Treatment Management Using Analytical Data from Continuous Monitoring Figure 4AThis is a flowchart illustrating an example method 400 for providing guidance on the management of kidney disease treatment using a continuous analyte monitoring system comprising at least continuous sensors for monitoring glucose and 1,5-AG levels, according to certain embodiments described herein. For example, this method is performed to provide guidance on the management of kidney disease treatment to a patient based on the levels of one or more analytes, including at least glucose and 1,5-AG levels. Figure 4B This is a flowchart illustrating an example method 401 for instructing patients to ensure their analyte levels are within range for subsequent calculation of the patient's reabsorption threshold, as shown in the reference. Figure 4A and Figure 5 As described in A. Methods 400 and 401 are referenced below. Figure 1 Figure 3 and its components are described below. As described in methods 400 and 401, Figures 7A to 9G Its components can be used for continuous monitoring and analysis of material data.
[0152] Method 400 is performed by treatment management engine 114 to collect and / or generate data, such as inputs 130 and indicators 132, including, for example, analyte data, patient information, and non-analyte sensor data (as mentioned above), to provide treatment management guidance related to the presence or staging of kidney disease, and / or recommendations for improving renal function and kidney disease staging. For example, treatment management engine 114 may perform method 400 by monitoring one or more analytes in a patient over multiple time periods, the analytes including at least 1,5-AG. In some examples, glucose and 1,5-AG are monitored simultaneously. In some examples, glucose is measured at a trigger time point, such as when or near the time when 1,5-AG levels begin to decline, determined using the change in 1,5-AG relative to baseline having crossed a threshold and / or the detected rate of decline in 1,5-AG, indicating that a threshold glucose level has been reached where glucose begins to competitively crowd out 1,5-AG, thus deriving a threshold glucose level. In other examples, glucose may not be measured, and reabsorption thresholds may be assigned to patients based on their historical glucose information or on patient demographics based on population data. The treatment management engine 114 then determines one or more glucose and 1,5-AG indicators for the patient and generates a prediction associated with kidney disease staging based at least on the glucose and 1,5-AG indicators. In some implementations, the treatment management engine 114 provides treatment recommendations (e.g., seeking medical intervention) based on the kidney disease prediction.
[0153] As discussed above, the treatment management engine 114 uses one of several models to provide patients with guidance on kidney disease treatment management and / or provides patients with recommendations for seeking medical interventions, medications, and / or lifestyle changes based on input. As described, input includes analyte data (e.g., received by the continuous analyte monitoring system 104), non-analyte data, and / or other patient information (e.g., retrieved from patient profiles or received via patient input). In implementations using rule-based models, for example, the model's input is mapped to specific kidney disease treatment management guidance. For instance, a rule-based model accepts input and determines whether a patient is at risk of developing kidney disease, has kidney disease, or is experiencing worsening kidney disease.
[0154] As an example rule, the treatment management engine 114 can determine that a patient has worsening kidney disease based on input indicating a diagnosis of mild kidney disease and additional analyte data from the continuous analyte monitoring system 104 (indicating that the patient's reabsorption threshold has changed (increased or decreased) from a first reabsorption threshold over time). In another example, the treatment management engine 114 can determine that a patient is developing kidney disease and / or is experiencing worsening kidney disease or renal function, or worsening glycemic management, based on current and / or historical 1,5-AG data (indicating that the patient's baseline 1,5-AG level has decreased over time without the use of medications such as SGLT2 inhibitors). In yet another example, the treatment management engine 114 can determine that a patient is at risk of developing kidney disease based on current and / or historical analyte data (indicating that the reabsorption threshold has changed over time but remains above the threshold indicating mild kidney disease). In yet another example, the treatment management engine 114 can determine that a patient's kidney disease is worsening or improving. In such an example, the treatment management engine 114 can recommend medical interventions for worsening kidney disease to a patient based on current and / or historical 1,5-AG and glucose data (indicating that the patient's reabsorption threshold has decreased over time to a level indicative of kidney function loss). By monitoring the reabsorption threshold, the treatment management engine 114 can determine whether a patient is experiencing kidney or glucose problems. The reabsorption threshold, the rate at which the reabsorption threshold changes (e.g., over hours, days, or longer), the baseline level of the reabsorption threshold, the baseline 1,5-AG, or other glucose or 1,5-AG indicators can be used by the treatment management engine 114 to determine whether a change in the reabsorption threshold is an indication that the patient has developed CKD or progressed to a late stage of CKD, or that the patient has developed AKI. Similarly, a change in the reabsorption threshold when 1,5-AG begins to be cleared rather than reabsorbed can indicate an improvement in kidney function.
[0155] In some implementations, the rules become more granular, such that the combination of rules and / or inputs allows the treatment management engine 114 to output predictions for, for example, kidney disease and / or diabetes.
[0156] In some implementations, instead of rule-based models, AI / ML models are used to output, for example, predictions of kidney disease development, kidney disease progression, and / or recommendations regarding treatment, medication, and / or lifestyle changes. Some or all of the inputs are used as input to the model, which is trained to output disease predictions, disease staging, and / or recommendations regarding the patient's treatment, medication, and / or lifestyle changes. In such cases, the model is trained using a dataset based on a historical cohort of many patients who have been identified as being at risk of developing kidney disease, having progressive kidney disease, various stages of kidney disease (e.g., mild, moderate, and / or severe), and / or diabetes. In such examples, the training dataset is labeled with this identification.
[0157] These rules are used to detect changes in a patient's renal function by determining whether the reabsorption threshold increases or decreases over time. These rules can also be used to determine the underlying cause and / or manner in which the reabsorption threshold changes. For example, an increase in a patient's reabsorption threshold is an indication of early chronic renal failure (e.g., early CKD) or worsening diabetes. Alternatively, a decrease in the reabsorption threshold is an indication of progression to a later stage of chronic renal failure (e.g., late stage of CKD) or acute kidney injury (e.g., AKI).
[0158] Method 400 begins at box 403, where the treatment management engine 114 determines the patient’s first reabsorption threshold at a first time point or first time period, and the patient’s second reabsorption threshold at a second time point or second time period.
[0159] In some implementations, a first reabsorption threshold and a second reabsorption threshold are generated by continuously monitoring the patient's glucose and 1,5-AG levels. For example, the treatment management engine 114 may first determine the patient's first reabsorption threshold (e.g., the glucose level at which the 1,5-AG level is at baseline (i.e., a relative maximum)). The determination of the first reabsorption threshold may be accomplished as an average over several time periods (e.g., a time period within a first time period) where the 1,5-AG level is stable (e.g., 1,5-AG is being reabsorbed into the bloodstream by the kidneys, and the glucose level is insufficient to competitively crowd out the reabsorption of 1,5-AG).
[0160] In another example, the first reabsorption level can be determined using the patient's historical glucose or 1,5-AG levels. In yet another example, the first reabsorption threshold can be determined based on population data of a group of patients similar to the patient, based on patient profiles 118 (e.g., demographic information 120, physiological information 122, disease information 124, medication information 126, or other deterministic factors).
[0161] In one example, the first reabsorption threshold can be set to a static value. In another example, the first reabsorption threshold is a cumulative average of the patient's reabsorption thresholds, which is periodically updated while monitoring glucose and 1,5-AG levels. In one example, the first reabsorption threshold is a reabsorption threshold calculated based on monitored patient glucose and 1,5-AG levels, and this calculated reabsorption threshold is further adjusted based on information within the patient profile 118.
[0162] Once the treatment management engine 114 determines the first reabsorption threshold based on one or more of the examples described above, it can determine the second reabsorption threshold. The treatment management engine 114 determines the second reabsorption threshold by monitoring 1,5-AG and determining when 1,5-AG begins to decline (e.g., exceeding the 1,5-AG baseline threshold or when the rate of change of 1,5-AG begins to decline). When 1,5-AG begins to decline, the patient's glucose level is then measured (or estimated) at or near the time corresponding to the start of the decline. This determination of the second reabsorption threshold can be a single measurement of the reabsorption threshold, or the average, maximum, minimum, or median of the patient's reabsorption threshold over a period of time.
[0163] Following box 403, at box 405, the treatment management engine 114 determines whether a change in the patient's second reabsorption threshold relative to the patient's first reabsorption threshold can be detected. In other words, the treatment management engine 114 compares the patient's second reabsorption threshold with the patient's first reabsorption threshold to determine the change between the two thresholds. In some embodiments, this change can be compared to an expected variation in the reabsorption threshold to determine if the change exceeds the expected variation. For example, if the patient's first reabsorption threshold is 180 mg / dL, the expected variation could be 5 mg / dL. Therefore, if the patient's second reabsorption threshold is 176 mg / dL, the treatment management engine 114 will not detect a change. Alternatively, if the patient's second reabsorption threshold is 170 mg / dL, the treatment management engine 114 detects a change. If the treatment management engine 114 detects a change, method 400 continues to box 407. If not, the treatment management engine 114 can return to box 403 to continue monitoring the first and second reabsorption thresholds.
[0164] At box 407, it is determined whether the change in the second reabsorption threshold relative to the first reabsorption threshold is an increase or a decrease. That is, whether the second reabsorption threshold (i.e., the latest reabsorption threshold) at the current time period or point in time is higher or lower than the patient's first reabsorption threshold. If an increase is detected, method 400 proceeds to box 409. On the other hand, if a decrease is detected, method 400 proceeds to box 413.
[0165] At box 409, in response to the treatment management engine 114 determining that a change in the reabsorption threshold indicates an increase in the reabsorption threshold, the treatment management engine 114 determines how this increase occurs. For example, an increase in the reabsorption threshold is often an indication of worsening glycemic control and early chronic renal failure or declining renal function.
[0166] However, if an increase in the reabsorption threshold indicates recovery from a previous decrease in the reabsorption threshold or from a reabsorption threshold that was previously below the expected threshold (e.g., below the healthy reabsorption threshold of 180 mg / dL), then the increase indicates improvement in a condition that previously caused the patient's reabsorption threshold to decrease to an undesirable level. Such conditions include later stages or exacerbations of chronic renal failure (e.g., as a result of advanced CKD) or acute deterioration of renal function (e.g., as a result of AKI). The detection of these conditions is discussed in more detail below.
[0167] Following box 409, at box 411, the treatment management engine 114 provides treatment management guidance to the patient based on a detected increase in the patient's reabsorption threshold. If the increase in the patient's reabsorption threshold indicates a recovery from a previous decrease in the reabsorption threshold, or a recovery from a reabsorption threshold below the expected threshold, the treatment management engine 114 may continue to monitor the reabsorption threshold over time. If the increase in the reabsorption threshold is not a recovery from a previous decrease, the treatment management engine 114 provides treatment management guidance to the patient to seek medical intervention for early chronic renal failure and / or declining kidney health.
[0168] At box 413, in response to the treatment management engine 114 determining that a change in the reabsorption threshold indicates a decrease in the reabsorption threshold, the treatment management engine 114 determines how this decrease occurs. This determination may be based on the magnitude of the change in the reabsorption threshold over a time period between a first reabsorption threshold and a second reabsorption threshold, the time taken for the change to occur, and whether one or more changes across several time periods have been detected.
[0169] There are several possible reasons for a decreased reabsorption threshold. The first is chronic deterioration of kidney function, which occurs, for example, when a patient progresses to a late stage of chronic kidney failure (e.g., late stage CKD). In this case, the decrease in the patient's reabsorption threshold will be gradual and will occur over a long period of time (e.g., weeks, months, or years). Therefore, if the treatment management engine 114 determines that the reabsorption threshold is gradually decreasing over weeks, months, or years, the treatment management engine 114 determines that the patient has or is developing late-stage chronic kidney failure.
[0170] Alternatively, a relatively abrupt change in the reabsorption threshold (e.g., within hours or days, rather than weeks, months, or years) typically indicates acute kidney failure, which may indicate AKI. Therefore, if this change occurs abruptly, the treatment management engine 114 determines that the patient is experiencing AKI. The treatment management engine 114 can continue to monitor the patient's reabsorption threshold to determine if the threshold continues to decrease, thus indicating a further decline in kidney function over time. If the reabsorption threshold continues to decrease over time after an abrupt decrease, the treatment management engine 114 determines that the patient has developed chronic kidney failure due to AKI.
[0171] Alternatively, if a decreased 1,5-AG clearance rate is observed, and this change occurs at a slower rate but is also observed at a lower reabsorption threshold, the patient may be experiencing damage to the proximal convoluted tubules of the kidney. This would also indicate AKI. In another example, identifying the underlying cause as CKD rather than AKI could be based on prior patient history; that is, if the patient is in a late stage of CKD, the engine could determine that the patient is in end-stage CKD with a more rapid change in the 1,5-AG reabsorption threshold.
[0172] Conversely, as the treatment management engine 114 continues to monitor the patient's reabsorption threshold, the reabsorption threshold may increase over time after decreasing. In one example, this could be a gradual increase over time, such as in response to food intake, or it could occur in response to the patient taking a 1,5-AG supplement. In this example, the rate at which the reabsorption threshold increases can also be determined. The treatment management engine 114 can then use this increase and the rate at which the reabsorption threshold increases to determine whether AKI has been reversed (e.g., an increase in the reabsorption threshold to the healthy reabsorption threshold of 180 mg / dL is detected) and the time taken for reversal. This pattern of reabsorption threshold increase, including the rate of increase, can also be used to titrate medications used to assist in AKI reversal.
[0173] Therefore, an improvement in the patient's renal function is detected if a decrease in the reabsorption threshold follows a previous increase in the reabsorption threshold from the first reabsorption threshold, or if the decrease progresses toward a more acceptable reabsorption threshold than the patient has previously experienced (i.e., the decrease in the reabsorption threshold brings the reabsorption threshold closer to the healthy reabsorption threshold of 180 mg / dL).
[0174] Following box 413, at box 415, the treatment management engine 114 can provide treatment management guidance to the patient based on a detected decrease in the patient's reabsorption threshold. If the decrease in the reabsorption threshold follows a previous increase in the reabsorption threshold (e.g., from a first reabsorption threshold), or if the decrease progresses toward a healthy reabsorption threshold (e.g., 180 mg / dL), the treatment management engine 114 can provide the patient with treatment management guidance indicating that their renal function has improved.
[0175] Alternatively, if a patient experiences a gradual decline in the reabsorption threshold over weeks, months, or years, the treatment management engine 114 can provide the patient with treatment management guidance to seek medical intervention for CKD. If a patient experiences a sudden decline in the reabsorption threshold over hours or days, the treatment management engine 114 can provide the patient with treatment management guidance to seek medical intervention for AKI.
[0176] In some implementations, patients are prescribed medications that affect their reabsorption threshold, such as SGLT2 inhibitors. If a patient is known to be taking an SGLT2 inhibitor, the treatment management engine 114 determines the patient's reabsorption threshold when not taking the SGLT2 inhibitor and compares the reabsorption threshold before the patient started taking the SGLT2 inhibitor with the reabsorption threshold after the patient started taking the SGLT2 inhibitor. If the time periods between when the patient took and did not take the SGLT2 inhibitor are consecutive or close in time (e.g., several days or weeks apart), the lower reabsorption threshold when the patient took the SGLT2 inhibitor can be attributed to the SGLT2 inhibitor. In this case, the treatment management engine 114 determines that the reduction in the reabsorption threshold is not due to an improvement in kidney health (e.g., after a previous increase in the reabsorption threshold) or to the development of AKI or CKD as described in reference box 413. This change in the reabsorption threshold caused by the SGLT2 inhibitor can be used as individual and / or population data to determine the expected reduction in the reabsorption threshold caused by the SGLT2 inhibitor.
[0177] In some implementations, the treatment management engine 114 determines a patient's SGLT2 inhibitor adherence and / or the patient's ideal SGLT2 inhibitor dosage based on the patient's reabsorption threshold. Specifically, if a specific SGLT2 inhibitor dosage is prescribed to a patient, the treatment management engine 114 determines the patient's expected reabsorption threshold based on the patient's first reabsorption threshold and / or the reabsorption threshold of a group of patients taking similar SGLT2 inhibitor dosages. If the patient is not taking the SGLT2 inhibitor dosage appropriately, the SGLT2 inhibitor dosage is below the effective level for the patient, or the patient has become desensitized to the SGLT2 inhibitor dosage, the patient may not experience the expected reduction in reabsorption threshold in response to their SGLT2 inhibitor dosage. In some implementations, the treatment management engine 114 then provides feedback to the patient to take the SGLT2 inhibitor as prescribed, increase the SGLT2 inhibitor dosage, or switch to an alternative medication to achieve the desired reduction in the reabsorption threshold.
[0178] In some implementations, in addition to determining the presence of kidney disease and / or monitoring kidney function over time, the treatment management engine 114 also determines a diagnosis or risk of health complications related to kidney disease and / or diabetes based on the patient's reabsorption threshold. For example, the treatment management engine 114 determines the risk or diagnosis of retinopathy and / or microvascular disease based on various additional analyte indicators, such as the time glucose is within a target range or the frequency of hyperglycemia. Based on the determined risk, the treatment management engine 114 provides feedback to the patient to seek follow-up testing to confirm the risk of retinopathy and / or microvascular disease. In some implementations, if the patient is known to have a condition or disease that results in low and / or altered 1,5-AG levels (making it possible that 1,5-AG levels may not accurately characterize kidney function), the treatment management engine 114 determines that the patient's kidney function cannot be accurately determined. For example, if, based on patient input, the treatment management engine 114 determines that the patient has end-stage renal failure, is on dialysis, has advanced cirrhosis, is pregnant, is receiving steroid treatment, etc., the treatment management engine 114 determines that 1,5-AG cannot accurately determine the patient's kidney function. In one example, a patient in such a case could take a 1,5-AG supplement to increase their 1,5-AG levels, thus allowing for accurate determination of kidney function even in patients with such conditions.
[0179] Figure 4B Method 401 is an example method for providing guidance to patients to ensure that their analyte levels are within the range. This method may be performed before or during method 400, or before or during method 500, for example, to calculate the patient's reabsorption threshold.
[0180] Method 401 begins at box 402, whereby the treatment management engine 114 uses a continuous analyte monitoring system 104 to monitor the patient's levels of one or more analytes. For example, the continuous analyte monitoring system 104 includes a continuous glucose and / or 1,5-AG sensor 202 to measure the patient's glucose and / or 1,5-AG levels. Additionally, the treatment management engine 114 receives data from patient input. Patient input can be received in various ways. For example, input can be received or retrieved from a patient profile 118, which includes demographic information 120, physiological information 122, disease progression information 124, medication information 126, inputs 130, indicators 132, etc. Input can also be received as patient input via the patient interface of the display device 107.
[0181] In some implementations, monitoring a patient's 1,5-AG and / or glucose levels may optionally include determining one or more 1,5-AG and / or glucose parameters, such as reabsorption threshold, rate of change, baseline, minimum, or maximum, based on measured glucose and / or 1,5-AG levels. At box 406, the treatment management engine 114 determines, based on glucose and / or 1,5-AG levels, from historical patient data and / or patient population data, that a patient's glucose level is out of range (e.g., greater than 110 mg / dL) and / or the patient's 1,5-AG level is out of range (e.g., less than 25 μg / mL).
[0182] At box 410, the treatment management engine 114 determines whether the patient's glucose level is outside the range (e.g., below 70 mg / dL or above 110 mg / dL). If the patient's glucose level is above the ideal range (e.g., based on the patient's historical glucose range and / or based on population data), the treatment management engine 114 proceeds to box 420 to determine whether the patient has recently (e.g., within the past 3 hours) ingested food and / or a meal. If the patient has recently ingested food and / or a meal, the treatment management engine 114 proceeds to box 422. At box 422, the treatment management engine 114 returns to box 402 to continue monitoring glucose levels until glucose levels return to normal (e.g., below 110 mg / dL).
[0183] Alternatively, if the patient has not recently consumed food and / or meals, the treatment management engine 114 proceeds to box 424. At box 424, the treatment management engine 114 provides the patient with treatment management guidance to seek medical intervention in response to the risk and / or presence of hyperglycemia / diabetes.
[0184] Returning to box 410, if the patient's glucose level is below the ideal range (e.g., below 70 mg / dL), the treatment management engine 114 proceeds to box 426. At box 426, the treatment management engine 114 recommends that the patient ingest complex carbohydrates, ingest small amounts of glucose over time, and / or administer an insulin bolus after food or a meal to increase glucose levels. By ingesting complex carbohydrates and / or administering an optional insulin bolus (e.g., long-acting insulin or low-dose rapid-acting insulin) after a meal, the patient can ensure that their glucose levels gradually increase over time. By ingesting small amounts of glucose over time, the amount of glucose can be metered so that the patient reaches specific glucose levels after each given amount of glucose ingested, such as 100 mg / dL, 110 mg / dL, 120 mg / dL, 130 mg / dL, 140 mg / dL, etc. In some other embodiments, instead of the patient ingesting glucose over time, glucose can be administered, for example, via intravenous infusion, to control the patient's glucose levels when the treatment management engine 114 determines a reabsorption threshold. In each of the above embodiments, once glucose and 1,5-AG levels are within the range, the gradual increase in glucose allows the treatment management engine 114 to accurately determine the patient's reabsorption threshold.
[0185] In some other embodiments, the treatment management engine 114 predicts or extrapolates a patient's reabsorption threshold based on the rate of change in the patient's glucose and / or 1,5-AG levels. For example, if a patient's glucose levels increase too rapidly, the treatment management engine 114 determines the rate of change in the patient's glucose levels and the time when 1,5-AG levels begin to decrease to determine the patient's reabsorption threshold (e.g., the glucose level at which glucose begins to competitively crowd out 1,5-AG absorption). Additionally or alternatively, the treatment management engine 114 predicts or extrapolates the patient's reabsorption threshold based on the negative rate of change in glucose (e.g., glucose clearance rate) and 1,5-AG levels when glucose levels begin to return to baseline after an increase (such as when insulin begins to clear glucose from the body or when the patient completes a period of exercise). For example, when glucose levels begin to decrease (in response to insulin or otherwise), the treatment management engine 114 determines an approximate glucose level at which 1,5-AG begins to be reabsorbed based on the time when 1,5-AG levels begin to increase and the glucose clearance rate, thereby indicating the patient's reabsorption threshold.
[0186] In some implementations, the treatment management engine 114 recommends that the patient ingest glucose as needed to induce mild hyperglycemia, combined with insulin administration, to ensure that glucose levels gradually increase to the desired level over time. The treatment management engine 114 continues to monitor glucose levels over time to determine when the patient's glucose levels are within the desired range.
[0187] Returning to box 410, if the patient's glucose level is within the expected range (e.g., within the desired range), the treatment management engine 114 proceeds to box 428. At box 428, the treatment management engine 114 determines if the patient's 1,5-AG level is low (e.g., below 25 µg / mL). If the patient's 1,5-AG level is low, the treatment management engine 114 proceeds to box 432. At box 432, the treatment management engine 114 provides the patient with treatment management guidance to ingest foods and / or supplements containing 1,5-AG. Although 1,5-AG is not a critical compound that must be supplemented in the body, the 1,5-AG level must be above a threshold (e.g., greater than 25 µg / mL) to capture the patient's reabsorption threshold and thus provide the patient with treatment management guidance for kidney disease. The treatment management engine 114 continues to monitor the patient's 1,5-AG level to determine when the patient's 1,5-AG level returns to the desired range.
[0188] Starting at box 428, if the patient's 1,5-AG level is not low (e.g., above 25 µg / mL), the treatment management engine 114 returns to box 430. At box 430, the treatment management engine 114 returns to box 406 to determine whether the patient's glucose and 1,5-AG levels are within ranges, thereby monitoring the patient's reabsorption threshold.
[0189] In some implementations, the patient's 1,5-AG levels do not increase in response to the intake of foods and / or supplements containing 1,5-AG. The treatment management engine 114 then monitors the patient over time (e.g., over a 2-week period) to determine if the patient's 1,5-AG levels increase spontaneously. If the patient's 1,5-AG levels do not increase spontaneously over time, the treatment management engine 114 determines that the patient has impaired renal function or that the patient has not ingested foods containing 1,5-AG. In some implementations, if the patient's 1,5-AG levels remain low (e.g., below 25 µg / mL) for an extended period (e.g., more than 2 weeks), indicating that the patient excretes 1,5-AG faster than healthy patients and / or reabsorbs 1,5-AG less rapidly than healthy patients, this indicates renal dysfunction.
[0190] In some implementations, in patients with kidney disease, the variability of 1,5-AG over time may be higher than expected and / or increase over time. Additionally, patients with impaired kidney function and / or kidney disease may have lower baseline 1,5-AG levels than healthy patients. If the treatment management engine 114 determines that a patient's 1,5-AG levels exhibit high variability over time and / or that the patient's baseline 1,5-AG is lower than that of healthy patients, the treatment management engine 114 provides the patient with treatment management guidance for impaired kidney function.
[0191] Figure 5 Example method 500 is described, according to certain embodiments of this disclosure, using an analyte monitoring system configured to measure at least 1,5-AG levels to determine a patient's filtration score and provide guidance for the management of kidney disease treatment. Method 500 is referenced below. Figure 1 Figure 3 and its components are described below. As described in method 500. Figures 7A to 9G Its components can be used for continuous monitoring and analysis of material data.
[0192] Method 500 begins at box 502, where the treatment management engine 114 detects a decrease in 1,5-AG levels. In some embodiments, the treatment management engine 114 detects a decrease in 1,5-AG levels if the patient reaches a specified or defined reabsorption threshold, which indicates that the patient's 1,5-AG levels have begun to decline because 1,5-AG is cleared from the body rather than reabsorbed through the kidneys. In some embodiments, as the treatment management engine 114 continuously monitors the patient's 1,5-AG levels, a decreasing trend in 1,5-AG levels is detected or predicted. The treatment management engine 114 predicts or detects a decreasing trend in 1,5-AG levels based on historical information, based on 1,5-AG levels indicating a negative rate of change, or based on 1,5-AG levels that meet a change threshold relative to the baseline 1,5-AG level (which indicates a decrease in 1,5-AG).
[0193] Once the treatment management engine 114 detects a decrease in 1,5-AG levels at box 502, it proceeds to box 504. At box 504, the treatment management engine 114 initiates a monitoring period at time T0. In some embodiments, the treatment management engine 114 may instruct the patient to fast overnight before initiating the monitoring period to ensure the patient's glucose levels reach baseline levels and that the patient's 1,5-AG levels are at a stable baseline level (e.g., maximum). The treatment management engine 114 then instructs the patient to ingest a specified amount of glucose to increase the patient's glucose levels to a known level (e.g., reaching or exceeding the patient's reabsorption threshold). This known level may be a glucose level that begins to competitively displace 1,5-AG, resulting in the initiation of 1,5-AG clearance and a decrease in 1,5-AG levels. In some embodiments, the filtration score is calculated via a urine sample. In such an example, at T0, the patient is prompted to provide a urine sample. This urine sample may be discarded because it serves to establish a baseline in the patient for comparison with future urine samples collected in subsequent steps.
[0194] At box 506, the treatment management engine 114 determines the first 1,5-AG level at T0 (e.g., the initial level of 1,5-AG). For example, if the analyte measurements are periodic, the first 1,5-AG level will be the 1,5-AG measurement closest to T0, such as the 1,5-AG measurement at T0, just before T0, or immediately after T0. In some embodiments, the first 1,5-AG level corresponding to time T0 is calculated using the average of one or more periodic 1,5-AG measurements (e.g., 3 to 5 measurements) over a period of time including time T0.
[0195] Method 500 then proceeds to box 508, where the treatment management engine 114 periodically (e.g., every 1 minute, 5 minutes, 10 minutes, etc.) monitors the patient's 1,5-AG levels. Furthermore, in some embodiments, the treatment management engine 114 periodically determines the rate of change of 1,5-AG, which may be the same as or different from the period for monitoring 1,5-AG levels.
[0196] At box 510, the treatment management engine 114 determines a second 1,5-AG level at a second time point T1 based on the determination that a predetermined amount of 1,5-AG has been cleared from the body. For example, T1 could be at or before the time point at which the patient's 1,5-AG level reaches a threshold level indicating that 1,5-AG has been cleared from the body (e.g., 0 µg / mL, below 10 µg / mL, or another predefined threshold). In some embodiments, T1 is the time when the measured rate of decrease in 1,5-AG falls below a threshold rate of change (e.g., a rate of change of 0 or close to 0, or less than 5 µg / mL per minute), indicating a slowing rate of decrease. A slowing rate of decrease indicates that 1,5-AG clearance has slowed or stopped.
[0197] Alternatively or additionally, T1 may be based on glucose levels measured during the monitoring period. As described above, when glucose levels reach a specific level (e.g., a reabsorption threshold), glucose competitively displaces 1,5-AG from renal reabsorption. Therefore, at this specific glucose level, 1,5-AG is cleared from the body, and a decrease in 1,5-AG levels is observed. Thus, once a decrease in 1,5-AG levels is detected, the treatment management engine 114 can begin monitoring glucose levels. If the treatment management engine 114 detects a decrease in glucose levels toward the patient's reabsorption threshold, then T1 is the time before the glucose level begins to decrease, so as to capture 1,5-AG levels before they begin to be reabsorbed by the kidneys into the bloodstream (e.g., 1,5-AG levels will begin to stabilize).
[0198] In another example, T1 is fixed at a predefined time after T0. For example, T1 could be fixed at 15 minutes, 20 minutes, 30 minutes, or any similar time period from T0. In yet another example, T1 is any time after T0 when the treatment management engine 114 detects a decrease in 1,5-AG levels relative to T0. For example, in the case of a urine test, T1 is the time to collect a urine sample. For example, the treatment management engine 114 prompts the patient to provide a urine sample at T1, where T1 is calculated based on any of the methods mentioned herein. In some embodiments, the treatment management engine 114 instructs the patient to maintain or increase their glucose levels relative to T0 throughout the period between T0 and T1 to ensure that 1,5-AG is cleared from the body rather than reabsorbed throughout the period between T0 and T1. For example, the treatment management engine 114 could instruct the patient to consume a glucose drink or glucose supplement to maintain or increase the patient's glucose levels. Alternatively, the treatment management engine 114 can guide patients to take medications (e.g., SGLT2 inhibitors) to clear 1,5-AG from the body, regardless of the patient's glucose levels.
[0199] Once the treatment management engine 114 determines T1, it determines the second 1,5-AG level at T1. For example, since 1,5-AG measurements are periodic, the 1,5-AG level closest to T1 is determined, such as the 1,5-AG measurement at T1, just before T1, or immediately after T1. In some embodiments, the second 1,5-AG level corresponding to T1 is calculated using the average of one or more periodic 1,5-AG measurements (e.g., 3 to 5 measurements) taken over a period including T1.
[0200] At box 512, the treatment management engine 114 calculates a value representing the total clearance of 1,5-AG based on the difference between the first 1,5-AG level corresponding to T0 and the second 1,5-AG level corresponding to T1, calculated in boxes 506 and 510, respectively. Alternatively or additionally, if a urine sample is collected at T1, a urine test is used to measure the total clearance of 1,5-AG.
[0201] Next, at box 514, the treatment management engine 114 calculates the total 1,5-AG mass removed from the body via urine. The 1,5-AG volume is calculated as follows: (1) based on the urine volume when a urine test is used, or (2) based on the patient's total body water volume when a urine test is not used.
[0202] When using urine testing, the total mass of 1,5-AG is the urine concentration of 1,5-AG at T1 multiplied by the volume of urine collected.
[0203] Without using a urine test, the total mass of 1,5-AG is calculated by multiplying the difference between the first 1,5-AG level at T0 and the second 1,5-AG level at T1 by the total body water volume.
[0204] Total body water volume (TBW) is an estimate of the volume of usable water in the body and can be calculated using the patient's weight, age factor multiplier, and sex factor multiplier. Other multipliers may also be included to account for other factors that can contribute to differences in the patient's water-to-weight ratio. Equation 3 shows an example of a total body water volume estimate (TBW) calculated solely based on the patient's weight; Equation 4 shows an example of TBW calculation in men; and Equation 5 shows an example of TBW calculation in women. TBW = body weight Equation 3, 0.58 TBW = 2.447 - (0.09156 (age) + (0.1074) Height) + (0.3362) Equation 4 (body weight) TBW = (0.1069 Height) + (0.2466) (Weight) - 2.097 Equation 5 At box 516, the treatment management engine 114 determines the patient's filtration score. The patient's filtration score is determined by: (1) dividing the total volume of cleared 1,5-AG as determined at box 514 by the mean 1,5-AG level from T0 and T1, and then (2) dividing the output of (1) by the time between T0 and T1. The filtration score may be representative of or similar to the GFR score currently measured in the laboratory. A filtration score calculated using real-time analyte levels can be more effective by using analyte levels that are averaged over time or selected at the optimal time based on observed patient patterns.
[0205] At box 518, the treatment management engine 114 provides treatment management guidance to the patient based on the patient's filtration score. For example, the treatment management engine 114 can display the filtration score to the patient on display device 107, can use the filtration score to create graphs for the patient to view on display device 107, and can use the filtration score to provide treatment management guidance to the patient. The filtration score is an indicator of a patient's kidney health; therefore, calculating the filtration score multiple times over a specified time period (e.g., one week, one month, or another time period) can be used to calculate an average filtration score, which can then be displayed to the patient as their filtration score or used to provide treatment management guidance.
[0206] The filtration score can be further plotted and / or stored in memory to be compared with one or more filtration scores over various time periods, thereby detecting patterns. Detected patterns can indicate deterioration or improvement in renal function. For example, if a patient exhibits a higher filtration score over time, the treatment management engine 114 determines that the patient's renal function is improving. Alternatively, if a patient exhibits a slower filtration rate over time, the treatment management engine 114 determines that the patient's renal function has deteriorated. This determination of the patient's renal function over time can be displayed to the patient via a display device 107.
[0207] Figure 6 This is a block diagram depicting a computing device 600 configured to execute a treatment management engine (e.g., treatment management engine 114) according to certain embodiments disclosed herein. Although depicted as a single physical device, in embodiments, computing device 600 may be implemented using virtual devices and / or across multiple devices (such as in a cloud environment). As illustrated, computing device 600 includes a processor 605, memory 610, storage device 615, network interface 625, and one or more I / O interfaces 620. In the illustrated embodiment, processor 605 retrieves and executes programming instructions stored in memory 1010 and stores and retrieves application data residing in storage device 615. Processor 605 typically represents a single CPU and / or GPU, multiple CPUs and / or GPUs, a single MCU, a CPU and / or GPU with multiple processing cores, etc. Memory 610 is typically included to represent random access memory. Storage device 615 can be any combination of disk drives, flash-based storage devices, etc., and can include fixed and / or removable storage devices, such as fixed disk drives, removable memory cards, caches, optical storage devices, network-attached storage devices (NAS), or storage area networks (SANs).
[0208] In some embodiments, input and output (I / O) devices 635 (such as keyboards, monitors, etc.) may be connected via I / O interface 620. Furthermore, computing device 600 may be communicatively coupled to one or more other devices and components (such as patient database 110) via network interface 625. In some embodiments, computing device 600 is communicatively coupled to other devices via a network (which may include the Internet, a local area network, etc.). This network may include wired connections, wireless connections, or a combination of wired and wireless connections. As illustrated, processor 605, memory 610, storage device 615, network interface 625, and I / O interface 620 are communicatively coupled via one or more interconnects 630. In some embodiments, computing device 600 represents a display device 107 associated with a patient. In some embodiments, as discussed above, display device 107 may include the patient's laptop, computer, smartphone, etc. In another embodiment, computing device 600 is a server operating in a cloud environment.
[0209] In the illustrated embodiment, storage device 615 includes patient profile 118. Memory 610 includes a treatment management engine 114, which itself includes a DAM 116. The treatment management engine 114 is executed by computing device 600 to perform… Figure 3B Method 300 Figure 4A Method 400 Figure 4B The operation in method 401, and / or Figure 5 The operation in method 500.
[0210] As mentioned above, regarding Figure 1 The described continuous analyte monitoring system 104 can be a multi-analyte sensor system including multiple analyte sensors. Figures 7 and 8 illustrate example multi-analyte sensors for measuring multiple analytes.
[0211] During the general operation of an analyte measuring device, biosensor, sensor, sensing region, sensing portion, or sensing mechanism, a biological sample (e.g., blood or interstitial fluid) or its components are contacted directly or after passing through one or more membranes with an enzyme (e.g., glucose oxidase), ionophore, DNA, RNA, or a protein or aptamer, such as one or more periplasmic binding proteins (PBPs) or their mutants or fusion proteins having one or more analyte-binding regions, each region capable of specifically or reversibly binding to and / or reacting with at least one analyte. The interaction between the biological sample or its components and the analyte measuring device, biosensor, sensor, sensing region, sensing portion, or sensing mechanism results in signal transduction that allows for qualitative, semi-qualitative, quantitative, or semi-quantitative determination of analyte levels (e.g., glucose, pyranose, ketones, lactate, potassium, etc.) in the biological sample.
[0212] In one example, the sensing region or sensing portion may include at least a portion of a conductive substrate or at least a portion of a conductive surface (e.g., a wire (coaxial) or conductive trace or a substantially planar substrate including substantially planar traces) and a membrane. In one example, the sensing region or sensing portion may include a non-conductive body; an electrochemically reactive surface formed at one location on the body and an electronically connected working electrode, reference electrode, and counter electrode (optionally) formed at another location on the body; and a sensing membrane attached to the body and covering the electrochemically reactive surface. In some examples, the sensing membrane may also include an enzyme domain (e.g., an enzyme domain) and an electrolyte phase (e.g., a free-flowing liquid phase including an electrolyte-containing fluid as further described below). These terms are broad enough to include the entire device or only its sensing portion (or something thereof).
[0213] In another example, the sensing region may include one or more periplasmic binding proteins (PBPs) (including mutants or fusion proteins thereof), or an aptamer having one or more analyte-binding regions, each capable of specifically and reversibly binding at least one analyte. Changes in the aptamer or mutations in the PBP may contribute to or alter one or more binding constants, long-term protein stability (including thermal stability), to bind the protein to a specific encapsulation matrix, membrane, or polymer, or to attach a detectable reporter group or “tag” to indicate changes in the binding region or to transduce a signal corresponding to one or more analytes present in the biofluid. Specific examples of changes in the binding region include, but are not limited to, changes in hydrophobic / hydrophilic environments, three-dimensional conformational changes, changes in the orientation of amino acid / nucleic acid side chains in the protein binding region, and the redox state of the binding region. Such changes in the binding region provide transduction of a detectable signal corresponding to one or more analytes present in the biofluid.
[0214] In one example, the sensing region determines selectivity between one or more analytes, such that only the analyte that must be measured produces (transduces) a detectable signal. This selection can be based on any chemical or physical identification of the analyte by the sensing region, where the chemical composition of the analyte remains unchanged, or where the sensing region induces or catalyzes an analyte reaction that alters the chemical composition of the analyte.
[0215] As used herein, the term "sensitivity" is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its specific or custom meaning), and refers to (but is not limited to) the quantity of a signal (e.g., in the form of current and / or voltage) generated by a predetermined amount (unit) of analyte. For example, in one example, the sensor has a sensitivity (or slope) of about 1 picoampere to about 100 picoampere current per 1 mg / dL of analyte.
[0216] The phrase "signal medium" or "transmission medium" should be considered to include any form of modulated data signal, carrier wave, etc. The phrase "modulated data signal" refers to a signal whose one or more characteristics are set or altered in a manner that encodes information in the signal.
[0217] As used herein, the term "transduction" and its grammatical equivalents are broad terms and will be given to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) optical, electrical, electrochemical, acoustic / mechanical, or colorimetric techniques and methods. Electrochemical properties include the modulation or measurement of current and / or voltage, inductance, capacitance, impedance, transconductance, and charge. Optical properties include absorbance, fluorescence / phosphorescence, fluorescence / phosphorescence decay rate, wavelength shift, dual-wavelength phase modulation, bioluminescence / chemiluminescence, reflectivity, light scattering, Raman shift, and refractive index. For example, a sensing region transduces the identification of an analyte into a semi-quantitative or quantitative signal.
[0218] As used herein, the phrase "transduction element" is a broad term and will be given its common and conventional meaning (and not limited to a specific or custom meaning) to those skilled in the art, and refers to (but not limited to) an analyte recognition portion capable of directly or indirectly facilitating the transduction of a detectable signal corresponding to the presence and / or concentration of the identified analyte. In one example, a transduction element is one or more enzymes, one or more aptamers, one or more ion carriers, one or more capture antibodies, one or more proteins, one or more biological cells, one or more oligonucleotides, and / or one or more single-stranded or double-stranded DNA or RNA portions. Transdermal continuous multianalyte sensors can be used in vivo for various time lengths. The continuous multianalyte sensor system discussed herein can be a percutaneous device, as a portion of the device can be inserted through the host's skin into the underlying soft tissue, while another portion remains on the surface of the host's skin. In one aspect, to overcome problems associated with noise or other sensor functionality in the short term, one example employs a material that facilitates the formation of a fluid capsule around the sensor, such as a porous biointerface membrane or matrix that creates space between the sensor and surrounding tissue. In some examples, the sensor is provided with a spacer adapted to provide a fluid capsule between the sensor and the user's tissue. It is believed that the spacer (e.g., a biointerface material, matrix, structure, etc., as described in more detail elsewhere in this article) transports oxygen and / or glucose to the sensor.
[0219] Membrane systems The membrane systems disclosed herein are suitable for use in implantable devices that come into contact with biological fluids. For example, the membrane systems can be used with implantable devices such as those for monitoring and determining analyte levels in biological fluids, e.g., devices for monitoring glucose levels in individuals with diabetes. In some examples, the analyte measurement device is a continuous device. The analyte measurement device can employ any suitable sensing element to provide the raw signal, including but not limited to sensing elements involving enzyme elements, chemical elements, physical elements, electrochemical elements, spectrophotometric elements, current measuring elements, potentiometric elements, polarimetric elements, thermal measuring elements, radiation measuring elements, immunochemical elements, etc.
[0220] Suitable membrane systems for the aforementioned multianalyte systems and devices may include, for example, membrane systems disclosed in U.S. Patent Nos. 6,015,572, 5,964,745 and 6,083,523, the entire contents of which are incorporated herein by reference for their teachings on membrane systems.
[0221] Typically, membrane systems comprise multiple domains, such as electrode domains, interference domains, enzyme domains, resistivity domains, and biointerface domains. Membrane systems can be deposited on exposed electroactive surfaces using known thin-film techniques (e.g., vapor deposition, electrodeposition, plasma polymerization, electrospraying) or thick-film techniques (spraying, dip coating, spin coating, pad printing, screen printing, discrete distribution, inkjet deposition, slot coating, brush coating, thin-film coating, droplet coating, etc.). Additional steps, such as drying, annealing, and curing (e.g., UV curing, thermal curing, moisture curing, radiation curing, etc.), can be applied after membrane material deposition to enhance certain properties, such as mechanical properties, signal stability, and selectivity. In a typical process, after depositing the resistivity domain film, a bio-interface / drug release layer with a "dry film" thickness of approximately 0.05 micrometers (μm) or less, ranging from approximately 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 11 μm, 12 μm, 13 μm, 14 μm, 15 μm, or 16 μm, is formed. "Dry film" thickness refers to the thickness of the cured film produced by casting from a coating formulation using standard coating techniques.
[0222] In some examples, the biointerface / drug release layer is formed from a biointerface polymer comprising one or more membrane domains and one or more zwitterionic repeating units, the membrane domains comprising polyurethane and / or polyurea segments. In some examples, the biointerface / drug release layer coating is formed from a polyurethane urea incorporating carboxybetaine groups in polymeric and nonionic hydrophilic polyethylene oxide segments, wherein the polyurethane urea polymer is dissolved in an organic or non-organic solvent system according to a predetermined coating formulation, crosslinked with an isocyanate crosslinking agent, and cured at a moderate temperature of about 50°C. The solvent system can be a single solvent or a mixture of solvents to aid in the dissolution or dispersion of the polymer. The solvent can be selected as a polymerization medium or added after polymerization. The solvent is selected from solvents with low boiling points to facilitate drying and have low toxicity for implant applications. Examples of such solvents include aliphatic ketones, esters, ethers, alcohols, hydrocarbons, etc. Depending on the final thickness of the biointerface / drug release layer and the solution viscosity (related to the percentage of polymer solids), the coating can be applied in a single step or multiple repeated steps (such as impregnation) of the selected process to achieve the desired thickness. In other examples, the bioprotective polymer is formed from polyurethane urea in which carboxylic acid groups and carboxybetaine groups are incorporated into polymeric and nonionic hydrophilic polyethylene oxide segments. The polyurethane urea polymer is dissolved in an organic or non-organic solvent system in the coating formulation and crosslinked with carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)) and cured at a moderate temperature of about 50°C.
[0223] In other examples, the biointerface / drug release layer coating is formed from a polyurethane urea incorporating sulfobetaine groups into polymeric and nonionic hydrophilic polyethylene oxide segments. The polyurethane urea polymer is dissolved in an organic or non-organic solvent system according to a predetermined coating formulation, crosslinked with an isocyanate crosslinking agent, and cured at a moderate temperature of approximately 50°C. The solvent system can be a single solvent or a mixture of solvents to aid in the dissolution or dispersion of the polymer. The solvent can be selected as a polymerization medium or added after polymerization. The solvent is selected from solvents with low boiling points to facilitate drying and have lower toxicity for implant applications. Examples of such solvents include aliphatic ketones, esters, ethers, alcohols, hydrocarbons, etc. Depending on the final thickness of the biointerface / drug release layer and the solution viscosity (related to the percentage of polymer solids), the coating can be applied in a single step or multiple repeated steps (such as impregnation) of the selected process to achieve the desired thickness. In other examples, the biointerface polymer is formed from polyurethane urea, incorporating unsaturated hydrocarbon groups and sulfobetaine groups into polymeric and nonionic hydrophilic polyethylene oxide segments. The polyurethane urea polymer is dissolved in an organic or non-organic solvent system within a coating formulation and crosslinked by heat or radiation (including UV, LED light, electron beam, etc.) in the presence of an initiator, and cured at a moderate temperature of approximately 50°C. Examples of unsaturated hydrocarbons include allyl, vinyl, acrylate, methacrylate, olefin, and alkyne.
[0224] In some examples, tethering is used. Tethering is a polymer or chemical component that does not participate in the (electro)chemical reaction involved in sensing but forms chemical bonds with the (electro)chemically active components of the membrane. In some examples, these bonds are covalent bonds. In one example, tethering can be formed in solution prior to the formation of one or more interlayers of the membrane, wherein the tethering bonds two (electro)chemically active components directly to each other, or alternatively, the tethering bonds the (electro)chemically active components to the polymer backbone structure. In another example, the (electro)chemically active components are co-mixed with a crosslinking agent (and optionally a polymer) of tunable length, and the tethering reaction occurs as an in-situ crosslinking. Tethering can be used to maintain a predetermined number of degrees of freedom of NAD(P)H to achieve efficient enzyme catalysis, wherein “efficient” enzyme catalysis enables the analyte sensor to continuously monitor one or more analytes over a period of approximately 5 days to approximately 15 days or longer.
[0225] Membrane manufacturing Polymers can be processed using solution-based techniques such as electrodeposition, plasma polymerization, electrospraying, spraying, dip coating, casting, electrospinning, vapor deposition, spin coating, pad printing, screen printing, discrete distribution, inkjet deposition, slot coating, brush coating, thin film coating, droplet coating, coating, etc. Aqueous polymer emulsions can be fabricated into films using methods similar to those used for solvent-based materials. In both cases, the evaporation of the volatile liquid (e.g., organic solvents or water) leaves behind a polymer film. Crosslinking of the deposited film or layer can be achieved using a variety of methods employing multifunctional reactive components. Liquid systems can be cured by heat, moisture, high-energy radiation, ultraviolet light, or by completing a reaction, or otherwise crosslinked, resulting in the final polymer in a mold or on the substrate to be coated.
[0226] In some examples, the wetting properties of a membrane (and the degree of sensor drift as exhibited by the extended sensor) can be tuned and / or controlled by forming covalent crosslinks between polymers containing surface-active groups, polymers containing functional groups, polymers with zwitterionic groups (or their precursors or derivatives), and combinations thereof. Crosslinking can have a substantial impact on the membrane structure, which in turn can affect the surface wetting properties of the membrane, including the hydrophilic and hydrophobic water regions dispersed throughout the membrane. Crosslinking can also affect the membrane's tensile strength, mechanical strength, water absorption rate, and other properties.
[0227] Crosslinked polymers can have different crosslinking densities. In some examples, a crosslinking agent is used to promote crosslinking between the layers. In other examples, heat is used to form crosslinks instead of (or in addition to) the crosslinking techniques described above. For example, in some examples, imide and amide bonds can be formed between two polymers due to the high temperature. In some examples, photocrosslinking is performed to form covalent bonds between the polycationic and polyanionic layers. A major advantage of photocrosslinking is that it provides the possibility of patterning. In some examples, photocrosslinking is used for patterning to modify the membrane structure and thus tune the wetting properties of the membrane and membrane system, as discussed herein.
[0228] Polymers having functionalized domains or segments to allow crosslinking can be prepared by at least the methods discussed herein. For example, polyurethane urea polymers having aromatic or aliphatic segments containing electrophilic functional groups (e.g., carbonyl, aldehyde, acid anhydride, ester, amide, isocyanate, epoxy, allyl, or halogen groups) can be crosslinked with crosslinking agents having multiple nucleophilic groups (e.g., hydroxyl, amine, urea, carbamate, or thiol groups). In another example, polyurethane urea polymers having aromatic or aliphatic segments containing nucleophilic functional groups can be crosslinked with crosslinking agents having multiple electrophilic groups. Additionally, polyurethane urea polymers having hydrophilic segments containing nucleophilic or electrophilic functional groups can be crosslinked with crosslinking agents having multiple electrophilic or nucleophilic functional groups. Unsaturated functional groups on polyurethane urea can also be used for crosslinking by reacting with polyvalent radical reagents. Non-limiting examples of suitable crosslinking agents include isocyanates, carbodiimides, glutaraldehyde, aziridine, silanes or other aldehydes, epoxy resins, acrylates, free radical-based reagents, ethylene glycol diglycidyl ether (EGDE), poly(ethylene glycol) diglycidyl ether (PEGDE), or dicumyl peroxide (DCP). In one example, about 0.1% to about 15% by weight of the crosslinking agent is added relative to the total dry weight of these components added during blending of the crosslinking agent and the polymer. In another example, about 1% to about 10% by weight of the crosslinking agent is added relative to the total dry weight of these components added during blending of the crosslinking agent and the polymer. In yet another example, about 5% to about 15% by weight of the crosslinking agent is added relative to the total dry weight of these components added during blending of the crosslinking agent and the polymer. During the curing process, it is assumed that substantially all of the crosslinking agent reacts, and substantially no detectable unreacted crosslinking agent remains in the final film.
[0229] The polymers disclosed herein can be formulated into mixtures that can be drawn into films or applied to surfaces using methods such as spraying, self-assembled monolayers (SAM), coating, dip coating, vapor deposition, electrodeposition, plasma polymerization, electrospraying, pad printing, spin coating, discrete dispensing, inkjet deposition, slot coating, molding, 3D printing, photolithography (e.g., optical lithography), micropipette and nanopipette printing, screen printing, and silkscreen printing. The mixtures can then be cured at high temperatures (e.g., from about 30°C to about 150°C). Other suitable curing methods may include, for example, ultraviolet radiation, electron beam, or gamma radiation.
[0230] In some cases, with continuous multianalyte monitoring systems employing sensors configured with bioprotective and / or drug-release membranes, foreign body reactions are believed to be a major event surrounding prolonged implantation of the implanted device and can be managed or manipulated to support rather than hinder or block analyte transport. On the other hand, to extend sensor lifespan, one example is the use of materials that promote inward growth of vascularized tissue within porous biointerface membranes. For instance, tissue inward growth into porous biointerface materials surrounding the sensor can enhance sensor function over extended time periods (e.g., weeks, months, or years). Inward growth and formation of tissue beds have been observed to take up to 3 weeks. Tissue inward growth and tissue bed formation are considered part of the foreign body reaction. As will be discussed herein, the foreign body reaction can be manipulated by using porous bioprotective materials surrounding the sensor and promoting inward growth of tissue and microvascular systems over time.
[0231] Therefore, sensors as discussed in the examples herein may include a bio-interface layer. Bio-interface layers, such as drug delivery layers, may include, but are not limited to, porous bio-interface materials comprising, for example, solid portions and interconnecting cavities, all of which are described in more detail elsewhere herein. Bio-interface layers can be used to improve sensor functionality over the long term (e.g., after tissue inward growth).
[0232] Therefore, sensors as discussed in the examples herein may include drug-release membranes that at least partially function as biointerface membranes or are in combination with biointerface membranes. Drug-release membranes may include, for example, materials comprising hard-soft segment polymers having hydrophilic and optionally hydrophobic domains, all of which are described in more detail elsewhere herein and can be used to improve sensor function over the long term (e.g., after tissue inward growth). In one example, a material comprising a hard-soft segment polymer having hydrophilic and optionally hydrophobic domains is configured to release dexamethasone or a derivative of dexamethasone acetate in combination with dexamethasone, thereby achieving one or more different release rates of the anti-inflammatory agent and extending the sensor's lifespan. Other suitable drug delivery membranes disclosed herein may be selected from organosilicon polymers; polytetrafluoroethylene; expanded polytetrafluoroethylene; polyethylene-co-tetrafluoroethylene; polyolefins; polyesters; polycarbonates; bio-stabilized polytetrafluoroethylene; homopolymers, copolymers, and terpolymers of polyurethanes; polypropylene (PP); polyvinyl chloride (PVC); polyvinylidene fluoride (PVDF); polyvinyl alcohol (PVA); polyvinyl acetate; ethylene vinyl acetate (EVA); polybutylene terephthalate (PBT); polymethyl methacrylate (PMMA); polyether ether ketone (PEEK); polyamides; polyurethanes and their copolymers and blends; polyurethane urea polymers and their copolymers and blends; cellulose polymers and their copolymers and blends; poly( Ethylene oxide and its copolymers and blends; poly(propylene oxide) and its copolymers and blends; polysulfone and its block copolymers, including, for example, diblock, triblock, alternating, random and graft copolymers; cellulose; hydrogel polymers; poly(2-hydroxyethyl methacrylate) (pHEMA) and its copolymers and blends; hydroxyethyl methacrylate (HEMA) and its copolymers and blends; polyacrylonitrile-polyvinyl chloride (PAN-PVC) and its copolymers and blends; acrylic acid copolymers and their copolymers and blends; nylon and its copolymers and blends; polydifluoroethylene; polyanhydride; poly(l-lysine); poly(l-lactic acid); hydroxyethyl methacrylate and its copolymers and blends; hydroxyapatite and its copolymers and blends.
[0233] Exemplary multianalyte sensor membrane configuration Embodiments of this disclosure advantageously provide continuous multianalyte sensors with various membrane configurations suitable for simultaneously, intermittently, and / or sequentially facilitating signal transduction corresponding to analyte concentrations. In one example, such sensors can be configured using a signal transducer comprising one or more transduction elements. Such continuous multianalyte sensors can employ various transduction means and methods, such as amperometrics, voltammetry, chronoamperometrics, coulometrics, chronocoulometrics, potentiometry, conductivity, and impedance methods, as well as other techniques.
[0234] In one example, a transduction element comprises one or more membranes, which may include one or more layers and / or domains, each of which may independently include one or more signal transducers, such as enzymes, ionopeptides, RNA, DNA, aptamers, binding proteins, etc. As used herein, transduction elements include enzymes, ionopeptides, RNA, DNA, aptamers, binding proteins, and are used interchangeably.
[0235] In one example, the transductive element is present in one or more membranes, layers, or domains formed on the sensing region. In one example, such a sensor may be configured using one or more enzyme domains (e.g., membrane domains including enzyme domains, also referred to as EZ layers (“EZLs”)), each enzyme domain comprising one or more enzymes. The term “enzyme layer” as used below is intended to include all or part of the enzyme domains, any of which may be all or part of a membrane system as discussed herein, such as as a monolayer, as two or more layers, as a pair of bilayers, or as a combination thereof.
[0236] In one example, the continuous multianalyte sensor uses one or more of the following analyte / oxidase pairs: for example, glucose / glucose oxidase, pyranose / pyranose oxidase, alcohol / alcohol oxidase, cholesterol / cholesterol oxidase, galactose / galactose oxidase, choline / choline oxidase, glutamate / glutamate oxidase, glycerol / glycerol-3-phosphate oxidase (or glycerol oxidase), bilirubin / bilirubin oxidase, ascorbic acid / ascorbic acid oxidase, uric acid / uric acid oxidase, pyruvate / pyruvate oxidase, hypoxanthine:xanthine / xanthine oxidase, lactate / lactic acid oxidase, L-amino acid oxidase, catechol / catechol oxidase, β-hydroxybutyrate / β-hydroxybutyrate oxidase, and glycine / sarcosine oxidase. Other analyte-substrate / enzyme pairs may be used, including those containing genetically modified enzymes, immobilized enzymes, mediator ligases, enzyme cascades, dimerizing enzymes, and / or fusion enzymes.
[0237] based on NAD Multianalyte sensor platform Nicotinamide adenine dinucleotide (NAD(P)) + NAD(P)H is a coenzyme, such as a dinucleotide composed of two nucleotides linked by their phosphate groups. One nucleotide contains an adenine nucleobase, and the other contains nicotinamide. NAD exists in two forms, such as the oxidized form (NAD(P)+) and the reduced form (NAD(P)H) (H = hydrogen). The reaction between NAD+ and NADH is reversible; therefore, the coenzyme can be produced within NAD(P)+. + It cycles continuously with the NAD(P)H form and is essentially not consumed. +Both NAD(P)H and NAD(P)H are electroactive and can undergo reduction and oxidation reactions respectively under appropriate bias potentials.
[0238] In one example, one or more enzyme domains of the sensing region of the continuous multianalyte sensor device disclosed herein include a certain amount of NAD+ or NADH for providing transduction of a detectable signal corresponding to the presence or concentration of one or more analytes. In another example, one or more enzyme domains of the sensing region of the continuous multianalyte sensor device disclosed herein include an excess of NAD+ or NADH for providing extended transduction of a detectable signal corresponding to the presence or concentration of one or more analytes.
[0239] In one example, redox-active cofactors NAD, NADH, NAD+, NAD(P)+, ATP, flavin adenine dinucleotide (FAD), magnesium (Mg++), pyrroloquinoline quinone (PQQ), and their functionalized derivatives can be used in combination with one or more enzymes in a continuous multianalyte sensor device. In one example, NAD, NADH, NAD+, NAD(P)+, ATP, flavin adenine dinucleotide (FAD), magnesium (Mg++), pyrroloquinoline quinone (PQQ), and functionalized derivatives are bound to the sensing region. In one example, NAD, NADH, NAD+, NAD(P)+, ATP, flavin adenine dinucleotide (FAD), magnesium (Mg++), pyrroloquinoline quinone (PQQ), and functionalized derivatives are dispersed or distributed in one or more membranes or domains of the sensing region.
[0240] In one aspect of this disclosure, continuous sensing of one or more analytes using an NAD+-dependent enzyme is provided in one or more membranes or domains of a sensing region. In one example, the membrane or domain provides for the retention and stable recycling of NAD+ and a mechanism for the oxidation of NADH or the reduction of NAD+ into a current measurable by galvanometry. In one example, as described below, continuous sensing of multiple analytes is provided, wherein the multiple analytes are reversibly bound or at least one of the analytes is oxidized or reduced by an NAD+-dependent enzyme, such as glucose (glucose dehydrogenase), pyranose (pyranose dehydrogenase), ketone (β-hydroxybutyrate dehydrogenase), glycerol (glycerol dehydrogenase), cortisol (11β-hydroxysteroid dehydrogenase), alcohol (alcohol dehydrogenase), aldehyde (aldehyde dehydrogenase), pyranose (pyranose oxidase), and lactate (lactate dehydrogenase). In other examples, as described below, membranes are provided that enable continuous, in vivo sensing of a variety of analytes using FAD-dependent dehydrogenases, such as fatty acid (acyl-CoA dehydrogenase)
[0241] An exemplary configuration of one or more membranes or portions thereof is an arrangement for providing NAD+ retention and recycling. Thus, the electrode surface or planar conductive surface of the wire (coaxial) is coated with at least one layer comprising at least one enzyme, such as... Figure 7A As depicted. Reference. Figure 7B One or more optional layers can be positioned between the electrode surface and one or more enzyme domains. For example, one or more interference domains (also known as "interference blocking layers") can be used to reduce or eliminate signal contributions from unwanted substances present, or one or more electrodes (not shown) can be used to assist wetting, system equilibration, and / or initiation. Figures 7A to 7B As shown, one or more membranes provide NAD+ reservoir domains, serving as reservoirs for NAD+. In one example, by using one or more interfering agents to block the membrane and utilizing a potentiostat to measure H2O2 production or O2 consumption by an enzyme (such as or similar to NADH oxidase), the NAD+ reservoir and enzyme domain locations can be switched to promote better consumption of excess NAD+ and slower unwanted outward diffusion. Exemplary sensor configurations can be found in U.S. Provisional Patent Application No. 63 / 321340, filed March 18, 2022, entitled “CONTINUOUS ANALYTE MONITORING SENSOR SYSTEMS AND METHODS OF USING THE SAME,” the entire contents of which are incorporated herein by reference.
[0242] In one example, one or more mediators optimal for NADH oxidation are incorporated into one or more electrode or enzyme domains. In one example, organic mediators such as phenanthrolinedione, methylene blue, or nitrosoaniline are used. In another example, organometallic mediators such as ruthenium-phenanthroline-dione or osmium(bpy)₂Cl, polymers containing covalently coupled organic mediators, or organometallic coordination mediator polymers, such as polyvinylimidazole-Os(bpy)₂Cl, or polyvinylpyridine-organometallic coordination mediators (including ruthenium-phenanthrolinedione), are used. Other mediators may be used, as discussed further below.
[0243] Another example of a configuration for the detection of a continuous ketone analyte of myocardial flavin enzyme / NAD+ / dehydrogenase coupled with an electrode-associated mediator is described below: In one example, myocardial flavin is electrically coupled to an electrode having an organometallic coordination mediator polymer. In another example, myocardial flavin is covalently coupled to an electrode having an organometallic coordination mediator polymer. Alternatively, multiple enzyme domains can be used in the enzyme layer, for example, separating the electrode-associated myocardial flavin (closest to the electrode surface) from adjacent NAD+ or dehydrogenases on a more distal side, thereby substantially decoupling NADH oxidation from analyte oxidation. Alternatively, NAD+ may be closer to the electrode surface than adjacent enzyme domains including dehydrogenases. In one example, NAD+ and / or HBDH are present in the same or different enzyme domains, and either of them can be immobilized, for example, using an amine-reactive crosslinking agent (e.g., glutaraldehyde, epoxides, NHS esters, imine esters). In one example, NAD+ is coupled to a polymer and is present in the same or different enzyme domains as HBDH. In one example, the molecular weight of NAD+ is increased to prevent or eliminate migration from the sensing region, for example, by dimerizing NAD+ with any amine-reactive crosslinking agent using the C6-terminal amine of NAD+. In one example, NAD+ can be covalently coupled to an aspect of the enzyme domain that has a higher molecular weight than NAD+, which can improve the stable distribution of NAD+ and thus enhance the ability to retain and / or immobilize NAD+ within the enzyme domain. For example, dextran-NAD.
[0244] In one example, the sensing region includes one or more NADH:receptor oxidoreductases and one or more NAD-dependent dehydrogenases. In another example, the sensing region includes one or more NADH:receptor oxidoreductases and one or more NAD(P)-dependent dehydrogenases, wherein NAD(P)+ or NAD(P)H is present as a cofactor in the sensing region. In yet another example, the sensing region includes a certain amount of myocardial flavin enzyme.
[0245] In one example, a single analyte sensor configuration is provided that is suitable for combination with another analyte sensor configuration. Therefore, an EZL layer of approximately 1 μm to 20 μm thickness is prepared by providing a 10 mM HEPES EZL solution composition in water containing approximately 20 μL of 500 mg / mL HBDH, approximately 20 μL of [500 mg / mL NAD(P)H, 200 mg / mL of approximately 400 MW polyethylene glycol diethylene glycol ether (PEG-DGE)], approximately 20 μL of 500 mg / mL cardiac flavin, and approximately 40 μL of 250 mg / mL polyvinylimidazolium-osmium bis(2,2'-bipyridine) chloride (PVI-Os(bpy)2Cl) to a substrate such as a working electrode. This provides, upon drying, approximately 15% to 40% by weight of HBDH, approximately 5% to 30% by weight of cardiac flavin, approximately 5% to 30% by weight of NAD(P)H, approximately 10% to 50% by weight of PVI-Os(bpy)2Cl, and approximately 1% to 12% by weight of NAD(P)H. PEG-DGE (400MW). The substrate of the working electrode discussed herein may be formed of gold, platinum, palladium, rhodium, iridium, titanium, tantalum, chromium and / or alloys or combinations thereof, or carbon (e.g., graphite, glassy carbon, carbon nanotubes, graphene or doped diamond, and combinations thereof).
[0246] The resistive domain (also referred to as the resistive layer (“RL”) is contacted with the enzyme domain described above. In one example, the RL comprises approximately 55% to 100% PVP and approximately 0.1% to 45% PEG-DGE. In another example, the RL comprises approximately 75% to 100% PVP and approximately 0.3% to 25% PEG-DGE. In yet another example, the RL comprises approximately 85% to 100% PVP and approximately 0.5% to 15% PEG-DGE. In still another example, the RL comprises essentially 100% PVP.
[0247] like Figures 7A to 7BThe exemplary continuous analyte sensor depicted, comprising an NAD(P)H reservoir domain, is configured such that NAD(P)H is not rate-limiting in any enzyme domain of the sensing region. In one example, the loading of NAD(P)H in the NAD(P)H reservoir domain is greater than about 20 wt%, 30 wt%, 40 wt%, or 50 wt%. One or more membranes, or portions of one or more membrane domains (hereinafter also referred to as “membranes”), may also contain polymer or protein binders, such as zwitterionic polyurethane, and / or albumin. Alternatively, in addition to NAD(P)H, the membrane may also contain one or more analyte-specific enzymes (e.g., HBDH, glycerol dehydrogenase, etc.), such that optionally, the NAD(P)H reservoir membrane also provides catalytic functionality. In one example, NAD(P)H is dispersed or distributed in or with a polymer (or protein) and may be cross-linked to a degree that still allows sufficient enzyme / cofactor functionality and / or reduces the flux of NAD(P)H within the domain.
[0248] In one example, NADH oxidase is used alone or in combination with superoxide dismutase (SOD) in one or more membranes of the sensing region. In one example, superoxide dismutase (SOD) is used to remove some or most of the amount of one or more free radicals generated by NADH oxidase. In one example, NADH oxidase is used alone or in combination with superoxide dismutase (SOD) in combination with NAD(P)H and / or a functionalized polymer, wherein NAD(P)H is immobilized from a C6-terminal amine in one or more membranes of the sensing region onto the polymer.
[0249] In one example, NAD(P)H is immobilized to the extent that its catalytic functionality is maintained. In another example, dimerized NAD(P)H is used to retain NAD(P)H within one or more membranes, which is achieved by crosslinking their respective C6-terminated amines with a suitable amine-reactive crosslinking agent, such as glutaraldehyde or PEG-DGE.
[0250] The aforementioned continuous analyte sensor configuration can be adapted for use with other analytes or in combination with other sensor configurations. For example, analyte-dehydrogenase combinations can be used in any membrane within the sensing region, and these combinations include: glucose (glucose dehydrogenase); pyranose (pyranose dehydrogenase); glycerol (glycerol dehydrogenase); cortisol (11β-hydroxysteroid dehydrogenase); alcohol (alcohol dehydrogenase); aldehyde (aldehyde dehydrogenase); and lactate (lactate dehydrogenase).
[0251] In one example, a semipermeable membrane is used in or adjacent to one or more membranes within or near the sensing region to attenuate the flux of at least one analyte or chemical substance. In another example, the semipermeable membrane attenuates the flux of at least one analyte or chemical substance to provide a linear response from the transduction signal. In yet another example, the semipermeable membrane prevents or eliminates the outflow of NAD(P)H from the sensing region or any membrane or domain. In one example, the semipermeable membrane may be an ion-selective membrane that is selective for ions of interest, such as ammonium ions.
[0252] In another example, a continuous multianalyte sensor configuration comprising one or more enzymes and / or at least one cofactor was prepared. Figure 7C An exemplary configuration of an enzyme domain 750 is depicted, comprising an enzyme having a cofactor, located near at least a portion of the surface of a working electrode (“WE”), wherein the WE comprises an electrochemical reaction surface. In one example, a second membrane 751 comprising a cofactor is located adjacent to the first enzyme domain. The cofactor in the second membrane may provide an excess of the enzyme, for example, to extend sensor lifetime. One or more resistance domains 752 (“RL”) are located adjacent to the second membrane (or may be located between the membranes). RL may be configured to block the diffusion of the cofactor from the second membrane. The electron transfer transduction from the cofactor to the WE corresponds directly or indirectly to a signal corresponding to the analyte concentration.
[0253] Figure 7D An alternative enzyme domain configuration is depicted, comprising a first membrane 751 having a certain amount of cofactor, the first membrane being located closer to at least a portion of the WE surface. An enzyme domain 750 comprising a certain amount of enzyme is located adjacent to the first membrane.
[0254] exist Figures 7C to 7D In the depicted membrane structure, the generation of electrochemically active substances in the enzyme domain diffuses to the WE surface and transduces signals directly or indirectly corresponding to analyte concentrations. In some examples, the electrochemically active substances include hydrogen peroxide. For sensor configurations that include cofactors, cofactors from the first layer can diffuse to the enzyme domain to extend sensor lifetime, for example, by regenerating the cofactors. For other sensor configurations, cofactors can be optionally included to improve performance properties such as stability. For example, a continuous ketone sensor may include NAD(P)H and divalent metal cations, such as Mg. +2 One or more resistive domains RL may be located adjacent to the second membrane (or between layers). RL may be configured to block the diffusion of cofactors from the second membrane and / or the arrival of interfering substances at the WE surface. Other configurations may be used in the foregoing configurations, such as electrodes, resistors, biointerfaces, and drug release membranes, layers, or domains. In other examples, the continuous analyte sensor includes one or more cofactors that contribute to sensor performance.
[0255] Glucose sensor configuration In some implementations, a continuous glucose sensor device configuration is provided. In one example, glucose oxidase (GOx) may be included in one or more enzyme domains and located adjacent to the working electrode surface. GOx is used to catalyze the production of hydrogen peroxide from glucose in the presence of dissolved oxygen, which can be qualitatively or quantitatively detected and / or measured using amperometry, voltammetry, chronoamperometry, coulometric spectroscopy, chronocoulometric spectroscopy, potentiometry, conductivity spectroscopy, and impedance spectroscopy.
[0256] In some embodiments, the sensing region for substrate-oxidase preparation has one or more enzyme domains including one or more electrodes. In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes) and one or more interference-blocking membranes (e.g., selectively permeable membranes and / or charge-repellent membranes). The one or more interference-blocking membranes can reduce the diffusion of one or more interfering substances across the membrane to the working electrode. In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes) and one or more resistive domains (with or without one or more interference-blocking membranes). In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes), one or more resistive domains (with or without one or more interference-blocking membranes), and one or more biointerface membranes and / or drug release membranes. The one or more biointerface membranes and / or drug release membranes reduce the diffusion of one or more analytes or enzyme substrates and, upon insertion, reduce the host's immune response.
[0257] In one example, one or more interference-blocking films are deposited on a surface preceding the working electrode and / or the electrode surface. In another example, one or more interference-blocking films are deposited directly near the working electrode and / or the electrode surface. In yet another example, one or more interference-blocking films are deposited between another layer, membrane, or domain adjacent to the working electrode or electrode surface to attenuate the diffusion of one or all analytes through the sensing region. Such films can be used to attenuate glucose itself, as well as other electrochemically active substances or other analytes that, if diffused to the working electrode, might otherwise cause interference by generating a signal. The films can be engineered to allow glucose permeation to occur relatively unaffected. The permeation selectivity can be based on molecular weight.
[0258] In one example, the working electrode used contains platinum, and the applied potential is approximately 0.6 volts.
[0259] In one example, such as in a Clark-type electrode setup or in different configurations, electrochemical sensing of changes in oxygen levels can be achieved, for example, by using one or more polymers (such as NAFION).™ This is achieved by coating one or more membrane electrodes. Based on changes in potential, changes in oxygen concentration can be recorded, which are directly or indirectly related to glucose concentration. When properly designed to follow stoichiometric behavior, the presence of a specific concentration of glucose should cause a corresponding reduction in local oxygen, and this reduction should be directly (linearly) related to the glucose concentration. Therefore, a multi-analyte sensor for both glucose and oxygen can be provided.
[0260] In another example, the glucose sensor configuration mentioned above may include one or more mediators. In one example, one or more mediators are present in, on, or around one or more electrodes or electrode surfaces, and / or are deposited on or otherwise associated with the surface of the WE or reference electrode (“RE”). In one example, one or more mediators eliminate or reduce the direct oxidation of interfering substances that can reach the WE or RE. In one example, one or more mediators provide a reduction in the WE / RE operating potential, for example, from about 0.6V to about 0.3V or lower on a platinum electrode, which can reduce or eliminate the oxidation of endogenous interfering substances. Examples of one or more mediators provided above include methylene blue, polyvinylimidazole-Os(bpy)₂Cl, etc. Other electrodes, such as counter electrodes, may be used.
[0261] In one example, additional enzymes or additives may be added to the polymer mixture constituting any part of the sensing region to increase the stability of the aforementioned sensor and / or reduce or eliminate byproducts of the glucose / glucose oxidase reaction. In another example, the additive may also be a protein (e.g., bovine serum albumin (BSA)) or a cross-linking agent (e.g., glutaraldehyde, N,N'-carbonyldiimidazole (CDI)). Increased stability includes storage or shelf-life and / or operational stability (e.g., retention of enzyme activity during use). For example, byproducts of the enzyme reaction may be undesirable for extended shelf life and / or operational stability, and therefore may need to be reduced or removed. In one example, xanthine oxidase may be used to remove byproducts of one or more enzyme reactions.
[0262] In another example, dehydrogenases are used together with oxidases to detect glucose alone or in combination with oxygen. Thus, in one example, glucose dehydrogenase oxidizes glucose to gluconate-δ-lactone in the presence of reduced nicotinamide adenine dinucleotide (NAD(P)H) or reduced nicotinamide adenine dinucleotide phosphate (NAD(P)+). To provide a continuous source of NAD(P)H or NAD(P)+, NADH oxidase or NADPH oxidase is used to oxidize NAD(P)H or NAD(P)+, consuming oxygen in the process. In another example, cardiac flavin enzyme may be used instead of or in combination with NADH oxidase or NADPH oxidase. Alternatively, excess NAD(P)H may be bound to one or more enzyme domains and / or one or more electrodes in an amount adapted to the expected duration of the sensor's planned lifetime.
[0263] In the aforementioned dual-enzyme configuration, the signal can be sensed by: (1) electrocoupling of glucose dehydrogenase (GDH), for example, using an electroactive hydrogel polymer containing one or more mediators; or (2) oxygen electrochemical sensing to measure the oxygen consumption of NADH oxidase. In an alternative example, the cofactor NAD(P)H or NAD(P)+ can be coupled to a polymer (such as dextran), and the polymer is immobilized in the enzyme domain along with GDH. This provides retention of the cofactor and its availability at the GDH active site. In the above examples, any combination of electrodes, interference, resistors, and biointerface membranes can be used to optimize signal, durability, reduce drift, or extend service life. In one example, electrocoupling can be provided, for example, directly or indirectly via covalent or ionic bonds to at least a portion of the transduction element (such as an aptamer, enzyme, or cofactor) and at least a portion of the electrode surface. Chemical components capable of facilitating the transfer of electrons from the enzyme or cofactor to the electrode surface can be used, including one or more mediators as described below.
[0264] In one example, any of the aforementioned continuous glucose sensor configurations is combined with any of the aforementioned continuous analyte monitoring configurations to provide a continuous multianalyte sensor device as further described below. In another example, a continuous glucose monitoring configuration is combined with any one or more of the aforementioned continuous analyte sensor configurations to provide a continuous multianalyte sensor device as further described below.
[0265] Pyranose sensor configuration In another example, a continuous pyranose sensor device configuration is provided. Thus, in one example, pyranose oxidase (POx) may be included within one or more enzyme domains and located adjacent to the working electrode surface. In the presence of oxygen, POx catalyzes the production of hydrogen peroxide from pyranose, which can be qualitatively or quantitatively detected and / or measured using amperometry, voltammetry, chronoamperometry, coulometrics, chronocoulometrics, potentiometry, conductivity, impedance spectroscopy, and other techniques.
[0266] In some embodiments, the sensing region for substrate-oxidase preparation has one or more enzyme domains including one or more electrodes. In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes) and one or more interference-blocking membranes (e.g., selectively permeable membranes and / or charge-repellent membranes). The one or more interference-blocking membranes can reduce the diffusion of one or more interfering substances across the membrane to the working electrode. In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes) and one or more resistive domains (with or without one or more interference-blocking membranes). In some embodiments, the sensing region has one or more enzyme domains (with or without one or more electrodes), one or more resistive domains (with or without one or more interference-blocking membranes), and one or more biointerface membranes and / or drug release membranes. The one or more biointerface membranes and / or drug release membranes reduce one or more analytes or enzyme substrates and, upon insertion, reduce the host's immune response.
[0267] In one example, one or more interference-blocking films are deposited adjacent to the working electrode and / or the electrode surface. In another example, one or more interference-blocking films are deposited directly adjacent to the working electrode and / or the electrode surface. In yet another example, one or more interference-blocking films are deposited between another layer, membrane, or domain adjacent to the working electrode or electrode surface to attenuate the diffusion of one or all analytes other than oxygen through the sensing region. Such films can be used to attenuate pyranose itself, as well as other electrochemically active substances or other analytes that, if diffused to the working electrode, might otherwise cause interference by generating a signal.
[0268] In one example, the working electrode used contains platinum, and the applied potential is approximately 0.6 volts.
[0269] In one example, such as in a Clark-type electrode setup or in different configurations, electrochemical sensing of changes in oxygen levels can be achieved, for example, by using one or more polymers (such as NAFION). ™One or more membrane-coated electrodes are used for this purpose. Based on changes in potential, changes in oxygen concentration can be recorded, which are directly or indirectly related to the concentration of pyranose. When properly designed to follow stoichiometric behavior, the presence of a specific concentration of pyranose should cause a corresponding reduction in local oxygen, and this reduction should be directly (linearly) related to the pyranose concentration. Therefore, a multi-analyte sensor for both pyranose and oxygen can be provided.
[0270] In another example, the pyranose sensor configuration mentioned above may include one or more mediators. In one example, one or more mediators are present in, on, or around one or more electrodes or electrode surfaces, and / or are deposited on or otherwise associated with the surface of the WE or RE. In one example, one or more mediators eliminate or reduce the direct oxidation of interfering substances that can reach the WE or RE. In one example, one or more mediators provide a reduction in the WE / RE operating potential, for example, from about 0.6V to about 0.3V or lower on platinum, gold, or carbon electrodes, which can reduce or eliminate the oxidation of endogenous interfering substances. Examples of suitable mediators are provided below. Other electrodes, such as counter electrodes, may be used.
[0271] In one example, additional enzymes or additives may be added to the polymer mixture constituting any part of the sensing region to increase the stability of the aforementioned sensor and / or reduce or eliminate byproducts of the pyranose / pyranose oxidase reaction. In some embodiments, the enzymes or additives that may be added to increase stability may be cross-linked polymers and / or enzyme stabilizers. Increased stability includes storage or shelf-life and / or operational stability (e.g., retention of enzyme activity during use). For example, byproducts of the enzyme reaction may be undesirable for extended shelf life and / or operational stability, and therefore may need to be reduced or removed. In one example, xanthine oxidase may be used to remove byproducts of one or more enzyme reactions.
[0272] In another example, dehydrogenases are used together with oxidases to detect pyranose alone or in combination with oxygen. Thus, in one example, pyranose is oxidized to 2-dehydropyranose using a pyranose dehydrogenase in the presence of reduced nicotinamide adenine dinucleotide (NAD(P)H) or reduced nicotinamide adenine dinucleotide phosphate (NAD(P)+). To provide a continuous source of NAD(P)H or NAD(P)+, NADH oxidase or NADPH oxidase is used to oxidize NAD(P)H or NAD(P)+, consuming oxygen in the process. In another example, cardiac flavin enzyme may be used instead of or in combination with NADH oxidase or NADPH oxidase. Alternatively, excess NAD(P)H may be bound to one or more enzyme domains and / or one or more electrodes in an amount suitable for the expected duration of the sensor's planned lifetime. In some configurations, the NAD(P)H can be directly oxidized by applying a suitable bias potential.
[0273] In the aforementioned dual-enzyme configuration, the signal can be sensed by: (1) electrocoupling of pyranose dehydrogenase (PDH), for example, using an electroactive hydrogel polymer containing one or more mediators; (2) oxygen electrochemical sensing to measure the oxygen consumption of NADH oxidase; or (3) hydrogen peroxide electrochemical sensing to measure the production of hydrogen peroxide by NADH oxidase in the presence of NADH and oxygen. In an alternative example, the cofactor NAD(P)H or NAD(P)+ can be coupled to a polymer (such as dextran) that is immobilized in the enzyme domain along with the PDH. This provides retention of the cofactor and its availability at the PDH active site. In the above examples, any combination of electrodes, interference, resistors, and biointerface membranes can be used to optimize signal, durability, reduce drift, or extend service life. In one example, electrocoupling can be provided, for example, directly or indirectly via covalent or ionic bonds to at least a portion of the transduction element (such as an aptamer, enzyme, or cofactor) and at least a portion of the electrode surface. Chemical components capable of facilitating the transfer of electrons from an enzyme or cofactor to the electrode surface may be used, including one or more mediators as described below.
[0274] In one example, any of the aforementioned continuous pyranose sensor configurations is combined with any of the aforementioned continuous analyte monitoring configurations to provide a continuous multianalyte sensor device as further described below. In one example, the continuous pyranose monitoring configuration is combined with the aforementioned continuous glucose sensor configuration to provide a continuous multianalyte sensor device as further described below.
[0275] Single working electrode configuration for dual analyte detection In one example, a dual-enzyme domain configuration is provided, where each layer contains one or more specific enzymes and optionally one or more cofactors. More broadly, an example of a continuous multi-analyte sensor configuration is depicted in... Figure 8A The membrane 755 (EZL1) of at least one enzyme (enzyme 1) in at least two enzyme domain configurations is adjacent to at least one surface of the WE. One or more analyte-substrate enzyme pairs having enzyme 1 transduc at least one detectable signal to the WE surface via direct electron transfer or via mediated electron transfer corresponding directly or indirectly to the analyte concentration. A second membrane 756 (EZL2) having at least one second enzyme (enzyme 2) is located adjacent to 755 ELZ1 and is generally further away from the WE than EZL1. One or more resistance domains (RL) 752 may be provided adjacent to EZL2 756 and / or between EZL1 755 and EZL2 756. Different enzymes catalyze the conversion of the same analyte, but at least one enzyme in EZL2 756 provides hydrogen peroxide, and at least one other enzyme in EZL1 755 does not provide hydrogen peroxide. Therefore, each measurable substance (e.g., hydrogen peroxide and other measurable substances that are not hydrogen peroxide) generates a signal associated with its concentration.
[0276] For example, in Figure 8A In the configuration shown, the first analyte diffuses through RL 752 and into EZL2 756, thereby generating hydrogen peroxide via interaction with enzyme 2. The hydrogen peroxide diffuses at least through EZL1 755 to WE and transduces a signal directly or indirectly corresponding to the concentration of the first analyte. A second analyte, different from the first analyte, diffuses through RL 752 and EZL2 756 and interacts with enzyme 1, resulting in electron transfer to WE and transducing a signal directly or indirectly corresponding to the concentration of the second analyte.
[0277] like Figure 8B As shown, the above configuration is adapted for wire electrode construction, wherein at least two different enzyme-containing layers are constructed on the same WE having a single active surface. In one example, the single WE is a wire, wherein the active surface is positioned around the longitudinal axis of the wire. In another example, the single WE is a conductive trace on a substrate, wherein the active surface is positioned around the longitudinal axis of the trace. In one example, the active surface is substantially continuous around the longitudinal axis or radius.
[0278] In the configuration described above, at least two different enzymes may be used and they catalyze the conversion of different analytes, wherein at least one enzyme in EZL2 756 provides hydrogen peroxide and at least another enzyme in EZL1 755 does not provide hydrogen peroxide, for example, providing direct or indirect electron transfer to the WE surface corresponding to the analyte concentration.
[0279] In one example, the inner layers of at least two enzyme domains, EZL1 755 and EZL2 756, include at least one immobilized enzyme in combination with at least one mediator, which facilitates lower bias operation of the WE compared to the absence of a mediator. In one example, a potential P1 is used for this type of direct electron conduction. In one example, at least a portion of the inner layer EZL1 755 is closer to the WE surface and may have one or more intervening electrode domains and / or covering interference and / or biointerfaces and / or drug release membranes, provided that at least one mediator facilitates lower bias operation of the WE surface. In another example, at least a portion of the inner layer EZL1 755 is directly adjacent to the WE.
[0280] Figure 8B The second layer (outer layer EZL2 756) of at least the dual-enzyme domain contains at least one enzyme that causes one or more catalytic reactions that ultimately produce a certain amount of hydrogen peroxide, which can electrochemically transduce a signal corresponding to the analyte concentration. In one example, the generated hydrogen peroxide diffuses through layer EZL2 756 and through inner layer EZL1 755 to the WE surface and undergoes redox at a potential of P2, where P2 ≠ P1. In this way, electron transfer and electrolysis (redox) can be selectively controlled by controlling the potentials P1 and P2 applied to the same WE surface. Any duration of the applied potential can be used for P1 and P2, such as equal / periodic durations, staggered durations, random durations, and various potential measurement sequences, cyclic voltammetry, pulsed amperometric detection, linear sweep voltammetry, differential pulse voltammetry, square wave voltammetry, etc. In some examples, impedance measurement sensing can be used. In one example, phase shift (e.g., time lag) can be caused by detecting two signals from two different working electrodes, each generated by a different EZL (EZL1, EZL2, 755, 756) associated with each electrode. The two (or more) signals can be decomposed into fractions to detect individual signals and signal artifacts generated by each of EZL1 and EZL2 in response to the detection of two analytes. In some examples, each EZL detects a different analyte. In other examples, both EZLs detect the same analyte.
[0281] In another alternative exemplary configuration, such as Figures 8C to 8DAs shown, a multi-enzyme domain configuration as described above is provided for a continuous multi-analyte sensor device using a single WE having two or more active surfaces. In one example, the multi-enzyme domain configuration discussed herein is formed on a planar substrate. In another example, the single WE is coaxial, for example configured as a wire, having two or more active surfaces positioned around the longitudinal axis of the wire. Additional wires may serve, for example, as a reference electrode and / or a counter electrode. In yet another example, the single WE is a conductive trace on a substrate, wherein two or more active surfaces are positioned around the longitudinal axis of the trace. At least a portion of the two or more active surfaces is discontinuous, thereby providing at least two physically separated WE surfaces (e.g., WE1, WE2) on the same WE wire or trace. In one example, the first analyte detected by WE1 is glucose, and the second analyte detected by WE2 is pyranose.
[0282] therefore, Figures 8C to 8D An exemplary configuration of a continuous multianalyte sensor construction is depicted, wherein EZL1 755, EZL2 756, and RL 752 (resistance domains) as described above are arranged, for example, by a sequential dip-coating technique on a single coaxial wire comprising spatially separated electrode surfaces WE1, WE2. One or more parameters, such as thickness, length along the axis from the distal end of the wire, etc., of the enzyme domain, resistance domain, etc., can be independently controlled along the longitudinal axis of WE. In one example, at least a portion of the spatially separated electrode surfaces has the same composition. In another example, at least a portion of the spatially separated electrode surfaces has different compositions. Figures 8C to 8D In this context, WE1 represents the first working electrode surface configured to operate under P1, WE2 represents the second working electrode surface configured to operate under P2, WE1 and WE2 are electrically insulated, and RE represents a reference electrode electrically isolated from both WE1 and WE2. Figure 8C The configuration provides a resistor domain covering RE and WE1, WE2. Figure 8D The configuration provides an additional resistance domain that essentially covers only WE2 and extends thereon. Additional electrodes, such as counter electrodes, can be used. Such configurations (whether single-lead or dual-lead) can also be used to measure the same analyte using two different techniques. Using different signal generation sequences and different RL, data collected from measurements in two different modes provides increased fidelity, improved performance, and device life. A non-limiting example is a glucose oxidase (producing hydrogen peroxide) and glucose dehydrogenase (electrically coupled) configuration. Measuring glucose from two different electrodes at two potentials provides more data points and accuracy. Such methods may not be necessary for glucose sensing but can be applied alone or in combination with glucose sensing to the range of other analyte biomarkers, such as pyranose sensing and glucose / pyranose sensing.
[0283] exist Figures 8C to 8D In the depicted alternative configuration, two or more wire electrodes are presented that can be collinear, intertwined, or otherwise juxtaposed, wherein WE1 and WE2 are separated, for example, separated from other elongated electrodes. An insulating layer electrically isolates WE1 and WE2. In this configuration, independent electrode potentials can be applied to the corresponding electrode surfaces, wherein independent electrode potentials can be provided to WE1 and WE2 simultaneously, sequentially, or randomly. In one example, the electrode potentials presented to the corresponding electrode surfaces WES1 and WES2 are different. One or more additional electrodes, such as a reference electrode and / or a counter electrode, may be present. In one example, WES2 is positioned in an elongated arrangement distal to the longitudinal direction of WES1. Using, for example, dip coating, WES1 and WES2 are coated with enzyme domain EZL1, while WES2 is coated with a different enzyme domain EZL2. Based on the dip coating parameters or enzyme domains of different thicknesses, multilayer enzyme domains may be employed, each layer independently comprising enzymes and / or cofactors and mediators with different loadings and / or compositions. Similarly, one or more resistance domains (RLs) can be applied, each with a different thickness along the longitudinal axis of the electrode, and can be applied to different electrodes and enzyme domains, for example, by controlling the impregnation length and other parameters. (Reference) Figure 8D This describes such an arrangement of RL', in which the additional RL 752' is adjacent to WES2, but is not essentially in WES1.
[0284] In one example of measuring two different analytes, the above configuration includes an enzyme domain EZL1 755 comprising one or more enzymes and one or more mediators for at least one enzyme in EZL1 to provide direct electron transfer to WES1 and determine the concentration of at least a first analyte. Furthermore, an enzyme domain EZL2 756 may include at least one enzyme that provides peroxides (e.g., hydrogen peroxide) or consumes oxygen during catalysis with its substrate. The peroxides or oxygen generated in EZL2 756 migrate to WES2 and provide a detectable signal directly or indirectly corresponding to the second analyte. For example, EZL1 755 may be a pyranose oxidase, EZL2 756 may be a glucose oxidase, and WES2 may be carbon wired to the glucose oxidase to measure glucose, while WES1 may be platinum, which measures the peroxides generated by the pyranose oxidase / pyranose in EZL1 755. The combinations of electrode materials and enzymes disclosed herein are exemplary and not limiting.
[0285] In one example, the potentials of P1 and P2 can be separated by a certain amount of potential separation, allowing two signals (from direct electron transfer from EZL1755 and from hydrogen peroxide electrolysis at WE) to be activated and measured separately. In one example, the sensor's electronic module can continuously switch between the two sensing potentials in a continuous or semi-continuous periodic manner, such as a time period (t1) at potential P1 and a time period (t2) at potential P2, optionally with rest periods where no potential is applied. The extracted signals can then be analyzed to measure the concentrations of two different analytes. In another example, the sensor's electronic module can undergo cyclic voltammetry, providing current changes as potentials P1 and P2 are swept, which can be correlated, respectively, with transduction signals from direct electron transfer or hydrogen peroxide electrolysis. In one example, the sensing mode is not limited and can include different amperometric techniques, such as pulsed amperometric detection. In one example, an alternative configuration is provided, but the generation of hydrogen peroxide in EZL2 is replaced by another suitable electrolytic compound (such as oxygen) that maintains the P2≠P1 relationship and at least one enzyme-substrate combination that provides the other electrolytic compound.
[0286] In one example, electrodes WE1 or WE2 may be, for example, composite materials, such as gold electrodes, having platinum ink deposited on top, a carbon / platinum mixture, and / or trace amounts of carbon on top of platinum, or a porous carbon coating on a platinum surface. In one example, the electrode surface contains two different materials; for example, carbon is used for linkerase and electron transfer, while platinum is used for hydrogen peroxide reduction and detection. Figure 8E As shown, an example of such a composite electrode surface is illustrated, wherein an extended platinum-covered wire 757 is partially coated with carbon 758 to facilitate multiple sensing on two different surfaces of the same electrode. In one example, WE2 may be grown on or extend from a portion of the surface or distal end of WE1, for example, by vapor deposition, sputtering, or electrolytic deposition.
[0287] Additional examples include composite electrode materials that can be used to form one or both of WE1 and WE2. In one example, a platinum-carbon electrode WE1 comprising an EZL1 with glucose dehydrogenase is wired to a carbon surface, and an outer EZL2 comprising a lactate oxidase that generates hydrogen peroxide, which can be detected by the platinum surface of the same WE1 electrode. Other examples of this configuration may include pyranose (e.g., 1,5-AG) sensing (electro-coupled pyranose dehydrogenase in EZL1 755) and glucose sensing (glucose oxidase in EZL2 756). Other membranes may be used in the foregoing configuration, such as electrodes, resistors, biointerfaces, and drug delivery membranes. In other examples, one or both of the working electrodes (WE1, WE2) may be gold-carbon (Au-C), palladium-carbon (Pd-C), iridium-carbon (Ir-C), rhodium-carbon (Rh-C), or ruthenium-carbon (Ru-C). In some examples, the carbon in the working electrode discussed herein may alternatively or additionally include graphene, graphene oxide, or other materials suitable for forming the working electrode, such as commercially available carbon ink.
[0288] Planar analyzer sensor Figures 9A to 9G A schematic diagram of a planar analyte sensor is depicted. Each of the planar analyte sensors discussed herein can be configured to measure the concentration of one or more analytes. Planar analyte sensors can be readily manufactured and produce reproducible results. Planar analyte sensors can be configured to monitor (including continuously monitor) at least one analyte, and in some examples, to monitor two or more analytes. Planar analyte sensors can be configured differently and can be described based on the geometry of their electrode layout. Sensor types can include single-sided or double-sided layouts. In... Figures 9A to 9G In the depicted single-sided layout, the electrodes can be conductive traces and can be arranged in a coplanar, stacked, or staggered configuration. In the double-sided layout, the electrodes can be arranged in a coplanar configuration (aligned along a shared plane in a single layer along each substrate side), a stacked configuration (aligned along a shared plane perpendicular to the substrate side), or a staggered configuration (offset along one or more planes or axes), and the connector pads can be arranged on one side of the sensor or on both sides of the sensor.
[0289] Figures 9A to 9GA single-sided coplanar analyzer sensor assembly 900 is illustrated according to one example. The sensor assembly may have a first end 912 and a second end 914. The sensor assembly 900 may include a substrate 910, a conductive trace 921, a connector pad 922, a working electrode 924, a counter electrode 926, an insulator 930, and a reference electrode 940. In the sensor assembly 900, a single-sided planar configuration is used. In the sensor assembly 900, a three-electrode sensor is shown, which has a working electrode (WE) 924, a counter electrode (CE) 926, and a reference electrode (RE) 940. In the sensor assembly 900, the electrodes are coplanar. In one or more specific embodiments, the underlying configuration of the one-sided coplanar analyte sensor assembly 900 or other sensor assembly, as discussed herein, allows one or more of the reference electrode (e.g., 940) or counter electrode (e.g., 926) to be removed from the sensor assembly 900 or other sensor assembly discussed herein to an external location (e.g., as part of a wearable device, such as a smartwatch), rather than deployed subcutaneously. This has the advantage of freeing up space in the user's pocket (e.g., in a wound pocket where the sensor assembly 900 is inserted) where the one-sided coplanar analyte sensor assembly 900 or other sensor assembly is deployed for additional working electrodes and / or for detecting additional analytes.
[0290] Furthermore, by configuring wearable devices as discussed herein to include a reference electrode (940) and a counter electrode (926), such that these electrodes are deployed externally, the amount of material inserted into the body is limited. Therefore, the host's foreign body response (e.g., the host's immune system response) can be reduced. In one or more configurations, for example, the reference electrode (940) may include silver chloride (AgCl) or otherwise be formed from silver chloride. However, some hosts may have a sensitivity to silver chloride. Therefore, configuring wearable devices as discussed herein to include a reference electrode (940), rather than incorporating the reference electrode (940) as part of the in vivo portion of the sensor assembly discussed herein, can reduce the immune response in such hosts, such as reducing eye and / or skin irritation.
[0291] Figures 9A to 9D A top-down schematic diagram of a sensor assembly 900 in production is shown. Figures 9E to 9G A schematic diagram of the cross-section of the sensor assembly 900 at different points along its length is depicted.
[0292] The sensor assembly 900 may extend between a first end 912 and a second end 914, and is substantially planar along its length, as measured from the first end 912 to the second end 914. The first end 912 may be, for example, a connection end, such as for allowing the sensor assembly 900 to be electrically connected to a reader, a computer, or other components for interpreting signals detected by the sensor assembly 900. The first end 912 may accommodate one or more connector pads 922.
[0293] The second end 914 can be, for example, a sensing end, for connection to or implantation in a patient, such as for detecting glucose or other analytes. The second end 914 may accommodate electrodes 924, 926, and 940. The second end 914 can be an implantable portion of the sensor assembly 900. The first end 912 of the sensor, having a connector pad 922, can be the proximal end of the sensor assembly 900. The second end 914 of the sensor, having an implantable portion containing sensing electrodes, can be the distal end of the sensor assembly 900.
[0294] like Figure 9A As shown, substrate 910 may extend between a first end 912 and a second end 914. Substrate 910 may be a relatively planar material; for example, substrate 910 may be a thin, flexible layer for accommodating other components. In some cases, substrate 910 may be a polymer film, such as liquid crystal polymer (LCP), polyimide (PI), polyethylene terephthalate (PET), combinations thereof, or similar polymer films. Substrate 910 may have a thickness of about 25 µm to about 450 µm, such as about 75 µm to 100 µm. In some examples, a substrate thickness of about 40 µm to about 80 µm may be used.
[0295] Conductive trace 921, connector pad 922, working electrode 924, and counter electrode 926 may be made of a conductive layer 920 constructed on a substrate. Connector pad 922 may be located on or at a first end 912 of the assembly 900 and allow electrical connection of the sensor assembly 900. Working electrode 924 and counter electrode 926 may be sensing electrodes exposed at a second end 914 of the assembly 900, used for implantation and sensing analytes in the patient environment. Conductive trace 921 connects electrodes 924 and 926 to connector pad 922.
[0296] like Figure 9BAs shown, a conductive layer 920 may be constructed on a substrate 910, wherein conductive traces 921, connector pads 922, a working electrode 924, and a counter electrode 926 are in a single plane or layer. For example, the conductive layer 920 may be made of sputtered metal, such as a titanium / gold / platinum or platinum / gold / platinum sputtered metal layer. In this case, the associated sensing surface, such as at the working electrode 924, may have exposed platinum for electrical connection and sensing. A reference electrode 940 may be deposited on the base metal pad and may be connected via additional conductive traces.
[0297] In some examples, the conductive layer 920 is formed from a single conductor, such as gold or platinum. In other examples, the conductive layer 920 may be formed from more than one material, such as a thin palladium layer covered with gold and platinum. The composition, geometry, and exposed conductor surfaces can depend on the manufacturing method, desired mechanical properties, and sensing chemistry requirements. For example, the base conductive material may be formed from a less expensive material, such as silver, which is covered with platinum in key locations for use as an active sensing surface. In some cases, gold may be plated as the base conductor, which may be covered with platinum to provide both mechanical robustness and an active sensing surface for sensing hydrogen peroxide.
[0298] The conductive layer 920, including the working electrode 924, the counter electrode 926, the connector pad 922, and the conductive trace 921, can be formed by a variety of techniques, such as electroplating, sputtering, or printing. To form a patterned structure of the conductive layer, standard photolithography, laser ablation, or printing (e.g., inkjet printing or screen printing) can be used.
[0299] Although some electrode names are shown in the supporting documentation, it should be understood that size, shape, and electrode identification can vary depending on the specific use case, such as the specific analyte to be identified. The general size and shape of the sensor is 3mm to 4mm wide at the proximal end (connector end) and 300µm-500µm wide in the narrow, implantable distal end. The overall length of the sensor depends on the requirements of the wearable / insertion but is typically between 15mm and 25mm.
[0300] like Figure 9C As shown, insulator 930 can be stacked on top of conductive layer 920 as needed. The insulating material may be referred to as a "solder mask," "dielectric," or "insulator." These materials can be used to prevent conductive traces from being exposed to the sample matrix and environment, and to improve the accuracy and reliability of measurements by defining the area of the sensing electrode. An opening 931 can be fabricated for later deposition of reference electrode 940.
[0301] Here, the insulator 930 may be made of an electrically insulating material deposited on top of the conductive layer to protect the conductive trace 921 and define openings for the connector pad 922 and electrodes 924, 926, as well as an opening 931 for the reference electrode 940. The insulator 930 may be, for example, a solder mask thin layer.
[0302] like Figure 9D As shown, reference electrode 940 material can be deposited on a designated reference electrode opening in insulator 930. Reference electrode 940 material can be, for example, a silver / silver chloride formulation. It can be deposited on a designated sensing electrode pad. This reference electrode material can be deposited using printing techniques (such as screen printing) or by discrete dispensing (such as a jet valve dispenser).
[0303] Figures 9E to 9G The cross-sections of component 900 at different points along its body are depicted. Figure 9E It is shown that along the central portion of component 900 Figure 9D The cross-section of line EE. At this part of component 900, conductive trace 921 can be seen between insulator 930 and substrate 910. Figure 9F It is shown that along the second end 914 of component 900 Figure 9D The cross-section of line FF. At this part of component 900, reference electrode 940 can be seen on top of conductive trace 921. Figure 9G A cross-section of the component along line GG near the second end 914 is depicted. The working electrode 924 is visible here. The component 900 is arranged in a single-sided coplanar configuration for electrodes 924, 926, and 940.
[0304] Used to determine glucose and pyranose from glucose and pyranose sensors 1,5-AG Horizontal method As described herein, the continuous analyte monitoring system 104 includes one or more single analyte sensors and / or multiple analyte sensors configured coaxially or coplanarly. In some embodiments, the continuous analyte monitoring system monitors a patient's glucose and pyranose levels to determine the patient's 1,5-AG level. Because the continuous pyranose sensor device captures the levels of all pyranoses in the body (including glucose and 1,5-AG, and a few other negligible pyranoses), the current measured on the pyranose-selective electrode will represent the sum of the patient's glucose and 1,5-AG levels. Although glucose and 1,5-AG constitute the majority of pyranoses, it should be understood that additional pyranoses are also present in trace concentrations, but these trace concentrations are generally not expected to interfere with the accuracy of 1,5-AG level measurements.
[0305] In one embodiment having one or more single analyte sensors, to determine a patient's real-time 1,5-AG level, the signal from the continuous glucose sensor device is subtracted from the signal from the continuous pyranose sensor device. The result of this subtraction is a signal representing the 1,5-AG level, from which the 1,5-AG level can be inferred.
[0306] In one embodiment with a multianalyte sensor, to determine a patient's real-time 1,5-AG level, the signal from the glucose-selective electrode is subtracted from the signal from the pyranose-selective electrode. The result of this subtraction is a signal representing the 1,5-AG level, from which the 1,5-AG level can be inferred.
[0307] In some implementations, the difference between the signals from the glucose-selective electrode and the pyranose-selective electrode is calculated in analog or digital hardware. For example, using analog hardware, a differential amplifier, differential amplifier, or subtractor (or similar analog device or circuitry) is used to subtract the analog signal from the glucose-selective electrode from the analog signal from the pyranose-selective electrode. The differential amplifier produces an output analog signal to be converted into a digital signal.
[0308] When the difference is calculated using digital hardware, the two analog signals from the glucose-selective electrode and the pyranose-selective electrode are digitized independently and subtracted from each other by a digital subtractor. Alternatively, in the digitized form, the signals from the glucose-selective electrode and the pyranose-selective electrode are subtracted from each other in firmware and / or software (e.g., by an embedded algorithm that executes a mathematical function to subtract the glucose-selective sensor signal value from the pyranose-selective sensor signal value).
[0309] As used herein, the phrases “analyte measurement device,” “analyte monitoring device,” “analyte sensing device,” and / or “multi-analyte sensor device” are broad terms and are intended to give to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) apparatus and / or systems responsible for detecting or transducing signals associated with a particular analyte or combination of analytes. For example, these phrases may, without limitation, refer to an instrument responsible for detecting a particular analyte or combination of analytes. In one example, the instrument includes a sensor coupled to circuitry disposed within a housing and configured to process signals associated with analyte concentrations into information. In one example, such apparatus and / or systems are capable of using biometric elements combined with transducing (detection) elements to provide specific quantitative, semi-quantitative, qualitative, and / or semi-qualitative analytical information.
[0310] As used herein, the terms “biosensor” and / or “sensor” are broad terms and are intended to give to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) a portion of an analyte measurement device, analyte monitoring device, analyte sensing device, and / or multi-analyte sensor device responsible for detecting or transducing a signal associated with a particular analyte or combination of analytes. In one example, a biosensor or sensor typically includes a body, a working electrode, a reference electrode, and / or a counter electrode, which are coupled to the body and form surfaces configured to provide a signal during an electrochemical reaction. One or more membranes may be immobilized to the body and cover the electrochemical reaction surface. In one example, such a biosensor and / or sensor is capable of providing specific quantitative, semi-quantitative, qualitative, or semi-qualitative analytical signals using biorecognition elements combined with transduction (detection) elements.
[0311] As used herein, the phrases “sensing portion,” “sensing membrane,” and / or “sensing mechanism” are broad terms and are intended to give to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) a biosensor and / or a portion of a sensor responsible for detecting or transducing a signal associated with a particular analyte or combination of analytes. In one example, a sensing portion, sensing membrane, and / or sensing mechanism typically includes an electrode configured to provide a signal during an electrochemical reaction with one or more membranes covering an electrochemically reacting surface. In one example, such a sensing portion, sensing membrane, and / or sensing mechanism may use a biometric element combined with a transduction (detection) element to provide a specific quantitative, semi-quantitative, qualitative, or semi-qualitative analytical signal.
[0312] The terms “biointerface membrane” and “biointerface layer”, which are used interchangeably herein, are broad terms and will be given to those skilled in the art their common and conventional meanings (and not limited to their specific or custom meanings), and refer to (but are not limited to) a permeable membrane (which may include multiple domains) or layer that acts as a bioprotective interface between a user’s tissue and an implantable device. The terms “biointerface” and “bioprotective” are used interchangeably herein.
[0313] As used herein, the term "cofactor" is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its specific or custom-designed meaning), and refers to (but is not limited to) one or more substances whose presence contributes to or is necessary for the analyte-related activity of an enzyme. Analyte-related activity may include, but is not limited to, any or a combination of binding, electron transfer, and chemical transformation. Cofactors include coenzymes, non-protein compounds, metal ions, and / or organometallic complexes. Coenzymes include prosthetic groups and co-substrates.
[0314] As used herein, the term “continuous” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and refers to (but not limited to) an uninterrupted or continuous portion, domain, coating or layer.
[0315] As used herein, the phrases “continuous analyte sensing” and “continuous multianalyte sensing” are broad terms and are to be given their common and conventional meaning (and not limited to specific or custom meanings) to those skilled in the art, and refer to (but not limited to) a cycle in which analyte concentrations are monitored continuously, persistently, and / or intermittently (but periodically) (e.g., about once per second or less to about once per week or more). In other examples, this may be approximately every 2, 3, 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 seconds to approximately 1.25 minutes, 1.50 minutes, 1.75 minutes, 2.00 minutes, 2.25 minutes, 2.50 minutes, 2.75 minutes, 3.00 minutes, 3.25 minutes, 3.50 minutes, 3.75 minutes, 4.00 minutes, 4.25 minutes, 4.50 minutes, or every 1.25, 1.50, 1.75 minutes, 2.00 minutes, 2.25 minutes, 2.50 minutes, 2.75 minutes, 3.00 minutes, 3.25 minutes, 3.50 minutes, 3.75 minutes, 4.00 minutes, 4.25 minutes, or 4.50 minutes. Assay concentration monitoring is performed every 10 minutes, 4.75 minutes, 5.00 minutes, 5.25 minutes, 5.50 minutes, 5.75 minutes, 6.00 minutes, 6.25 minutes, 6.50 minutes, 6.75 minutes, 7.00 minutes, 7.25 minutes, 7.50 minutes, 7.75 minutes, 8.00 minutes, 8.25 minutes, 8.50 minutes, 8.75 minutes, 9.00 minutes, 9.25 minutes, 9.50 minutes, or 9.75 minutes. In another example, analyte concentration monitoring is performed approximately every 10 minutes, 20 minutes, 30 minutes, 40 minutes, or 50 minutes, or approximately every 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours. In yet another example, analyte concentration monitoring is performed approximately every 8 hours, or approximately every 12 hours, 16 hours, 20 hours, or 24 hours. In another example, analyte concentration monitoring is performed approximately daily to approximately every 1.5, 2, 3, 4, 5, 6, or 7 days. In yet another example, analyte concentration monitoring is performed approximately weekly to approximately every 1.5, 2, 3, or more weeks.
[0316] As used herein, the term “coaxial” should be interpreted broadly to include a sensor architecture having elements aligned around a core along a shared axis, the core being configured to have circular, elliptical, triangular, polygonal, or other cross-sections, such elements including electrodes, insulating layers, or other elements that can be circumferentially positioned around the core, such as core electrodes or core polymer wires.
[0317] As used herein, the term “coupling” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and refers to (but not limited to) at least one of two or more system elements or components configured to be electronically attached, mechanically attached, thermally attached, operatively attached, chemically attached, or otherwise attached. For example, an element is “coupled” if it is covalently connected, interconnectedly connected, electrostatically connected, thermally connected, mechanically connected, magnetically connected, or ionicly associated with another element, or physically trapped, adsorbed, or absorbed by another element. Similarly, the phrases “operatively connected,” “operatively linked,” and “operatively coupled” as used herein can refer to one or more components linked to another component in a manner that facilitates the transmission of at least one signal between these components. In some examples, components are part of the same structure and / or integrated with each other, such as being covalently, electrostatically, mechanically, thermally, magnetically, ionicly associated, or physically trapped or absorbed (i.e., “directly coupled,” as without an intermediary element). In other examples, components are connected via remote components. For example, one or more electrodes can be used to detect analytes in a sample and convert that information into a signal; that signal can then be transmitted to a circuit. In this example, the electrodes are “operably linked” to an electronic circuit. The phrase “removably coupled” as used herein can mean that two or more system elements or components are configured to be attached and detached, either electrically, mechanically, thermally, operably, chemically, or otherwise, without damaging any of the coupled elements or components. The phrase “permanently coupled” as used herein can mean that two or more system elements or components are configured to be attached, either electrically, mechanically, thermally, operably, chemically, or otherwise (e.g., covalently, electrostatically, or ionicly associated, physically embedded, or absorbed), but cannot be decoupled without damaging at least one of the coupled elements or components.
[0318] As used herein, the term “discontinuous” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and refers to (but not limited to) a disjointed, interrupted or separate part, layer, coating or domain.
[0319] As used herein, the term “far” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its special or customary meaning), and refers to (but not limited to) a region that is relatively far from a reference point (such as a starting point or attachment point).
[0320] As used herein, the term “domain” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to a particular or custom meaning), and refers to (but is not limited to) a region of a membrane system, which may be a layer, a homogeneous or non-homogeneous gradient (e.g., an anisotropic region of a membrane), or a portion of a membrane capable of sensing one, two, or more analytes. Domains discussed herein may be formed as a single layer, two or more layers, pairs of bilayers, or combinations thereof.
[0321] As used herein, the term "electrochemically reacting surface" is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its specific or custom meaning), and refers to (but is not limited to) the surface of an electrode where an electrochemical reaction occurs. In one example, the reaction is a Faraday reaction and results in a charge transfer between the surface and its environment. In one example, hydrogen peroxide produced by an enzyme-catalyzed reaction in which the analyte is oxidized on the surface leads to a measurable electron flow. For example, in the detection of glucose, glucose oxidase produces hydrogen peroxide (H₂O₂) as a byproduct. H₂O₂ reacts with the surface of the working electrode, producing two protons (2H₂O₂ and 2H₂O₂). + ), two electrons (2e - The electrons react with an oxygen molecule (O2) to generate the detected electron flow. In the counter electrode, a reducible substance (e.g., O2) is reduced on the electrode surface to balance the current generated by the working electrode.
[0322] As used herein, the term “electrolysis” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and refers to (but not limited to) the direct or indirect electro-oxidation or electro-reduction of a compound by one or more enzymes, cofactors or mediators (collectively, “redox”).
[0323] As used herein, the terms “indwelling,” “embedded,” “implantable,” or “implantable” are broad terms and will be given their common and customary meaning to those skilled in the art (and not limited to specific or custom meanings), and non-limitingly refer to objects including sensors inserted or configured to be inserted in a subcutaneous (i.e., in the fat layer between the skin and muscle), intradermal (i.e., penetrating the stratum corneum and positioned within the epidermis or dermis of the skin), percutaneous (i.e., penetrating, entering, or passing through intact skin), or subcutaneous (i.e., penetrating into a region of subcutaneous or adipose tissue beneath the skin), which may result in the sensor having both in vivo and external portions. The term “indwelling” also covers objects configured for subcutaneous, intradermal, or percutaneous insertion, whether or not they have been so inserted.
[0324] As used herein, the terms “interfering agent” and “interfering substance” are broad terms and will be given to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) effects and / or substances that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In one example of an electrochemical sensor, an interfering substance is a compound that produces a non-analyte-specific signal due to a reaction on an electrochemically active surface. Interfering substances may have their own electroactive properties or otherwise inhibit or activate enzymes present in the sensor that are involved in transduction operations. Interfering substances can also cause changes in one or more sensing membranes present, thereby modulating the flux of the desired analyte.
[0325] As used herein, the term “in vivo” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and includes (but is not limited to) portions of devices (e.g., sensors) suitable for insertion into and / or present within the user’s living body.
[0326] As used herein, the term “extracorporeal” is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its particular or custom meaning), and includes (but is not limited to) portions of devices (e.g., sensors) suitable for retention and / or presence outside the user’s living body.
[0327] As used herein, the terms and phrases “mediator” and “redox mediator” are broad terms and phrases and are intended to give to those skilled in the art their common and conventional meanings (and not limited to specific or custom meanings), and refer to (but not limited to) any compound or set of compounds capable of directly or indirectly transferring electrons between an analyte, analyte precursor, analyte substitute, analyte reducer or analyte oxidase or cofactor and an electrode surface maintained at a certain potential. In one example, the mediator accepts or transfers electrons from or to one or more enzymes or cofactors, and / or exchanges electrons with an electrode of a sensor system. In one example, the mediator is a transition metal-coordinated organic molecule capable of reversible oxidation and reduction reactions. In other examples, the mediator can be an organic molecule or metal capable of reversible oxidation and reduction reactions.
[0328] As used herein, the term "membrane" is a broad term and will be given its common and conventional meaning to those skilled in the art (and not limited to a particular or custom meaning), and non-limitingly refers to a structure configured to perform functions including, but not limited to: protecting exposed electrode surfaces from biological environments, resisting (restricting) the diffusion of analytes, acting as a matrix for catalysts (e.g., one or more enzymes) to enable enzymatic reactions, restricting or blocking interfering substances, providing hydrophilicity at electrochemical reaction surfaces at sensor interfaces, acting as an interface between host tissue and implantable devices, modulating host tissue responses via drug (or other substance) release, acting as an interface to attenuate foreign body reactions / fibrous capsules, and combinations thereof. When used herein, the terms "membrane" and "matrix" are intended to be used interchangeably.
[0329] As used herein, the phrase "membrane system" is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its specific or custom meaning), and refers to (but is not limited to) a permeable or semi-permeable membrane that may consist of two or more domains, two or more layers, or two or more layers within a single domain, and is typically made of a material several micrometers or greater in thickness, permeable to oxygen and optionally permeable to, for example, glucose or another analyte. In one example, the membrane system includes an enzyme that enables an analyte reaction to occur, thereby allowing the measurement of the analyte concentration.
[0330] As used herein, the term "plane" will be broadly interpreted to describe a sensor architecture having a substrate comprising at least a first surface and an opposing second surface, and including, for example, a plurality of elements disposed on one or more surfaces or edges of the substrate. These plurality of elements may include conductive or insulating layers or elements configured to operate as circuitry. The plurality of elements may or may not be electrically coupled or otherwise coupled. In one example, the plane includes one or more edges separating the opposing surfaces.
[0331] As used herein, the term "proximate" is a broad term and will be given to those skilled in the art its common and conventional meaning (and not limited to its specific or custom meaning), and refers to (but is not limited to) the spatial relationship between various elements compared to a particular reference point. For example, some examples of devices include membrane systems having a biological interface layer and an enzyme domain or layer. If the sensor is considered the reference point and the enzyme domain is positioned closer to the sensor than the biological interface layer, then the enzyme domain is closer to the sensor than the biological interface layer.
[0332] As used herein, the phrases “sensing portion,” “sensing membrane,” and / or “sensing mechanism” are broad terms and are intended to give to those skilled in the art their common and conventional meaning (and not limited to specific or custom meanings), and refer to (but not limited to) a biosensor and / or a portion of a sensor responsible for detecting or transducing a signal associated with a particular analyte or combination of analytes. In one example, a sensing portion, sensing membrane, and / or sensing mechanism typically includes an electrode configured to provide a signal during an electrochemical reaction with one or more membranes covering an electrochemically reacting surface. In one example, such a sensing portion, sensing membrane, and / or sensing mechanism is capable of providing specific quantitative, semi-quantitative, qualitative, or semi-qualitative analytical signals using biometric elements combined with transduction and / or detection elements.
[0333] Other precautions The methods disclosed herein include one or more steps or actions for implementing these methods. The method steps and / or actions may be interchanged without departing from the scope of the claims. In other words, unless a specific order of steps or actions is specified, the order and / or use of a particular step and / or action may be modified without departing from the scope of the claims.
[0334] As used in this article, the phrase “at least one” in a list of items refers to any combination of those items, including a single member. For example, “at least one of a, b, or c” is intended to cover a, b, c, ab, ac, bc, and abc, as well as any combination with multiple identical elements (e.g., aa, aaa, aab, aac, abb, acc, bb, bbb, bbc, cc, and ccc, or any other ordering of a, b, and c).
[0335] The foregoing description is provided to enable any person skilled in the art to practice the various aspects described herein. Various modifications to these aspects will be apparent to those skilled in the art, and the general principles defined herein may be applied to other aspects. Therefore, the claims are not intended to be limited to the aspects shown herein, but are consistent with the full scope of the language of the claims, wherein, unless specifically stated otherwise, reference to an element in the singular is not intended to mean “one and only one”, but rather “one or more”. Unless otherwise specifically stated otherwise, the term “some” means one or more. All structural and functional equivalents of elements throughout the various aspects described in this disclosure that are known or will later be understood by a person skilled in the art are expressly incorporated herein by reference and are intended to be included in the claims. Furthermore, nothing disclosed herein is intended to be offered to the public, whether or not this disclosure is expressly stated in the claims. No claim element should be interpreted in accordance with 35 USC §112(f) unless expressly stated using the phrase “component for…” or, in the case of a method claim, using the phrase “step for…”.
[0336] While various examples of the invention have been described above, it should be understood that they are presented by way of example only and not by way of limitation. Similarly, the figures may depict exemplary architectures or other configurations of this disclosure to aid in understanding the features and functions that may be included in this disclosure. This disclosure is not limited to the illustrated exemplary architectures or configurations, but may be implemented using a variety of alternative architectures and configurations. Furthermore, although this disclosure has been described above with reference to various exemplary examples and aspects, it should be understood that the various features and functions described in one or more of the various examples are not limited in their applicability to the specific examples describing them. They may be applied individually or in some combination to one or more other examples of this disclosure, whether or not such examples are described, and whether or not such features are presented as part of the described examples. Therefore, the breadth and scope of this disclosure should not be limited by any of the foregoing exemplary examples.
[0337] All references cited herein are incorporated herein by reference in their entirety. Where any cited publications and patents or patent applications contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.
[0338] Unless otherwise defined, all terms (including technical and scientific terms) shall be given their common and customary meaning to a person skilled in the art, and are not limited to specific or customary meanings, unless expressly defined herein.
[0339] Unless otherwise expressly stated, the terms and phrases used in this application, and their variations, particularly those used in the appended claims, shall be interpreted as open-ended rather than restrictive. As an example of the foregoing, the term "comprising" should be understood to mean "including but not limited to," "including but not limited to," etc.; as used herein, the term "comprising" is synonymous with "including," "containing," or "characterized in," and is inclusive or open-ended, and does not exclude additional, unlisted elements or method steps; the term "having" should be interpreted as "having at least"; the term "comprising" should be interpreted as "including but not limited to"; the term "example" is used to provide an example instance of the items discussed, not an exhaustive or limiting list thereof; adjectives such as "known," "normal," "standard," and similar terms should not be interpreted as limiting the described items to a given time period or to items available at a given time, but should be understood to cover known, normal, or standard techniques that are available or known at any time now or in the future; and the use of terms such as "preferred" or "desired," and words with similar meanings, should not be interpreted as implying that certain features are critical, necessary, or even important to the structure or function of the invention, but are only intended to highlight alternatives or additional features that may or may not be utilized in a particular example of the invention. Similarly, a group of items connected with the conjunction "and" should not be understood as requiring each of these items to be present in the group, but should be understood as "and / or", unless otherwise explicitly stated. Likewise, a group of items connected with the conjunction "or" should not be understood as requiring mutual exclusivity within the group, but should be understood as "and / or".
[0340] As used herein, the term “comprising” is synonymous with “including,” “containing,” or “characterized in,” and is inclusive or open-ended, and does not exclude additional, unlisted elements or methodological steps.
[0341] All figures used in this specification to indicate the amount of ingredients, reaction conditions, etc., should be understood to be modified by the term 'about' in all cases. Therefore, unless otherwise indicated, the numerical parameters described herein are approximate values and may vary depending on the desired properties sought. In any application claiming priority to this application, each numerical parameter should be interpreted in accordance with the number of significant figures and ordinary rounding methods, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claim.
[0342] Furthermore, although the foregoing has been described in considerable detail by way of illustration and example for the purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications can be made. Therefore, this specification and embodiments should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather covering all modifications and alternatives that conform to the true scope and spirit of the invention.
[0343] Example Implementation Plan Specific implementation examples are described in the following numbered clauses: Clause 1: A monitoring system comprising: one or more memories including executable instructions; and one or more processors communicating with the one or more memories and configured to execute the executable instructions to: calculate a first reabsorption threshold based on a patient's glucose and 1,5-AG measurements over a first time period, wherein: an analog-to-digital converter is configured to receive a second sensor current and convert the second sensor current generated by a continuous analyte sensor into a second set of digital signals; and the processor is configured to convert the second set of digital signals into a second set of analyte measurements indicating a second set of analyte levels in the patient, wherein the second set of analyte measurements includes a second set of glucose measurements and a second set of 1,5-AG measurements; the one or more processors are further configured to: calculate a second reabsorption threshold based on the second set of glucose and the second set of 1,5-AG measurements over a second time period.
[0344] Clause 2: A monitoring system comprising: one or more memories including executable instructions; and one or more processors communicating with the memories and configured to execute the executable instructions to: calculate a first reabsorption threshold based on a patient's glucose and 1,5-AG measurements over a first time period; calculate a second reabsorption threshold based on the patient's glucose and 1,5-AG measurements over a second time period; detect a change in the second reabsorption threshold relative to the first reabsorption threshold; determine whether the change in the second reabsorption threshold relative to the first reabsorption threshold is an increase or a decrease; and provide treatment management guidance to the patient based on the increase or decrease.
[0345] Clause 3: A monitoring system comprising: one or more memories including executable instructions; and one or more processors communicating with the one or more memories and configured to execute the executable instructions to: detect a decrease in a patient's 1,5-AG level; initiate a monitoring period at time T0; determine a first 1,5-AG level at time T0; periodically monitor the patient's 1,5-AG level; determine a second 1,5-AG level at time T1; calculate a value representing the total clearance of 1,5-AG; calculate the total mass of 1,5-AG cleared; determine the patient's filtration score; and provide treatment management guidance to the patient based on the patient's filtration score.
[0346] Clause 4: A monitoring system according to any one of Clauses 1 to 3, wherein the monitoring system further comprises: a continuous analyte sensor configured to penetrate a patient's skin and generate a sensor current indicating the patient's analyte level; a sensor electronics module coupled to the continuous analyte sensor, wherein the sensor electronics module comprises: an analog-to-digital converter configured to: receive the sensor current; and convert the sensor current generated by the continuous analyte sensor into a digital signal; a processor configured to convert the digital signal into a set of analyte measurements indicating the patient's analyte level; and a Bluetooth antenna configured to wirelessly transmit the set of analyte measurements to a wireless communication device using a Bluetooth or BLE communication protocol.
[0347] Clause 5: A monitoring system according to any one of Clauses 1 to 4, wherein the sensor electronics module further comprises a sensitivity profile of the monitoring system based on a calibration process performed during manufacturing, wherein the processor is configured to convert the digital signal into the set of analyte measurements, including the processor being configured to convert the digital signal into the set of analyte measurements based on the sensitivity profile.
[0348] Clause 6: A monitoring system according to any one of Clauses 1 to 5, wherein the continuous analyte sensor comprises: a percutaneous lead, the percutaneous lead comprising: a proximal portion coupled to the sensor electronics module; and a distal portion comprising a working electrode and a reference electrode, wherein the working electrode is configured to penetrate the skin and extend into the dermis or subcutaneous tissue of the patient.
[0349] Clause 7: A monitoring system according to any one of Clauses 1 to 6, wherein: the working electrode and the reference electrode are disposed on a substrate, and the sensor current is based at least in part on the voltage difference generated between the working electrode and the reference electrode.
[0350] Clause 8: A monitoring system according to any one of Clauses 1 to 7, wherein: the continuous analyte sensor is a multi-analyte sensor including a continuous glucose sensor and a continuous pyranose sensor, and the set of analyte measurements includes glucose measurements and 1,5-AG measurements, wherein the 1,5-AG measurements are determined by subtracting the signal from the continuous glucose sensor from the signal from the signal from the continuous pyranose sensor.
[0351] Clause 9: A monitoring system according to any one of Clauses 1 to 2 or 4 to 8, wherein the one or more processors are further configured to detect a change in the second reabsorption threshold relative to the first reabsorption threshold by comparing the second reabsorption threshold with the first reabsorption threshold.
[0352] Clause 10: A monitoring system according to any one of Clauses 1 to 2 or 4 to 9, wherein the one or more processors are further configured to determine whether the change of the second reabsorption threshold relative to the first reabsorption threshold is an increase or a decrease.
[0353] Clause 11: A monitoring system according to any one of Clauses 1 to 2 or 4 to 10, wherein, based on determining that the change of the second reabsorption threshold relative to the first reabsorption threshold is an increase, the one or more processors are further configured to determine how the increase occurs.
[0354] Clause 12: A monitoring system according to any one of Clauses 1 to 2 or 4 to 11, wherein the manner in which the increase is determined comprises determining (1) whether the increase occurs after a decrease in the patient's reabsorption threshold prior to the calculation of the first reabsorption threshold, or (2) whether the increase occurs in response to the patient's reabsorption threshold being below a predetermined threshold prior to the calculation of the first reabsorption threshold.
[0355] Clause 13: A monitoring system according to any one of Clauses 1 to 2 or 4 to 12, wherein if the increase does not occur after the decrease in the reabsorption threshold and the increase does not occur in response to the reabsorption threshold falling below the defined threshold, the one or more processors are further configured to provide the patient with treatment management guidance to seek medical intervention for the decline in renal function.
[0356] Clause 14: A monitoring system according to any one of Clauses 1 to 2 or 4 to 13, wherein if the increase occurs after the decrease in the reabsorption threshold, or if the increase occurs in response to the reabsorption threshold falling below the defined threshold, the one or more processors are further configured to continue calculating one or more subsequent reabsorption thresholds for the patient.
[0357] Clause 15: A monitoring system according to any one of Clauses 1 to 2 or 4 to 14, wherein, based on determining that the change of the second reabsorption threshold relative to the first reabsorption threshold is a decrease, the one or more processors are further configured to determine the manner in which the decrease occurs.
[0358] Clause 16: A monitoring system according to any one of Clauses 1 to 2 or 4 to 15, wherein determining the occurrence of the reduction comprises determining (1) the rate of change of the reabsorption threshold between the first reabsorption threshold and the second reabsorption threshold, or (2) a reduction of one or more reabsorption thresholds of the patient in a subsequent time period before the first reabsorption threshold is calculated.
[0359] Clause 17: A monitoring system according to any one of Clauses 1 to 2 or 4 to 16, wherein if the rate of change of the reabsorption threshold between the first reabsorption threshold and the second reabsorption threshold is higher than a defined threshold change rate, the one or more processors are further configured to provide the patient with treatment management guidance to seek medical intervention for acute kidney injury.
[0360] Clause 18: A monitoring system pursuant to any one of Clauses 1 to 2 or 4 to 17, wherein if one or more reabsorption thresholds of the patient decrease in a subsequent time period, the one or more processors are further configured to provide the patient with treatment management guidance to seek medical intervention for advanced chronic renal failure.
[0361] Clause 19: A monitoring system according to any one of Clauses 1 to 2 or 4 to 18, wherein determining that the reduction occurs comprises determining (1) whether the reduction occurs after an increase in the patient's reabsorption threshold prior to the calculation of the first reabsorption threshold, or (2) whether the reduction occurs in response to the patient's reabsorption threshold being higher than a predetermined threshold prior to the calculation of the first reabsorption threshold.
[0362] Clause 20: A monitoring system according to any one of Clauses 1 to 2 or 4 to 19, wherein if the decrease occurs after the increase in the reabsorption threshold, or if the decrease occurs in response to the reabsorption threshold being higher than the predetermined threshold, the one or more processors are further configured to notify the patient of the improvement in renal function and continue to calculate one or more subsequent reabsorption thresholds for the patient. Clause 21: A monitoring system according to any one of Clauses 1 to 2 or 4 to 20, wherein the one or more processors are further configured to determine whether the patient is taking an SGLT2 inhibitor.
[0363] Clause 22: A monitoring system according to any one of Clauses 1 to 2 or 4 to 21, wherein the one or more processors are further configured to determine, based on the glucose measurement and the 1,5-AG measurement, whether the glucose measurement and the 1,5-AG measurement are within a defined range, and to provide the patient with guidance on achieving the defined range.
[0364] Clause 23: A monitoring system according to any one of Clauses 3 to 8, wherein the one or more processors are configured to detect the decrease in the patient's 1,5-AG level includes the one or more processors being configured to detect the decrease in the patient's 1,5-AG level based on the patient reaching a specified reabsorption threshold, a decreasing trend in the 1,5-AG level, or a negative rate of change in the 1,5-AG level.
[0365] Clause 24: A monitoring system pursuant to any one of Clauses 3 to 8 or 23, wherein the one or more processors are further configured to initiate a monitoring period at time T0.
[0366] Clause 25: A monitoring system according to any one of Clauses 3 to 8 or 23 to 24, wherein the one or more processors are configured to determine the second 1,5-AG level at time T1 includes the one or more processors being configured to determine the second 1,5-AG level at time T1 based on determining that a predetermined amount of 1,5-AG has been cleared from the body.
[0367] Clause 26: A monitoring system according to any one of Clauses 3 to 8 or 23 to 25, wherein the time T1 is the time when the patient's 1,5-AG level reaches a threshold level indicating that 1,5-AG is being cleared from the body, or the time when the determined rate of decrease of 1,5-AG is below the threshold rate of change indicating that 1,5-AG clearance is slowing down or has stopped.
[0368] Clause 27: A monitoring system according to any one of Clauses 3 to 8 or 23 to 26, wherein the time T1 is the time when the patient's glucose level reaches a predefined level, or the time when the glucose level begins to decrease toward the patient's reabsorption threshold.
[0369] Clause 28: A monitoring system pursuant to any one of Clauses 3 to 8 or 23 to 27, wherein the time T1 is a predefined time following T0.
[0370] Clause 29: A monitoring system according to any one of Clauses 3 to 8 or 23 to 28, wherein the determination of the first 1,5-AG level at time T0 and the second 1,5-AG level at time T1 is based on a urine sample from the patient.
[0371] Clause 30: A monitoring system according to any one of Clauses 3 to 8 or 23 to 29, wherein the determination of the total volume of 1,5-AG cleared is based on the urine concentration of 1,5-AG at time T1 multiplied by the volume of urine collected from the patient's urine sample.
[0372] Clause 31: A monitoring system according to any one of Clauses 3 to 8 or 23 to 30, wherein the determination of the total volume of 1,5-AG cleared is based on the difference between the first 1,5-AG level at time T0 and the second 1,5-AG level at time T1, multiplied by the patient's total body water volume.
[0373] Clause 32: A monitoring system according to any one of Clauses 3 to 8 or 23 to 31, wherein the total body water volume is based on the patient's weight, the patient's age, and the patient's sex.
[0374] Clause 33: A monitoring system according to any one of Clauses 3 to 8 or 23 to 32, wherein one or more processors are further configured to provide treatment management guidance to the patient based on the patient's filtration score.
[0375] Clause 34: A monitoring system according to any one of Clauses 3 to 8 or 23 to 33, wherein the patient’s filtration score is provided to the patient via a display device.
[0376] Clause 35: A monitoring system according to any one of Clauses 3 to 8 or 23 to 34, wherein, based on the detected increase in the patient's filtration score over time, the one or more processors are further configured to provide the patient with treatment management guidance indicating that the patient's renal function is improving.
[0377] Clause 36: A monitoring system according to any one of Clauses 3 to 8 or 23 to 35, wherein, based on a detected decrease in the patient's filtration score over time, the one or more processors are further configured to provide the patient with treatment management guidance for the patient's deteriorating renal function.
[0378] Clause 37: A monitoring system according to any one of Clauses 3 to 8 or 23 to 36, wherein the one or more processors are further configured to determine, based on the glucose measurement and the 1,5-AG measurement, whether the glucose measurement and the 1,5-AG measurement are within a defined range, and to provide the patient with guidance on achieving the defined range.
[0379] Clause 38: A method for performing operations performed by the system described in Clauses 1 to 37.
[0380] Clause 39: An apparatus configured to perform operations performed by the systems described in Clauses 1 through 37.
[0381] Other precautions The methods disclosed herein include one or more steps or actions for implementing these methods. The method steps and / or actions may be interchanged without departing from the scope of the claims. In other words, unless a specific order of steps or actions is specified, the order and / or use of a particular step and / or action may be modified without departing from the scope of the claims.
[0382] As used in this article, the phrase “at least one” in a list of items refers to any combination of those items, including a single member. For example, “at least one of a, b, or c” is intended to cover a, b, c, ab, ac, bc, and abc, as well as any combination with multiple identical elements (e.g., aa, aaa, aab, aac, abb, acc, bb, bbb, bbc, cc, and ccc, or any other ordering of a, b, and c).
[0383] The foregoing description is provided to enable any person skilled in the art to practice the various aspects described herein. Various modifications to these aspects will be apparent to those skilled in the art, and the general principles defined herein may be applied to other aspects. Therefore, the claims are not intended to be limited to the aspects shown herein, but are consistent with the full scope of the language of the claims, wherein, unless specifically stated otherwise, reference to an element in the singular is not intended to mean “one and only one”, but rather “one or more”. Unless otherwise specifically stated otherwise, the term “some” means one or more. All structural and functional equivalents of elements throughout the various aspects described in this disclosure that are known or will later be understood by a person skilled in the art are expressly incorporated herein by reference and are intended to be included in the claims. Furthermore, nothing disclosed herein is intended to be offered to the public, whether or not this disclosure is expressly stated in the claims. No claim element should be interpreted in accordance with 35 USC §112(f) unless expressly stated using the phrase “component for…” or, in the case of a method claim, using the phrase “step for…”.
[0384] While various examples of the invention have been described above, it should be understood that they are presented by way of example only and not by way of limitation. Similarly, the figures may depict exemplary architectures or other configurations of this disclosure to aid in understanding the features and functions that may be included in this disclosure. This disclosure is not limited to the illustrated exemplary architectures or configurations, but may be implemented using a variety of alternative architectures and configurations. Furthermore, although this disclosure has been described above with reference to various exemplary examples and aspects, it should be understood that the various features and functions described in one or more of the various examples are not limited in their applicability to the specific examples describing them. They may be applied individually or in some combination to one or more other examples of this disclosure, whether or not such examples are described, and whether or not such features are presented as part of the described examples. Therefore, the breadth and scope of this disclosure should not be limited by any of the foregoing exemplary examples.
[0385] All references cited herein are incorporated herein by reference in their entirety. Where any cited publications and patents or patent applications contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.
[0386] Unless otherwise defined, all terms (including technical and scientific terms) shall be given their common and customary meaning to a person skilled in the art, and are not limited to specific or customary meanings, unless expressly defined herein.
[0387] Unless otherwise expressly stated, the terms and phrases used in this application, and their variations, particularly those used in the appended claims, shall be interpreted as open-ended rather than restrictive. As an example of the foregoing, the term "comprising" should be understood to mean "including but not limited to," "including but not limited to," etc.; as used herein, the term "comprising" is synonymous with "including," "containing," or "characterized in," and is inclusive or open-ended, and does not exclude additional, unlisted elements or method steps; the term "having" should be interpreted as "having at least"; the term "comprising" should be interpreted as "including but not limited to"; the term "example" is used to provide an example instance of the items discussed, not an exhaustive or limiting list thereof; adjectives such as "known," "normal," "standard," and similar terms should not be interpreted as limiting the described items to a given time period or to items available at a given time, but should be understood to cover known, normal, or standard techniques that are available or known at any time now or in the future; and the use of terms such as "preferred" or "desired," and words with similar meanings, should not be interpreted as implying that certain features are critical, necessary, or even important to the structure or function of the invention, but are only intended to highlight alternatives or additional features that may or may not be utilized in a particular example of the invention. Similarly, a group of items connected with the conjunction "and" should not be understood as requiring each of these items to be present in the group, but should be understood as "and / or", unless otherwise explicitly stated. Likewise, a group of items connected with the conjunction "or" should not be understood as requiring mutual exclusivity within the group, but should be understood as "and / or".
[0388] As used herein, the term “comprising” is synonymous with “including,” “containing,” or “characterized in,” and is inclusive or open-ended, and does not exclude additional, unlisted elements or methodological steps.
[0389] All figures used in this specification to indicate the amount of ingredients, reaction conditions, etc., should be understood to be modified by the term "about" in all cases. Therefore, unless otherwise indicated, the numerical parameters described herein are approximate values and may vary depending on the desired properties sought. In any application claiming priority to this application, each numerical parameter should be interpreted in accordance with the number of significant figures and ordinary rounding methods, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claim.
[0390] Furthermore, although the foregoing has been described in considerable detail by way of illustration and example for the purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications can be made. Therefore, this specification and embodiments should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather covering all modifications and alternatives that conform to the true scope and spirit of the invention.
Claims
1. A monitoring system, the monitoring system comprising: One or more memories, the one or more memories including executable instructions; and One or more processors, which communicate data with the one or more memories and are configured to execute the executable instructions to: The first reabsorption threshold was calculated based on the patient's glucose and 1,5-AG measurements during the first time period. The second reabsorption threshold was calculated based on the patient's glucose and 1,5-AG measurements during the second time period. Detect the change in the second absorption threshold relative to the first absorption threshold; Determine whether the change in the second reabsorption threshold relative to the first reabsorption threshold is an increase or a decrease; as well as Treatment management guidance is provided to the patient based on the increase or decrease mentioned above.
2. The monitoring system of claim 1, wherein, Based on the determination that the change in the second reabsorption threshold relative to the first reabsorption threshold is an increase, the one or more processors are further configured to determine how the increase occurs.
3. The monitoring system according to any one of claims 1 to 2, wherein determining that the increase occurs comprises determining (1) whether the increase occurs after a decrease in the patient's reabsorption threshold prior to the calculation of the first reabsorption threshold, or (2) whether the increase occurs in response to the patient's reabsorption threshold being lower than a predetermined threshold prior to the calculation of the first reabsorption threshold.
4. The monitoring system of any one of claims 1 to 3, wherein, If the increase does not occur after the decrease in the reabsorption threshold, and the increase does not occur in response to the reabsorption threshold falling below the defined threshold, then the one or more processors are further configured to provide the patient with treatment management guidance to seek medical intervention for the decline in renal function.
5. The monitoring system according to any one of claims 1 to 4, wherein, If the increase occurs after the decrease in the reabsorption threshold, or if the increase occurs in response to the reabsorption threshold falling below the defined threshold, then the one or more processors are further configured to continue calculating one or more subsequent reabsorption thresholds for the patient.
6. The monitoring system according to any one of claims 1 to 5, wherein, Based on the determination that the change in the second reabsorption threshold relative to the first reabsorption threshold is a decrease, the one or more processors are further configured to determine how the decrease occurs.
7. The monitoring system according to any one of claims 1 to 6, wherein determining the occurrence of the reduction comprises determining (1) the rate of change of the reabsorption threshold between the first reabsorption threshold and the second reabsorption threshold, or (2) a reduction in one or more reabsorption thresholds of the patient in a subsequent time period before the first reabsorption threshold is calculated.
8. The monitoring system according to any one of claims 1 to 7, wherein, If the rate of change of the reabsorption threshold between the first reabsorption threshold and the second reabsorption threshold is higher than the defined rate of change of the threshold, then the one or more processors are further configured to provide the patient with treatment management guidance to seek medical intervention for acute kidney injury.
9. The monitoring system according to any one of claims 1 to 8, wherein, If one or more reabsorption thresholds of the patient decrease in a subsequent time period, the one or more processors are further configured to provide the patient with treatment management guidance in order to seek medical intervention for advanced chronic renal failure.
10. The monitoring system according to any one of claims 1 to 9, wherein determining that the reduction occurs comprises determining (1) whether the reduction occurs after an increase in the patient's reabsorption threshold prior to the calculation of the first reabsorption threshold, or (2) whether the reduction occurs in response to the patient's reabsorption threshold being higher than a predetermined threshold prior to the calculation of the first reabsorption threshold.
11. The monitoring system according to any one of claims 1 to 10, wherein if the decrease occurs after the increase in the reabsorption threshold, or the decrease occurs in response to the reabsorption threshold being higher than the defined threshold, the one or more processors are further configured to notify the patient of the improvement in renal function and continue to calculate one or more subsequent reabsorption thresholds for the patient.
12. The monitoring system according to any one of claims 1 to 11, wherein the one or more processors are further configured to determine whether the patient is taking an SGLT2 inhibitor.
13. The monitoring system according to any one of claims 1 to 12, wherein the one or more processors are further configured to determine, based on the glucose measurement and the 1,5-AG measurement, whether the glucose measurement and the 1,5-AG measurement are within a defined range, and to provide the patient with guidance on reaching the defined range.
14. The monitoring system according to any one of claims 1 to 13, wherein the monitoring system further comprises: A continuous analyte sensor, the continuous analyte sensor being configured to penetrate a patient’s skin and generate a sensor current indicating the patient’s analyte level; A sensor electronics module coupled to the continuous analyte sensor, wherein the sensor electronics module includes: Analog-to-digital converter, the analog-to-digital converter being configured to: Receive the sensor current; and The sensor current generated by the continuous analyte sensor is converted into a digital signal; A processor configured to convert the digital signal into a set of analyte measurements indicating the patient's analyte levels; and A Bluetooth antenna configured to wirelessly transmit the set of analyte measurements to a wireless communication device using a Bluetooth or BLE communication protocol.
15. The monitoring system according to any one of claims 1 to 14, wherein: The continuous analyte sensor is a multi-analyte sensor that includes a continuous glucose sensor and a continuous pyranose sensor, and The set of analyte measurements includes the glucose measurement and the 1,5-AG measurement, wherein the 1,5-AG measurement is determined by subtracting the signal from the continuous glucose sensor from the signal from the continuous pyranose sensor.
Citation Information
Patent Citations
Implantable system for cell growth control
US5964745A
Implantable device containing GDNF secreting cells for treating nerve damage and methods of use
US6015572A
Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products
US6083523A
